The pathophysiology of paroxysmal nocturnal haemoglobinuria by Kelly, Richard John
 1 
 
 
 
The Pathophysiology of Paroxysmal 
Nocturnal Haemoglobinuria 
 
 
 
 
 
Richard John Kelly 
 
 
 
 
 
Submitted in accordance with the requirements for 
the degree of Doctor of Philosophy 
 
The University of Leeds 
 
School of Medicine 
 
January 2014 
 
 
 
 
 
 
 
 2 
 
 
 
Jointly-Authored Publications 
 
The candidate confirms that the work submitted is his own, except where work which has 
formed part of jointly authored publications has been included. The contribution of the 
candidate and the other authors to this work has been explicitly indicated below. The 
candidate confirms that appropriate credit has been given within the thesis where 
reference has been made to the work of others. 
The work in Chapter 3 of the thesis has appeared in publication as follows: Kelly RJ, Hill 
A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, 
Gregory WM, Hillmen P. Long-term treatment with eculizumab in paroxysmal nocturnal 
hemoglobinuria: sustained efficacy and improved survival. Blood 2011;117:6786-6792. 
I was responsible for designing the study, collecting and analysing the data and writing 
the paper. Dena Cohen and Walter Gregory performed the statistical analysis. All the 
other authors reviewed the paper. 
The work in Chapter 4 of the thesis has appeared in publication as follows: Kelly R, 
Arnold L, Richards S, Hill A, Bomken C, Hanley J, Loughney A, Beauchamp J, 
Khursigara G, Rother RP, Chalmers E, Fyfe A, Fitzsimons E, Nakamura R, Gaya A, 
Risitano AM, Schubert J, Norfolk D, Simpson N, Hillmen P. The management of 
pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J 
Haematol 2010;149:446-450. 
I was responsible for designing the study, collecting and analysing the data and writing 
the paper. All the other authors reviewed the paper. 
 
This copy has been supplied on the understanding that it is copyright material and that no 
quotation from the thesis may be published without proper acknowledgement. 
  
 3 
 
Abstract 
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, life-threatening condition caused 
by an expansion of a clone of haemopoietic stem cells (HSC) harboring a somatic 
mutation of the PIG-A gene. PNH blood cells are deficient in glycophosphatidylinositol-
linked (GPI) proteins rendering PNH erythrocytes susceptible to complement attack 
which leads to intravascular haemolysis and an increased tendency to develop 
thromboses. 
The survival of 79 consecutive patients treated with eculizumab was compared to both 
age and sex matched normal controls and to 30 similar patients managed in the era 
immediately prior to anti-complement therapy. The survival of those treated with 
eculizumab was no different that of the control group and was significantly better than 
the group with PNH that did not receive eculizumab (p=0.3). Transfusion requirements 
and documented thromboses were reduced with eculizumab. Sixty-six percent of 
transfusion dependent patients became transfusion independent and thrombotic events 
reduced from 5.6 to 0.8 events per 100 years. 
Eleven women were monitored through 15 pregnancies whilst on eculizumab. There was 
1 first trimester miscarriage and 15 healthy babies born. There were no maternal deaths 
observed and no thrombotic events occurred in the pregnancy or the postpartum period. 
Eculizumab did not appear to cross the placenta or be expressed in breast milk. 
Thirty-five patients were evaluated for PIG-M mutations to see if this mutation was 
prevalent in PNH. No PIG-M promoter mutations were identified. Two genes were 
evaluated to see if secondary mutations affecting them could account for clonal 
expansion in PNH. Thirty-six patients underwent JAK2 V617F mutation analysis with 1 
patient shown to have a JAK2 mutation. Forty-two patients were evaluated for increased 
HMGA2 levels by 2 different PCR methods. There was an overall reduction in HMGA2 
expression in PNH patients as compared to normal controls. 
An in vitro model of the bone marrow in PNH was developed and 18 PNH bone marrow 
samples were evaluated using this model. Colony forming assays (CFA) showed an 
increase in colony formation when T-cells were removed from the PNH bone marrow 
samples. This improvement was reversed when the T-cells were added back to the 
experiments. This work supports an immune mechanism for the expansion of the PNH 
clone. 
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NTproBNP  N-terminal pro-brain natriuretic peptide 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PNH  paroxysmal nocturnal haemoglobinuria 
qPCR  quantitative PCR 
RB  rinsing buffer 
RBC  red blood cell 
rh  recombinant human 
RIC  reduced intensity conditioning 
RNA  ribonucleic acid 
RPMI  roswell park memorial institute 
SAPEX shrimp alkaline phosphatase/exonuclease 
SLE  systemic lupus erythematosis 
TBE  Tris/Borate/EDTA  
TD  therapeutic dose 
TE  thrombotic event 
TIPPS  transjugular intrahepatic portosystemic shunt 
Tregs  regulatory T-cells   
ULBP  UL 16-binding proteins 
U-PAR urinary plasminogen activator receptor 
UTR  untranslated region 
WCC  white cell count 
 20 
 
 
Chapter 1 
 
 
Contents: 
 
Introduction 
 
1.1.1 Identifying the Genetic Defect 
1.1.2 Disruption of the Glycophosphatidylinositol Anchor  
1.1.3 Haemolysis in PNH 
1.2  Diagnosis 
1.2.1  Historical Background 
1.2.2  Current Techniques for Diagnosis 
1.3 A Classification of PNH 
1.4 The Relative Incidence of Molecular and Symptomatic PNH 
1.5 Clinical Features of PNH 
1.5.1 The Consequences of Haemolysis 
1.5.2 Thrombosis 
1.5.3 Renal Dysfunction 
1.5.4 Pulmonary Hypertension 
1.5.5 Quality of Life 
1.5.6 Pregnancy 
1.6 Mortality and Treatment Prior to Anti-complement Therapy 
1.6.1 General Measures 
1.6.2 Anticoagulation 
1.6.3 Allogeneic Bone Marrow Transplantation 
1.7 The Complement System 
1.7.1 Targeting Complement 
1.7.2 Anti-Complement Strategies in PNH 
1.7.3 CD59 Replacement 
1.7.4 Eculizumab 
 21 
 
1.7.5 Eculizumab Clinical Studies in PNH 
1.8 Pathogenesis 
1.8.1 Bone Marrow Failure 
1.8.2  Mutations in Normal Individuals, Other Conditions and in the Context of 
Antibody Therapy 
1.9  Clonal Expansion 
1.9.1  Multiple Clones and Clonal Dominance 
1.9.2  Hypotheses of Clonal Expansion 
1.9.3 Animal Models of PNH 
1.9.4  Potential Mechanisms Mediating HSC Destruction 
1.9.5 Humoral Antibody Dependent Cell Mediated Cytotoxicity (ADCC) and 
Complement 
1.9.6  Cell Mediated Immunity and Natural Killer (NK) cells 
1.9.7  The Wilms Tumour Gene 
1.9.8  Secondary Genetic Mutations – HMGA2 
1.9.9 Apoptosis 
1.10 Haematopoietic Stem Cell Immunophenotype and Long Term Bone Marrow 
Culture (LTBMC) Studies 
1.10.1 Early Progenitor Cells 
1.10.2 Long Term Bone Marrow Cultures in PNH and AA 
  
 22 
 
1.1 Identifying the Genetic Defect 
 
Paroxysmal Nocturnal Haemoglobinuria (PNH) was initially described by Strübing in 
1882 (Strübing, 1882). He presented a case of a 29 year old man with pale yellow-grey 
skin and episodes of dark brown urine in the mornings which would clear up by noon. 
During these episodes he experienced extreme loss of physical strength, fatigue and 
exhaustion after physical activities. No trigger for theses episodes was identified 
including cold temperatures, unlike in paroxysmal cold haemoglobinuria. Strübing 
proposed that there was a defect of the red cells and that the haemolysis observed was 
intravascular in nature and determined by sleep. In 1908 Chauffard and Troisier reported 
a further case of PNH, which was thought to be the first where PNH was described as a 
specific entity (Chauffard and Troisier, 1908). The true nature of the disease was not fully 
appreciated until further descriptions were published by Marchiafava in 1928 and by 
Micheli in 1931 (Marchiafava, 1928; Micheli, 1931). From these reports the disease 
became known as the Marchiafava-Micheli syndrome. It wasn’t until 1925 that the 
disease was first referred to as Paroxysmal Nocturnal Haemoglobinuria (Enneking, 
1925). 
 
Only recently has the underlying defect in PNH been identified after the development of 
immortalised cell lines with the defect present (Schubert et al, 1990; Hillmen et al, 1992; 
Nakakuma et al, 1994). This work lead to the finding of haemopoietic clones which 
harbour somatic mutations of the phosphatidyl inositol glycan synthetic pathway due to 
inactivation of the complementation class A gene (PIG-A) (Takeda et al, 1993). 
 
 
1.1.1 Disruption of the Glycophosphatidylinositol Anchor  
 
The PIG-A gene is one of over 25 genes required for the synthesis of the 
glycophosphatidyl inositol (GPI) anchor within the endoplasmic reticulum (ER) (Miyata 
et al, 1993). GPI biosynthesis occurs via a stepwise addition of sugar nucleotides and 
phospholipids within the ER before the completed protein is transferred to the cell surface 
(Vidugiriene and Menon, 1993) (Figure 1.1).  
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Protein Protein Function 
CD14 Binds lipopolysacharide binding proteins and 
apoptotic cells 
CD16 Receptor for IgG 
CD24 Cell adhesion 
CD28 Co-stimulatory signaling in T-cell activation 
CD48 Cell adhesion, binds to CD2 
CD52 Signal transduction 
CD55 Regulation of complement dependent lysis 
CD58 Cell adhesion, binds to CD2 
CD59  Regulation of complement dependent lysis 
CD66b Cell adhesion 
CD66c Cell adhesion 
CD87 (uPAR) Urokinase receptor 
CD108 Unknown 
CD109 Unknown 
CD157 Enzyme, facilitates pre-B cell growth 
NT5E Enzyme involved in lymphoid differentiation 
FCGR3B Possible role in Natural Killer (NK) cell mediated 
toxicity 
FOLR1 Receptor for folate and folic acid derivatives 
mediating delivery of 5-methyltetrahydrofolate into 
cells 
Neutrophil alkaline 
phosphatase, NAP 
Membrane bound enzyme 
CEACAM6 Cell adhesion 
CEACAM8 Cell adhesion 
THY1 Cell adhesion 
PRV-1 Unknown 
ULBPs Stress induced proteins 
Erythrocyte 
acetylcholinesterase 
Enzyme, unknown 
PRNP Unknown 
 
Table 1.1 Known GPI-linked proteins absent in PNH. 
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The GPI moiety serves as a membrane anchor for a variety of cell surface proteins 
(Mahoney et al, 1992). GPI-linked proteins are functionally diverse and play an 
important role in signal transduction and the immune response (Paulick and Bertozzi, 
2008). 
 
Functions of GPI-linked proteins include cell-cell contact and cell adhesion, enzyme 
catalysts and regulation of the complement cascade (Paulick and Bertozzi, 2008). GPI-
linked proteins associate with lipid rafts within the plasma membrane. Lipid rafts are 
microdomains within the plasma membrane with high cholesterol and sphingolipid levels 
that serve as signaling centres for different cellular functions like signal transduction and 
vesicle trafficking (Munro, 2003; Rajendran and Simons, 2005). Table 1.1 depicts GPI 
linked proteins that are known to have reduced or absent expression on PNH cells (Rotoli 
et al, 1993; Risitano and Rotoli, 2008; Paulick and Bertozzi, 2008; Parker, 2008).  
 
Mutations of the PIG-A gene disrupt the first step of GPI biosynthesis leading to an 
absence of the GPI anchor and, in turn, a marked deficiency of all GPI linked proteins 
(Kinoshita et al, 1997). PIG-A is located on the X chromosome, and is mono-allelically 
expressed. All the other the genes involved in GPI biosynthesis are autosomal (Kinoshita 
et al, 1997). A single mutation in the PIG-A gene is therefore sufficient to disrupt GPI 
assembly leading to complete loss of function. For all other genes in this pathway, both 
alleles would need to be mutated in the same cell to affect GPI production. This explains 
why all cases of acquired PNH that have been examined, harbour PIG-A mutations 
(Tomita, 1999; Rosti, 2000). 
 
The only exception to this has been described in three individuals in two unrelated 
consanguineous families who have a point mutation (C-G) at position -270 in the 
promoter of the phosphatidyl inositol glycan complementation class M gene (PIG-M) 
(Almeida et al, 2006). The gene encodes a mannosyltransferase, GPI-MT-I, that transfers 
the first mannose to GPI on the lumenal side of the ER (Figure 1.1). This point mutation 
is inherited in an autosomal recessive manner and individuals present with thrombosis 
and epilepsy in childhood. The mutation in the PIG-M promoter region disrupts binding 
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of the transcription factor SP1 and reduces transcription of PIG-M leading to a partial, but 
severe, deficiency of the GPI anchor and GPI-linked proteins. 
 
 
 
 
 
Figure 1.1 GPI biosynthesis in the endoplasmic reticulum. 
 
 
1.1.2 Haemolysis in PNH 
 
CD55 (decay accelerating factor, DAF) and CD59 (membrane inhibitor of reactive lysis, 
MIRL) are the most widely expressed GPI linked proteins present on all haemopoietic 
cells and are both involved in the regulation of complement activation.  
 
CD55 inhibits the formation of both C3 and C5 convertases in the complement cascade, 
thereby reducing the amount of C3 that is cleaved (Medof et al, 1985). CD59 inhibits C9 
binding to C5b, C6, C7 and C8 which together make up the membrane attack complex 
(MAC) (Holguin et al, 1989a; Davies et al, 1989; Rollins and Sims, 1990; Meri et al, 
1990). Once formed on the surface of a cell, usually a bacterial cell, the MAC is then 
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inserted into the cell membrane where it acts as transmembrane channels. The formation 
of these transmembrane channels is the terminal step in the complement cascade that 
disrupts the phospholipid bilayer, which initiates cell lysis and cell death (Figure 1.2) 
(Rollins and Sims, 1990).  
 
It was initially thought that the absence of CD55 on erythrocytes was responsible for the 
observed increased sensitivity to complement (Pangburn et al, 1983; Nicholson-Weller et 
al, 1983). However, there are no reports of individuals with inherited deficiencies of 
CD55 experiencing features of PNH. Indeed, individuals with inherited deficiencies of 
CD55 have been described as they develop anti-CD55 antibodies after  blood transfusions 
(Lin et al, 1988; Tate et al, 1989). On further examination of these cases, with exposure 
of their erythrocytes to Ham’s acidified lysis, no lysis is observed (Telen and Green, 
1989; Merry et al, 1989a; Merry et al, 1989b). This finding confirms that the absence of 
CD55 on PNH erythrocytes is not the cause of the increased sensitivity to complement. 
Further studies suggested factors other than CD55 that were also likely to be involved 
(Shin et al, 1986; Medof et al, 1987). 
 
The absence or reduced expression of CD59 on erythrocytes is responsible for their 
increased sensitivity to complement mediated attack and the subsequent intravascular 
haemolysis (Horstman et al, 1985; Holguin et al, 1989a; Yamashina et al, 1990; Meri et 
al, 1996; Rosse, 2001). Individuals with inherited deficiencies of CD59 also experience 
intravascular haemolysis and clinical features that are indistinguishable from PNH 
(Yamashina et al, 1990; Motoyama et al, 1992).  
 
Based on their sensitivity to complement attack erythrocytes in PNH have been classified 
into 3 groups (Rosse, 1973). Type I cells are normal red blood cells, type III cells have a 
complete deficiency of GPI anchored proteins and type II cells have a partial deficiency 
(Figure 1.3). 
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Figure 1.2 Terminal complement activation causing cell lysis. 
 
 
 
Rosse et al showed that type III cells are 15-25 times more sensitive to complement and 
type II cells 3-5 times more sensitive than the normal type I red blood cells (Rosse et al, 
1974). The degree of haemolysis suffered by individuals relates to the relative 
proportions of the type II and III cells present. In general, the larger the proportion of 
type III cells, the more severe the haemolysis suffered by the affected individual. 
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Figure 1.3 FACS plot of erythrocytes in a PNH patient. Type I express CD59 
normally, Type II have a reduced expression and Type III have no CD59 expression. 
 
 
1.2 Diagnosis 
 
1.2.1 Historical Background 
 
In 1937 Thomas Ham developed the Ham’s acid haemolysis test (Ham, 1937). Ham 
observed that PNH erythrocytes undergo lysis when left for 4 hours at 37oC. He also 
demonstrated that the observed lysis occurred quicker both in acidic conditions and when 
an increased level of carbon dioxide was present. In the Ham’s test red blood cells are 
exposed to acidified serum, and under these conditions complement is activated via the 
alternative pathway causing lysis of PNH cells, as they are sensitive to complement 
attack. (Rosse, 1991). The sucrose haemolysis test has also been used to diagnose PNH 
(Hartmann and Jenkins, 1965; Hansen, 1968). In this method erythrocytes are placed in a 
low-ionic-strength solution and observed for evidence of haemolysis. In this solution 
PNH erythrocytes adsorb complement onto their surface and in the presence of serum in 
the test are haemolysed. It was thought to be a more sensitive test for diagnosing PNH 
than the Ham’s test. These erythrocyte based assays were both non-specific and 
insensitive in diagnosing PNH. In 1966 Rosse and Dacie developed the complement lysis 
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sensitivity test, which was more specific (Rosse and Dacie, 1966). This method allowed 
the amount of complement required to lyse both PNH and normal erythrocytes to be 
determined and compared. It led to the identification of type I, II and III PNH red cells, as 
described above. As a technique it is time consuming and difficult to standardise between 
laboratories. 
 
All these diagnostic methods are unable to provide a quantitative evaluation on the 
proportion of PNH cells present. They were superseded by flow cytometry in the 1980s.  
 
 
1.2.2 Current Techniques for Diagnosis 
 
Flow cytometry has become the “Gold Standard” test for the diagnosis of PNH since its 
use was first described in 1985 (Kinoshita et al, 1985; Nicholson-Weller et al, 1985). It is 
routinely performed to evaluate the size of erythrocyte and granulocyte clones. The 
granulocyte clone size is believed to be the best marker for evaluating the extent of the 
bone marrow cells affected (Hall and Rosse, 1996; Navenot et al, 1996; Alfinto et al, 
1996). The erythrocyte clone size varies depending on whether an individual has had a 
recent red cell transfusion and with the degree of intravascular haemolysis experienced at 
the time (Brodsky et al, 2000; Sutherland et al, 2007). The granulocyte clone size also 
correlates well with the platelet clone size. Until recently there has been no uniformity in 
relation to testing for PNH with centres using both a variety of different monoclonal 
antibodies as well as different cell types evaluated (Richards et al, 2000; Brodsky et al, 
2000). 
 
Initially many centres used flow cytometry solely to look for the absence of CD55 and 
CD59, but especially CD59 as it is expressed on all haemopoietic cell lines (Brodsky, 
2009). In evaluating any cell line for PNH it is important to use 2 different antigens to 
rule out technical errors (Richards et al, 2000). There are also rare congenital deficiencies 
of CD55 and CD59, which can lead to a false positive result if these antigens are used as 
the sole diagnostic marker (Telen and Green, 1989; Yamashina et al, 1990). 
 
 30 
 
 
 
Figure 1.4 FACS plot depicting a large granulocyte PNH clone of 98.2% (Q3) 
identified using FLAER and CD16 (GPI linked protein) and using these markers the 
population of PNH and normal granulocytes can easily be identified. 
 
A recent development in the diagnosis of PNH is the development of the fluorescein-
labeled proaerolysin (FLAER) reagent (Brodsky, 2000). FLAER is a fluorescently 
labeled inactive variant of the protein aerolysin, which selectively binds directly to the 
GPI anchor. It is only practical for leukocyte analysis as its binding is inhibited by 
glycophorin which is present on erythrocytes, but it does provide a more accurate 
evaluation, especially of small PNH clones (Richards et al, 2007). Figure 1.4 shows a 
large PNH granulocyte clone (98.2%) identified by FLAER.  
 
Evaluation of erythroid clones is performed either by an analysis of CD55 or CD59 
expression on red cells (Figure 1.3). By using both of these in conjunction with 
multicolour flow cytometry, a red cell clone as small as 0.01% can be detected (Richards 
et al, 2007). The proportion of PNH platelets correlates well with the PNH granulocyte 
level (Jin et al, 1997). It is technically difficult to perform and not routinely assessed in 
clinical practice. Lymphocytes are also not generally assessed due to the longevity of 
Empty vessels make most noise 
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these cells that were made before PNH occurred. In 2010 Borowitz et al published 
guidance on PNH testing to provide a consensus view including who to test, how often to 
repeat testing and which monoclonal antibodies to use (Borowitz et al, 2010). 
 
 
1.3 A Classification of PNH 
 
The advent of high sensitivity flow cytometry lead to a classification of PNH as there was 
an increase in small PNH clones detected. This classification was proposed to try to aid 
clinicians (Parker et al, 2005). It incorporates three subcategories: 
 
1. Classical PNH – these patients have the characteristic symptoms of haemolytic PNH 
with intravascular haemolysis but also have no signs of any other bone marrow 
pathology. 
 
2. PNH in the setting of another specified bone marrow disorder – these patients have 
symptoms of intravascular haemolysis but also have, or previously had, an underlying 
bone marrow abnormality such as aplastic anaemia (AA) or myelodysplasia (MDS). 
 
3. Subclinical PNH – these patients have no evidence of ongoing haemolysis. They have 
small PNH clones present and are often seen in patients with bone marrow failure 
especially in AA and MDS. These patients have been identified due to the development 
of diagnostic flow cytometry as prior to this these small clones would have remained 
undetected. People with these small clones (subclinical PNH) are not known to be at 
increased risk of thrombosis but are at risk of developing symptomatic PNH (Sugimori et 
al, 2009). 
 
 
1.4 The Relative Incidence of Molecular and Symptomatic PNH 
 
The precise incidence and prevalence of PNH has not been well described. This is due, in 
part, to the condition being under diagnosed. All patients with PNH have blood cells in 
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their circulation that derive from a mosaic of normal and abnormal haemopoietic 
progenitors. Those with only a small percent of affected cells (a small PNH clone) are 
unlikely to develop clinical symptoms and will often remain undiagnosed. However, 
small clones may increase to levels where they cause symptoms and conversely large 
clones can reduce in size and even disappear (Hillmen et al, 1995). The reason for the 
variations in clone size over time is unknown. Granulocyte clones as low as 10% have 
been shown to increase the risk of thrombosis compared to the general population 
(Fowkes et al, 2003). 
 
The most reliable data on the incidence and prevalence of the disease is from work 
undertaken in Yorkshire (Hill et al, 2006a). In this study, the prevalence of patients with 
PNH clones of any size is 15.9 per million and the incidence is 1.3 per million of the total 
population. Eighty-two percent of these patients had a granulocyte clone size greater than 
1% with 43% of these greater than 10% and a quarter of these greater than 50%. 
 
 
1.5 Clinical Features of PNH 
 
PNH is a chronic illness characterised by intravascular haemolysis, a tendency to develop 
thrombosis and an association with bone marrow failure, usually AA (Hillmen et al, 
1995). It can occur at any age but it is commonest in young adults, with the median age 
of diagnosis being in the fourth decade (Nishimura et al, 2004; Socié G et al, 1996). The 
variability in disease manifestations means individuals with PNH may have been either 
undiagnosed or misdiagnosed for long periods of time before the diagnosis is ascertained 
(Dacie and Lewis, 1972). Although all patients with PNH can be symptomatic, in general 
the larger the proportion of PNH cells present, the more likely they are to experience 
disease symptoms (Moyo et al, 2004). A variety of factors have been reported to trigger 
exacerbations of the disease, including infection, trauma, stress, exercise and iron 
replacement therapy (Blum et al, 1967; Rosse and Gutterman, 1970). 
 
Affected individuals have a chronic intravascular haemolysis with episodes or 
“paroxysms” of more severe haemolysis and symptoms (Moyo et al, 2004). There is an 
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increased morbidity with symptoms including breathlessness, fatigue, dysphagia, erectile 
dysfunction and chest and abdominal pain occurring frequently (Hill et al, 2007; Lee et 
al, 2010). 
 
1.5.1 The Consequences of Haemolysis 
 
Intravascular haemolysis in PNH causes the release of free haemoglobin into the 
circulation (Yamashina et al, 1990). The observed haemolysis can be monitored by 
evaluating the serum level of the enzyme lactate dehydrogenase (LDH) which is usually 
markedly elevated in patients with PNH, more so than in other haemolytic anaemias 
(Tabarra, 1992; Paquette et al, 1997; Rosti, 2000; Hillmen et al, 2004; Hill et al, 2010b). 
The level of free haemoglobin released by intravascular haemolysis in PNH exhausts the 
ability of haptoglobin to bind to it and the excess free haemoglobin is then free to 
consume nitric oxide (Rother et al, 2005; Hill et al, 2010b). This consumption of nitric 
oxide correlates with the level of free haemoglobin in the plasma in a linear fashion (Hill 
et al, 2010b). 
 
Depletion of nitric oxide causes disruption to the regulation of vascular tone by 
increasing intracellular calcium levels (Rother et al, 2005).  It underlies a number of the 
symptoms seen in PNH, including dysphagia, abdominal discomfort and erectile 
dysfunction, due to smooth muscle dysfuncion (Radomski et al, 1987a; Radomski et al, 
1987b; Murry et al, 1995; Olsen et al, 1996; Przybelski et al, 1996; Moyo et al, 2004; 
Schafer et al, 2004; Rother et al, 2005). Corbin et al originally described the relationship 
between nitric oxide deficiency and erectile dysfunction (Corbin et al, 2002). 
 
1.5.2 Thrombosis 
 
 Thrombosis remains the commonest cause of death in the disease, occurring in 50% of 
patients, with a third of these being fatal (Hillmen et al, 1995; Socié G et al, 1996; de 
Latour et al, 2008). These thromboses predominantly occur in the venous system, often at 
unusual sites, such as the hepatic and cerebral veins (Hillmen et al, 1995). Arterial 
thrombosis accounts for around 15% of thrombotic events seen (Hillmen et al, 1995; 
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Hillmen et al, 2007). There appears to be a greater risk of thrombosis in patients from 
Western countries when compared to the Far East (Nishimura et al, 2004; Parker et al, 
2005). Hall et al reported the risk of thrombosis in English patients with a 50% or greater 
PNH granulocyte clone to be 44%, and those with a less than 50% PNH clone to be 5.8% 
(Hall et al, 2003). Although the risk is far greater in those with larger PNH clones, even 
those with small clones (as low as 10%) have a much higher thrombotic risk when 
compared with the general population (Fowkes et al, 2003; Hill et al, 2007). 
 
The mechanisms underlying thrombotic events in PNH remain unclear and are likely to 
be multifactorial in nature (Hill et al, 2013). Platelet activation is thought to be one of the 
most important causes of thrombosis in PNH (Hill et al, 2007; Hill et al, 2013). CD59 is 
absent from both the surface of both granulocytes and platelets, but unlike granulocytes 
where the affected cells are lysed, platelets do not appear to be consumed (Dixon and 
Rosse, 1977; Devine et al, 1987). Instead these platelets release microparticles with 
excess membrane attack complex by the process of exovesiculation (Wiedmer et al, 
1993). These microparticles are procoagulant in vitro and are readily found in individuals 
with PNH (Hugel et al, 1999). Platelet activation is also thought to occur due to the toxic 
effect of free haemoglobin (Olsen et al, 1996; Rother et al, 2005). 
 
Another important mechanism whereby free haemoglobin leads to platelet activation is 
thought to be by the depletion of nitric oxide (NO). The rate of NO depletion correlates 
with the severity of intravascular hemolysis of which LDH is a sensitive marker (Hill et 
al, 2010b). NO is known to inhibit both platelet aggregation and adhesion by increasing 
cGMP levels (Radomski et al, 1987a; Radomski et al, 1987b). Endothelial cell activation 
and dysfunction is also present in PNH and is likely to increase the risk of thrombus 
formation (Helley et al, 2010; Weitz et al, 2012). Other suggested mechanisms include 
chronic hypofibrinolysis due to a reduction of urinary plasminogen activator receptor (u-
PAR) on leukocytes (Sloand et al, 2006) and the effect of the complement protein C5a, 
which generates inflammatory cytokines (Monk et al, 2007). 
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1.5.3 Renal Dysfunction 
 
Kidney damage is common in patients with PNH affecting around 65% of patients and 
renal failure has been shown to contribute to 8-18% of PNH related deaths (Nishimura et 
al, 2004; Hillmen et al, 2010). The kidneys are the only organs able to remove the cell-
free haemoglobin from the circulation and there are a number of potential factors which 
may contribute to the development of renal disease in patients with PNH. Chronic 
exposure to cell-free plasma haemoglobin as a consequence of intravascular haemolysis 
can lead to renal cortical haemosiderosis and progressive tubulointerstitial inflammation 
(Mulopulos et al, 1986; Tanaka et al, 1993; Rimola et al, 2004). Hill et al evaluated 
patients in a MRI study and showed renal haemosiderosis was present in 9 out of the 10 
cases (Hill et al, 2006b). NO is crucial in maintaining vascular tone throughout the body 
and it is known to have a direct effect on renal afferent arterioles (Schlaich et al, 2008). 
The depletion of NO by cell-free haemoglobin in PNH can therefore have a profound 
direct effect on renal plasma flow and glomerular filtration rate (Delles et al, 2004; 
Schlaich et al, 2008). The occurrence of repeated microvascular thromboses might also 
contribute to the renal damage seen in PNH (Rimola et al, 2004). 
 
1.5.4 Pulmonary Hypertension 
 
Pulmonary hypertension is a complication of haemolytic anaemia that is associated with a 
poor outcome (Norris et al, 1992; Sutton et al, 1994; Castro et al, 2003; Morris et al, 
2003; Gladwin et al, 2004). The uptake of nitric oxide by cell-free plasma haemoglobin 
in PNH leads to endothelial and smooth muscle dysfunction and smooth muscle 
constriction which in turn causes increased pulmonary vascular resistance (Machado & 
Gladwin, 2005; Hu et al, 2010). Hill et al demonstrated elevated levels of N-terminal pro-
brain natriuretic peptide (NTproBNP) and cardiac dysfunction by doppler-
echocardiography in patients with PNH (Hill et al, 2010b; Hill et al, 2012). NTproBNP is 
released by cardiac myocytes in response to stretching of the heart muscles and is 
associated with cardiac failure and elevated pulmonary vascular resistance. 
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1.5.5 Quality of Life 
 
The symptoms that are experienced in PNH have a significant negative effect on the 
quality of life. Complications arise from thromboses, renal dysfunction and pulmonary 
hypertension as described already. However other symptoms such as fatigue, 
haemoglobinuria, dysphagia, recurrent abdominal and chest pain, as well as erectile 
dysfunction and the need for regular blood transfusions also contribute adversely for 
affected individuals, restricting their ability to perform everyday activities (Hillmen et al, 
2004; Rother et al, 2005; Hillmen et al, 2006; Hillmen et al, 2007; Brodsky et al, 2008; 
Hillmen et al, 2010; Hill et al, 2010b; Weitz et al, 2013). Urbano-Ispizua et al reported 
on 524 patients enrolled in the PNH global registry (Urbano-Ispizua et al, 2010) with 
76% of these experiencing fatigue. Meyers et al assessed symptoms in 29 patients with 
PNH (Meyers et al, 2007). Ninety-six percent of these patients reported fatigue with 76% 
describing disruptions in their daily activities and 17% being unable to work due to their 
illness. 
 
1.5.6 Pregnancy 
 
There is little published on PNH in pregnancy. It has been common for pregnancy to be 
discouraged as there is an increase in both maternal and foetal complications and a 
consequent increase in maternal and foetal mortality (Ray et al, 2000; Fieni et al, 2006; 
de Guibert et al, 2011). Maternal complications include thrombosis cytopenias, and 
infections (Ray et al, 2000). Foetal complications relate to preterm delivery, which occurs 
in 29-39% of cases (Fieni et al, 2006; de Guibert et al, 2011). Reported mortality rates 
are high with maternal deaths occurring in 8-11.6% of pregnancies and foetal deaths in 4-
7.2% (Fieni et al, 2006; de Guibert et al, 2011). The majority of thrombotic events 
observed occur in the post-partum period, and in de Guibert’s study all the thromboses 
complicating pregnancy were seen in the post-partum period. There is very little data on 
the use of eculizumab during pregnancy with only 2 cases reported (Danilov et al, 2010; 
Marasca et al, 2010). 
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1.6 Mortality and Treatment prior to Anti-complement Therapy 
 
1.6.1 General Measures 
 
PNH can occur at any age but is usually diagnosed early in the fourth decade (Nishimura 
et al, 2004; de Latour et al, 2008). The life expectancy for individuals with PNH is 
markedly reduced with the median survival from diagnosis being between 10 and 22 
years (Hillmen et al, 1997; de Latour et al, 2008). Until recently the mainstay of 
treatment for patients with haemolytic PNH has been supportive care. Folic acid is 
routinely taken, as in other haemolytic anaemias, in view of their increased red cell 
production as this can cause folate deficiency (Luzzatto and Notaro, 2005). A 
dependency on blood transfusions is common in an effort to alleviate symptoms related to 
anaemia. Some individuals develop iron overload due to the number of blood transfusions 
needed and have required treatment with iron chelation. The majority, however, remain in 
an iron deficient state due to their persistent haemoglobinuria and need to take oral iron 
supplements. 
 
1.6.2 Anticoagulation 
 
Prevention of thrombotic events is important as the first thrombosis observed can either 
be fatal or cause long term morbidity (Audebert et al, 2005; Hillmen et al, 2007). Hall et 
al evaluated the use of warfarin as primary prophylaxis against thrombosis in those with 
large PNH clones (granulocyte clone > 50%), who had not experienced a prior 
thrombosis (Hall et al, 2003). Thirty-nine patients taking warfarin were compared to 56 
patients not taking warfarin. No thrombotic events were observed in the group taking 
warfarin whereas the 10 year thrombosis rate in the group not taking warfarin was 36.5%. 
Two patients in the group taking warfarin experienced significant bleeding with one of 
these dying due to an intracranial haemorrhage. 
 
It is a different scenario once an initial thrombosis occurs. In this setting anticoagulation 
alone is often ineffective in preventing further thromboses (Moyo et al, 2004; Audebert et 
al, 2005). Anticoagulation is not always possible in patients with PNH due to the high 
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incidence of both thrombocytopaenia and of liver dysfunction present. There is also a 
small but significant risk of serious bleeding whilst taking anticoagulant therapies 
(Hollowell et al, 2003). 
 
1.6.3 Allogeneic Bone Marrow Transplantation 
 
An allogeneic bone marrow transplant is the only curative therapy available for people 
with PNH (Hegenbart et al, 2003; Takahashi et al, 2004). However, this is only an option 
for a minority of patients and the risks of treatment related mortality is high. 
 
Saso et al reported the results of an International Bone Marrow Transplant Registry study 
of 57 patients with PNH. Of these 48 were sibling donor transplants, 2 syngeneic, 1 
haploidentical and 6 were matched unrelated donor transplants (Saso et al, 1999).  The 
median survival amongst those receiving sibling donor transplants was 56% at 44 
months. The 2 individuals who received syngenic transplants were both alive at 8 and 12 
years, respectively, post transplant. Only 1 of the 6 patients receiving a matched unrelated 
donor transplant was alive at 5 years. The majority of these transplant related deaths 
occurred due to graft verses host disease.  
 
The development of reduced intensity conditioning (RIC) transplantation in the 1990s has 
led to allogeneic transplantation being a potential therapy for individuals for whom 
transplantation would not been considered (Barrett and Savani, 2006). Farah et al 
described 19 patients treated with RIC transplants. The median survival at 27.5 months 
was 78.9% and there was a high proportion of chronic graft disease seen (78%) (Farah et 
al, 2011). 
 
In 2012 a European Bone Marrow Transplant study of 211 patients with PNH treated 
with allogeneic bone marrow transplantation between 1978 and 2007 was published 
(Peffault de Latour et al, 2012). The overall survival rate at 5 years was 68% and the 
authors concluded that allogeneic bone marrow transplant cannot be considered the 
standard of care for these patients. 
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1.7 The Complement System 
 
Complement is a major part of the body’s innate immune system. It consists of a series of 
closely regulated plasma and membrane proteins. The system, when activated, triggers a 
cascade of enzymatic reactions that leads to chemotaxis, the activation of leucocytes, the 
deposition of complement fragments on the surface of pathological targets and the 
formation of the membrane attack complex (MAC) which has the potential to cause lysis 
of the target cells (Walport, 2001a; Walport, 2001b). Complement can be activated by 
any one of three pathways: the classical pathway, the lectin pathway and the alternative 
pathway (Figure 1.5).  
 
 
 
 
Figure 1.5 The complement cascade adapted from Kelly et al, 2007. 
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The classical pathway is activated when IgG or IgM antibodies bind to antigens forming 
immune complexes. The complement protein C1 then binds to the Fc portion of the 
antibody in the immune complex. Part of the complement protein C1, C1s, cleaves 
proteins C2 and C4 to make a C3 convertase, C4bC2a (Sarma and Ward, 2011). 
 
Activation of the lectin pathway occurs when mannose binding lectins or ficolin 
recognise and adhere to sugar patterns on the surface of pathogens. On binding to the 
pathogen serine proteases are activated, which in turn cleave the complement protein C2 
and C4. These in turn form C4bC2a, a C3 convertase (Sarma and Ward, 2011). 
 
The alternative pathway is continuously active at a low level and is further activated by 
C3b binding to proteins and carbohydrates on the surface of pathogens. Factor D then 
cleaves Factor B which when cleaved forms C3bBb, a C3 convertase (Sarma and Ward, 
2011). 
 
Activation of all three pathways leads to the formation of C3 convertase, which cleaves 
C3. Cleavage of C3 causes opsonisation of pathogens by C3b and C5 convertases, which 
cleave C5 to C5a and C5b. C3a and C5a are potent anaphylotoxins and C5b binds to C6, 
C7, C8 and multimers of C9 to form the MAC on the surface of the pathogen (Sarma and 
Ward, 2011).  
 
Activated complement proteins are quickly converted to inactive forms to stop damage 
occurring to host tissues (Meri and Jarva, 1998). This occurs by a number of different 
membrane bound proteins (Hourcade et al, 1989; Reid and Day, 1989; Morgan, 1995; 
Miwa et al, 2001; Miwa and Song, 2001). C3b and C4b are inactivated by the proteolytic 
enzymes, Factor I and Factor H. C5a is quickly cleaved and inactivated by serum 
carboxypeptidases. 
 
1.7.1 Targeting Complement 
 
Dysregulation or increased activation of complement leads to a wide variety of 
inflammatory and autoimmune diseases, which include systemic lupus erythematosis 
 41 
 
(SLE), atypical haemolytic uraemic syndrome and acute organ rejection, as well as PNH 
(Morgan and Harris, 2003; Mizuno and Morgan, 2004). The idea of targeting 
complement as a treatment for complement-mediated disorders is attractive as 
uncontrolled complement activation is central to many conditions.  
 
Initial work focused on the serine proteases (CR1, C1s, C2a, MASP-1, MASP-2, factor 
D, factor B and factor I) (Narayana et al, 2000). Unfortunately due to a lack of specificity 
and limited drug half-lives meant that this early work has not provided potential therapies 
(Ricklin and Lambris, 2007). The exception to this is for inhibition of C1 for the 
treatment of hereditary angioedema (Agostoni et al, 1980).  
 
Soluble complement regulatory proteins have also been evaluated as potential targets, 
including human complement receptor 1 (CR1) (Weisman et al, 1990), membrane 
cofactor protein (Christianson et al, 1996), CD55 (Moran et al, 1992) and CD59 (Sugita 
et al, 1994). The main problem with this strategy remains the short half-life of these 
proteins in the fluid phase. 
 
In order to overcome this issue a number of strategies have been tried (Harris et al, 
2002a; Holland et al, 2004; Brook et al, 2005; Ricklin and Lambris, 2007). A truncated 
form of soluble CR1 was developed by the addition of sialyl Lewis to soluble CR1 
(Rittershaus et al, 1999). This truncated form also binds to selectins, whose expression is 
up-regulated in stroke and lung injury, and showed increased protection of the 
reperfusion injury in stroke in rats when compared to CR1 alone (Huang et al, 1999) and 
in a rat model of lung injury following complement activation by cobra venom (Mulligan 
et al, 1999). A similar strategy of adding a membrane targeting moiety on both CR1 
(APT070) and CD59 (Smith and Smith, 2001, Fraser et al, 2003) have been reported. 
APT070, the truncated version of CR1, is significantly more active than CR1 alone and 
of benefit in arthritis in rat models (Linton et al, 2000). An alternative method for 
targeting a specific cell membrane is by attaching soluble complement regulatory proteins 
to the C-terminus of antibody fragments. CD59 and CD55 have been attached using this 
method (Zhang et al, 1999; Zhang et al, 2001). This method may allow specific targeting 
of active inflammation. An alternative way to deliver soluble complement regulatory 
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proteins to specific tissues involves the fusion of CD55 or CD59 to immunoglobulin Fc 
domains. (Fearon, 1991; Harris et al, 2002b). Using this method the half-life is 
significantly increased and a benefit was demonstrated in a rat model (Harris et al, 
2002b).  This method was enhanced further by using a prodrug with low complement 
regulatory activity that is cleaved at sites of inflammation to release the active regulator 
(Harris et al, 2003). 
 
Small molecule synthetic compounds are increasingly being assessed as potential 
therapies (Holland et al, 2004). These molecules are effective, have little or no toxicity in 
animal models and are likely candidates for the treatment of complement-mediated 
disorders. Small molecule inhibitors or antibodies against C5a may also have a role in 
specifically targeting C5a, which acts as a potent anaphylatoxin (Finch et al, 1999; 
Strachan et al, 2001; Laudes et al, 2002; Woodruff et al, 2005). Specifically targeting 
C5a allows the inflammatory effects of C5a to be inhibited without interrupting the 
overall function of the complement cascade (Wong et al, 1999; Allegretti et al, 2005; 
Proctor et al, 2006). In cases of sepsis there is a marked increase in C5a production and 
up-regulation of C5a receptors in the lung, liver, heart and kidneys, which when bound to 
C5a is associated with multi-organ failure (Riedmann et al, 2002). This increase in C5a 
can also lead to impaired neutrophil function from excessive neutrophil activation 
(Huber-Lang et al, 2002). The development of a specific antibody against C5a has the 
potential to prevent the damaging effects of C5a in septic shock whilst leaving the MAC 
unaffected to target the infecting cells in this group of critical patients (Ward et al, 2012). 
 
1.7.2 Anti-Complement Strategies in PNH 
 
Two potential strategies for treating PNH have been considered. Direct replacement of 
CD59 and targeting the elements that constitute the MAC to disrupt its formation.  
 
1.7.3 CD59 Replacement 
 
CD59 is the main complement regulatory protein responsible for protecting erythrocytes 
from complement attack (Holguin et al, 1989a; Wilcox et al, 1991). Replacing CD59 on 
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the surface of PNH cells would not only protect the cells form complement damage but 
would also not interfere with the defensive functions of the complement pathway. Soluble 
recombinant CD59, deficient of the carboxyl terminal, which is required for attachment 
to the GPI anchor, has been shown to inhibit complement driven haemolysis of guinea 
pig erythrocytes (Sugita et al, 1994). Although the level of this inhibition was 100 times 
lower than that of CD59 on the surface of erythrocytes, Holguin et al has previously 
showed that even low levels of CD59 on the surface of erythrocytes can prevent 
haemolysis in vitro (Holguin et al, 1989b). Soluble CD59 is rapidly filtered and excreted 
by the kidneys due to its low molecular weight (Sugita et al, 1994). GPI-linked proteins 
are able to reinsert into cell membranes (Dunn et al, 1996; Babiker et al, 2002) and PNH 
erythrocytes have been shown to develop resistance to haemolysis when incubated with 
normal erythrocytes in vitro, due to this phenomenom (Holguin et al, 1989b). 
Recombinant transmenbrane CD59 has been shown to inhibit complement-mediated 
haemolysis in vitro in a GPI deficient cell line (Rother et al, 1994). This strategy has been 
further tested using recombinant CD59 in a mouse model of PNH (Hill et al, 2006c).  
Administration of recombinant CD59 to the mice resulted in sufficient CD59 on the 
mouse erythrocytes to prevent complement-mediated damage. This therapeutic approach 
for treating PNH has not been developed further due to the successes of the anti-
complement antibody therapy, eculizumab. 
1.7.4 Eculizumab 
 
The complement protein C5 is an ideal point in the complement system to target in PNH 
as all 3 activation pathways come together to cleave C5 into its active components, C5a 
and C5b (Figure 1.5). Importantly by targeting C5, the function of the proximal 
components of complement, ending in the cleavage of C3 to form C3b remains intact. 
Individuals with inherited deficiencies of proximal complement are prone to develop 
autoimmune disease such as systemic lupus erythematosis and glomerulonephritis (Ross 
and Densen, 1984). Deficiency of C3 leads to recurrent infections with polysaccharide-
coated bacteria and increased mortality early in life (Ross and Densen, 1984; Sjoholm, 
1990; Overturf, 2003; Daha, 2010). Inherited deficiencies of terminal complement are 
only associated with an increased frequency of infection with Neisseria meningitidis and 
Neisseria gonorrhoeae (Ross and Densen, 1984; Sjoholm, 1990; Daha, 2010).  
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Eculizumab is a 148 kilodalton molecule. It is composed of murine complementary 
determining regions within human germline framework regions and IgG2 and IgG4 
heavy chain constant regions (Figure 1.6) (Rother et al, 2007). It is a humanised 
monoclonal antibody, which specifically binds to the complement protein C5 with a high 
affinity, blocking its cleavage to C5a and C5b (Thomas et al, 1996).  It therefore prevents 
the assembly of the terminal components of the complement cascade (C5b-C9) and stops 
the release of the pro-inflammatory molecule C5a (Figure 1.7).  
 
 
 
 
Figure 1.6 Structure of the monoclonal antibody eculizumab. 
 
 
 
There are no good animal models of PNH. PIG-A deficient mice do not develop clonal 
expansion of PNH-like cells. One clear explanation for the failure to develop a PNH like 
syndrome is that these mouse models do not have underlying bone marrow failure or 
immune insult (Jasinski et al, 2001; Rosti, 2002). In order to assess the ability of an anti-
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C5 antibody in blocking terminal complement in vivo, a surrogate anti-C5 mouse 
antibody, BB5.1 was used in an arthritis mouse model with a significant reduction in 
terminal complement activation (Wang et al, 1995). This work was followed by human 
clinical studies using eculizumab in rheumatoid arthritis, SLE and membranous 
nephropathy (Jain et al, 1999; Tesser et al, 2001; Appel et al, 2002; Rother et al, 2004). 
Although the response to eculizumab in these studies was disappointing, it provided 
information on dosing and safety in humans (Tesser et al, 2001; Rother et al, 2007). 
 
 
 
 
Figure 1.7 Action of eculizumab. 
 
 
1.7.5 Eculizumab Clinical Studies in PNH 
 
The first study evaluating eculizumab in PNH commenced in 2002. This pilot study of 11 
patients with haemolytic PNH was the first study to show beneficial outcomes for 
patients with this disease (Hillmen et al, 2004). This 12-week open label study showed a 
reduction in intravascular haemolysis and an increase in the proportion of type III 
erythrocytes present. The mean transfusion rate reduced from 2.1 to 0.6 units per patient 
per month. There was also both a 96% reduction in the number of haemolytic episodes 
that occurred, as well as a dramatic improvement in quality of life, as assessed using a 
validated quality of life questionnaire (EORTC QLQ-C30). Treatment was given as an 
infusion of 600mg of eculizumab weekly for the first 5 weeks followed by 900mg of 
eculizumab every 14 days. This regime has remained as the standard for treating patients 
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with eculizumab. The drug was safe and well tolerated with reported adverse events 
being similar to those reported in patients either on eculizumab or on placebo in other 
clinical trials. 
 
The pivotal report using eculizumab in PNH is that of the TRIUMPH study (Hillmen et 
al, 2006). TRIUMPH was a multinational, multicentre, double blinded study, comparing 
eculizumab to placebo over a 26 week period in 87 patients with PNH. Inclusion criteria 
included age >18 years old, a type III PNH erythrocyte clone of 10% or greater, a platelet 
count of >100 x 109/L, an LDH level of 1.5 times the upper limit of the normal reference 
range and being transfusion dependent – defined as requiring at least 4 transfusions in the 
preceding 12 months. These patients then underwent a 13 week screening period and if 
they required a transfusion during this period they were considered eligible for the study. 
Primary endpoints were stabilisation of haemoglobin levels and transfusion requirements. 
Secondary endpoints included transfusion independence, reduction of haemolysis 
evaluated by LDH levels and changes in fatigue using the Functional Assessment of 
Chronic Illness Therapy-Fatigue (FACIT-Fatigue) score and quality of life questionnaire 
(EORTC QLQ-C30). Stabilisation of haemoglobin levels was observed in 49% of the 
eculizumab treated group but not in any of the placebo group. At the 26th week of the 
study the mean number of units of blood transfused was significantly reduced in the 
eculizumab group compared in the placebo group (3 verses 11, respectively). Fifty-one 
percent of patients on eculizumab remained transfusion independent for the duration of 
the study whereas all of the placebo group needed transfusions. LDH levels, used as a 
marker of intravascular haemolysis fell to, and remained at near normal levels, in the 
eculizumab group and both fatigue and quality of life scores were significantly improved 
in those receiving eculizumab. 
 
The SHEPHERD study followed on from TRIUMPH and was open to a more diverse 
group of patients with PNH (Brodsky et al, 2008). The inclusion criteria included age 
>18 years old, a type III PNH erythrocyte clone of 10% or greater, a platelet count of > 
20 x 109/L, an LDH level of 1.5 times the upper limit of the normal reference range and 1 
transfusion in the preceding 24 months for anaemia or personal beliefs not allowing 
transfusions. Ninety seven patients were treated with eculizumab for 52 weeks with a 
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significant reduction in intravascular haemolysis as measured by LDH levels, a 52% 
reduction in transfusion requirements with 51% of patients becoming transfusion 
independent during the study, increased haemoglobin levels and significant improvement 
in fatigue scores. 
 
The patients that entered all these 3 clinical studies were evaluated as a common group to 
try to determine the effect of eculizumab on the occurrence of thrombosis, the most 
feared complication in PNH (Hillmen et al, 2007). The thrombotic event (TE) rate from 
diagnosis to starting eculizumab was compared with the TE rate since starting 
eculizumab. Although these time periods are not closely matched in duration the TE rate 
fell from 7.37 events/100 patient-years prior to eculizumab to 1.07 events/100 patient-
years on eculizumab therapy. 
 
Similarly renal function was assessed in patients from the 3 trials (Hillmen et al, 2010). 
Renal dysfunction or damage was observed in 64% of the study population at baseline 
with 21% of patients having moderate to severe kidney dysfunction, stage 3-5 chronic 
kidney disease (CKD), as described by the National Kidney Foundation (Levey et al, 
2003). An improvement in CKD score was observed in 34% of patients over an 18 month 
period. Most of the improvement occurred in those with stage 1 and 2 CKD. In the cases 
of stage 3-5 CKD the renal function remained stable in most instances but there was an 
improvement in the CKD score in 23% of patients over the 18 month period. This 
observed stabilisation of renal function is important as kidney failure in PNH is the 
second highest cause of death (Nishimura et al, 2004; Hillmen et al, 2010). The 
improvement in estimated glomerular filtration rate in some patients is likely to be due to 
the increased availability of nitric oxide causing a reduction in the vascular resistance of 
the afferent renal arterioles. 
 
Pulmonary hypertension in PNH is also improved by eculizumab treatment. Hill et al 
showed both a 50% reduction in serum NTproBNP levels after only 2 weeks of 
eculizumab therapy and a reduction in dyspnoea in the TRIUMPH study patients (Hill et 
al, 2010b).  
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There is an increased risk of meningococcal infection in patients on eculizumab therapy 
as it prevents the formation of the MAC. All individuals treated should be both educated 
about the signs and symptoms of meningococcal sepsis and be vaccinated against 
meningococcal infection with a quadravalent vaccine against serotypes A,C,W and Y to 
try to minimise this risk. The prevention of MAC formation in patients treated with 
eculizumab means that PNH erythrocytes are increasingly bound by C3 fragments 
causing an increase in C3-mediated extravascular haemolysis (Risitano et al, 2009; Hill et 
al, 2010a). In most cases this phenomenon does not cause observed clinical 
consequences. 
 
 
1.8 Pathogenesis 
 
1.8.1 Bone Marrow Failure 
 
There is a strong association between bone marrow failure, usually AA and PNH 
(Dameshek, 1967; Young, 1992; Griscelli-Bennaceur et al, 1995; Schrezenmeier et al, 
1995). It is likely that PNH only develops on a background of bone marrow failure, 
where there is an environment that allows the PNH clone to expand (Araten et al, 1999; 
Mukhina et al, 2001). Bone marrow failure may either precede PNH or the 2 conditions 
may be present at the same time (Hillmen et al, 1995; Nargarajan et al, 1995; Socie et al, 
1996). 
 
There is no evidence that GPI deficient cells have an intrinsic survival advantage over 
normal cells (Mukhina et al, 2001; Araten et al, 2002). Both in vitro and in vivo 
experiments have failed to show a proliferative advantage in PIG-A inactivated 
haemopoietic stem cells (Kawagoe et al, 1996; Rosti et al, 1997; Tremml et al, 1999). An 
intrinsic advantage would also not explain why a proportion of cases spontaneously 
recover (Hillmen et al, 1995). A cell extrinsic effect is therefore likely to explain the 
preferential development of PNH clones concurrent with bone marrow failure 
(Maciejewski et al, 1997; Young et al, 2002).  
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While the aetiology of AA is often poorly defined, a primary role for immune mediated 
destruction of haemopoietic marrow elements is generally accepted (Young et al, 2008). 
Consequently one of the main treatment modalities used in AA are immunosuppressive 
agents. The success of these therapies supports the proposed immune aetiology. 
Furthermore in vitro experiments demonstrate that removal of T-cells from aplastic bone 
marrow improves the number of colonies formed in tissue culture, and on adding these to 
normal bone marrow in culture, haematopoiesis was reduced (Young, 2000). Analysis of 
these T-lymphocytes has identified them as activated cytotoxic T-cells (CTL) (Sloand et 
al, 2002). Regulatory CD4+ T-cells are reduced in numbers at diagnosis in most cases of 
AA (Solomou et al, 2007). The cause of CTL activation in AA is unknown but drug 
exposure and viral infection are potential candidates. The role of immune activation in 
AA leads to the hypothesis that immune evasion is a mechanism for the emergence of the 
PNH clone. 
 
Investigators have reported PNH clones being present in over 50% of individuals with 
AA (Schubert et al, 1994; Tichelli et al, 1994; Dunn et al, 1999; Mukhina et al, 2001, 
Wang et al, 2002). The two most recent studies looking at this used high sensitivity flow 
cytometry and found PNH clones in as low as 26% in 1 study of 357 patients with AA 
(Movalia et al, 2011) and as high as 70% in a different analysis of 413 AA patients 
(Galili et al, 2009). It is not clear why only a small proportion of patients with AA and a 
PNH clone go on to develop symptomatic PNH. 
 
1.8.2 Mutations in Normal Individuals, Other Conditions and in the Context of 
Antibody Therapy 
 
Loss of surface GPI molecules due to PIG-A mutations has been identified by flow 
cytometry in granulocytes, lymphocytes and erythrocytes of normal individuals at very 
low levels (Araten et al, 1999; Ware et al, 2001; Hu et al, 2005). The PIG-A mutated 
cells in unaffected individuals also have been show to be transient in nature (Araten et al, 
1999). Hu et al isolated colony forming cells (CFC) from CD34+ bone marrow or from 
peripheral blood after stem cell mobilisation. PIG-A mutations in the CFCs from controls 
were polyclonal, and did not involve T-cells. These findings suggest that the occurrence 
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of a PIG-A mutation by itself is not enough to cause PNH and that these mutations may 
occur in differentiated progenitor cells rather than HSCs. The cells with PIG-A mutations 
present in normal individuals are present at a much lower level than those seen in 
subclinical PNH, discussed above, which are associated with bone marrow failure. This 
indicates that bone marrow failure itself provides a specific environment allowing the 
PNH clone to expand (Araten et al, 1999; Hu et al, 2005; Richards et al, 2007).     
 
Small PNH-like populations of erythrocytes have been described in other haematological 
disorders (Meletis J et al, 1997; Meletis et al, 2001; Varma et al, 2012). However, these 
populations have not been shown to be true “PNH” cells. The majority isolated have been 
shown to be deficient of CD55. Rarely are they also deficient of CD59 and none of the 
individuals had symptoms associated with PNH. It is not clear why these populations 
occur or their significance, but CD55 appears to be lost as a surface protein on some 
erythrocytes in malignant haematological conditions (Seya et al, 1994). 
 
Campath-IH is a monoclonal antibody directed against CD52, a GPI anchored surface 
antigen, which is mainly expressed on lymphocytes, monocytes and macrophages. It 
works by inducing both complement dependent lysis and antibody dependent cellular 
cytotoxicity (ADCC) (Xia et al, 1993). Campath-IH is has been used in the treatment of 
lymphoid malignancies and autoimmune disorders, and in bone marrow transplant 
conditioning regimes. Following Campath-IH therapy, GPI deficient T-lymphocytes have 
been identified (Hertenstein et al, 1995; Taylor et al, 1997). The presence of an 
abnormally large number of T-cell clones in a patient with a confirmed PIG-A mutation 
suggests that the genetic hallmark of PNH also provides a means for lymphocytes to 
escape the immune attack from Campath-IH treatment. 
 
Rawstron et al proposed that PIG-A mutations are present in a large proportion of the 
population at a level where they are not detectable by flow cytometry (Rawstron et al, 
1999). They looked at the emergence of GPI deficient T-lymphocytes in patients with 
chronic lymphatic leukaemia (CLL) treated with Campath-IH and demonstrated the 
presence of PIG-A mutations in these cells. These affected lymphocytes were evident 
soon after treatment and only occurred in the presence of the selective pressure mediated 
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by Campath-IH treatment. This supports the theory that in order to develop PNH, an 
individual needs to have a HSC with a PIG-A mutation, but then there needs to be a 
selective advantage for the PNH clone to expand.  
 
 
1.9 Clonal Expansion 
 
1.9.1 Multiple Clones and Clonal Dominance 
 
Some patients with haemolytic PNH have bee shown to have multiple PNH clones 
detectable (Bessler et al, 1994; Endo et al, 1996; Nishimura et al, 1997). Multiple clones 
are also found in those with PNH who have co-existing AA (Mortazavi et al, 2003). Endo 
et al. also reported other features in relation to the presence of multiple clones (Endo et 
al, 1996). Their study identified four PIG-A mutations in one PNH patient and they 
proposed that the phenotypic mosaicism was due to genotypic mosaicism. They 
hypothesised that this genotypic mosaicism was due to hypermutability of the PIG-A 
gene. The mutation rate of the PIG-A gene has since been reported to be normal (Araten 
and Luzzatto, 2006).  
 
In cases where multiple clones are present in a patient, one of these often makes up the 
majority of mature PNH cells. This domination of a single clone may be due to only one 
of the clones developing in the HSC pool (Traulsen et al, 2007), whereas the others are 
generated later during haemopoiesis in progenitor cells. Alternatively, accumulation of a 
dominant clone may reflect that an additional factor, not related to the PIG-A mutation, is 
responsible for clonal expansion. 
 
1.9.2 Hypotheses of Clonal Expansion 
 
Despite dramatic improvements in treating haemolytic PNH, the underlying process that 
determines the expansion of PNH clones remains unclear. Occurrence of a PIG-A mutant 
clone is not sufficient for development of PNH, since these occur frequently in the 
normal population (Araten et al, 1999). In view of the association with bone marrow 
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failure, and especially AA, it is likely that expansion of the clone is immune mediated. 
The simplest theory is that the immune attack in AA requires a GPI-linked protein and 
that absence of one of these proteins protects PNH cells from attack. Consequently in the 
absence of a PIG-A mutant clone an affected individual would present with AA, but in 
the presence of a PIG-A mutant clone haemopoiesis is rescued and the individual presents 
with PNH, the clinical manifestations of PIG-A deficient haemopoietic cells. An 
alternative to this might involve a GPI linked protein working to suppress cell growth. 
Absence of such a protein could provide the basis for clonal expansion. Such a model 
however does not readily explain the link with aplastic anaemia, the failure of PNH 
clones to become dominant in normal individuals, and the lack of intrinsic proliferative 
advantage in vitro. 
 
A two stage model for disease pathogenesis has bee proposed whereby clonal selection 
and clonal expansion occur by two separate events (Inoue et al, 2003) (Figure 1.8). In this 
model clonal selection relates to the PIG-A mutation, occurring in the setting of bone 
marrow failure with clonal expansion being due to a separate mutation within the PIG-A 
mutated HSC, which confers a proliferative advantage. Using mathematical modeling, 
Traulsen et al showed that the likelihood of 2 separate independent genetic mutations 
occurring as causative factors in PNH are remote, due to both the small size and the slow 
rate of replication of the active HSC pool available (Dingli and Pacheco, 2006; Traulsen 
et al, 2007). Another potential mechanism that has been proposed was that lack of GPI 
molecules on PNH cells renders cells resistant to apoptosis (Brodsky et al, 1997).  
 
1.9.3 Animal Models of PNH 
 
It has been difficult to create an animal model of PNH in the mouse. GPI-anchored 
proteins are essential for early development in mice and inactivation of the PIG-A gene in 
mice embryonic stem cells is a lethal event (Kawagoe et al, 1996; Rosti et al, 1997). 
Restriction of PIG-A inactivation to haemopoietic stem cells allows for GPI-deficient 
blood cells to be produced but these mice do not experience haemolysis or a tendency to 
develop thrombosis (Murakami et al, 1999; Tremml et al, 1999; Keller et al, 2001). Mice 
have a transmembrane complement regulatory protein, CRRY, that is not expressed in 
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humans, which may explain why, when murine erythrocytes are deficient of GPI-linked 
proteins the PNH phenotype is not observed (Miwa et al, 2002). 
 
 
 
 
 
Figure 1.8 A representation of the two hit hypothesis leading to expansion of PNH 
stem cells. 
 
1.9.4 Potential Mechanisms Mediating HSC Destruction 
 
There is a strong likelihood of an immune mediated cause for PNH. Human leukocyte 
antigens (HLA) mediate antigen presentation to T-lymphocytes and particular haplotypes 
are associated with susceptibility to autoimmunity. HLA-DR2 (Maciejewski et al, 2001) 
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and, more recently, other specific class I and class II alleles have been shown to occur at 
a significantly higher frequency in patients with PNH (Lombardi et al, 2008; Nowak et 
al; 2010; Nowak et al, 2013). Thus, these patients may have a genetic context that 
favours the development of immune activation, bone marrow injury and expansion of 
PIG-A mutant clones. 
 
1.9.5 Humoral Antibody Dependent Cell Mediated Cytotoxicity (ADCC) and 
Complement 
 
Humoral ADCC is mediated by B-lymphocytes that secrete specific antibodies against 
antigens on bacteria or virally infected cells. These antibodies bind to the target cell 
allowing recognition and lysis by monocytes and natural killer (NK) cells (Delves and 
Roitt, 2000). The presence of antigen bound by antibodies will also activate the 
complement cascade via the classical pathway, which leads to formation of MAC and 
subsequent cell lysis. There is no evidence suggesting abnormal ADCC in PNH although 
if autoantibodies against HSCs were found to be present and PNH HSCs were less 
susceptible to these antibodies, this would provide a mechanism for expansion of the 
PNH clone. 
 
 1.9.6 Cell Mediated Immunity and Natural Killer (NK) cells 
 
Cell-mediated immunity involves the activation of NK cells, macrophages and antigen-
specific cytotoxic T-lymphocytes (CTLs). CTLs recognize antigen by their T-cell 
receptor and target the cell for destruction (Delves and Roitt, 2000). This destruction can 
occur by secretion of perforin, which forms a transmembrane pore similar to the MAC in 
complement activation, or by other enzymes that damage the target cell or by the release 
of lymphokines that interact with the target cell to induce apoptosis. 
 
Direct evidence suggests that auto-reactive T-cells in PNH may attack non-PNH HSCs 
and spare PNH HSCs (Karadimitris and Luzzatto, 2001; Murakami et al, 2002; Poggi et 
al, 2005). Although Poggi et al did not observe any difference in the proportion of T-cells 
expressing NK receptors when compared to normal controls it has been since reported 
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that CD8+ T-cells, specifically expressing the NK activating receptors, KIR2DS4, 
NKG2C and NKG2D, are present in increased numbers in the bloodstream in people with 
PNH (Poggi et al, 2005; van Bijnen et al, 2011). Further evidence of a potential role for 
CD8+ CTLs was seen by increased reactivity of these CTLs to antigen presenting cells 
loaded with GPI (Gargiulo et al, 2013). The reactivity of these GPI-specific CTLs was 
dependent on the expression of CD1d, which is present on HSCs (Kotsianidis et al, 2006; 
Broxmeyer et al, 2012). This would potentially account for the bone marrow failure that 
can co-exist in PNH and allow for expansion of the PNH clone. 
 
Large granular lymphocytes (LGL), which include NK cells, are lymphocytes that make 
up 10-15 % of normal mononuclear cells. LGL clones have been found in patients with 
PNH (Risitano et al, 2005). Similar to pure red cell aplasia where LGLs have been shown 
to inhibit the growth of eyrthroid precursors (Handgretinger et al, 1999), in PNH these 
LGLs may target non-PNH HSCs (Karadimitris et al, 2001).  
 
NK cells represent a subset of large granular lymphocytes, which act to recognize virally 
infected cells, but lack expression of rearranging antigen receptor genes (Delves and 
Roitt, 2000). Instead NK cell activation is triggered by a combination of reduced major 
histocompatability complex (MHC) class I expression, and a shift in balance between 
activating and repressing surface glycoproteins on virally infected cells. The shift in 
balance of activating and repressing signals allows NK cells to distinguish infected and 
non-infected cells. Upon activation NK cells release granules into the space adjacent to 
the target cell. The most important enzyme released in this way is perforin, which as for 
CD8+ CTLs, mediates cell lysis. 
 
NK cell mediated cytotoxicity may also play an important role in the pathogenesis of 
PNH. Killer immunoglobulin-like receptors (KIR) are involved in regulation of the CTL 
response and may be expressed differently in PNH than in normal controls (Cosentini et 
al, 2012). This differential expression of KIR genes may have a role in the pathogenesis 
of PNH. GPI-positive NK cells in PNH patients have been shown to express the 
transmembrane activating receptor CD160. This receptor is only expressed as a GPI-
linked protein in normal controls. CD160 is an MHC class I receptor and it inhibits 
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interferon-γ, secreted by PNH lymphocytes (Giustiniani et al, 2012). This has also been 
proposed as a potential mechanism allowing selection of the PNH clone. 
 
Cytomegalovirus glycoprotein UL16 binding proteins (ULBP) are GPI-linked inducible 
proteins present on the surface of cells that are up-regulated during periods of stress such 
as infection (Cosman et al, 2001; Rölle et al, 2003). Hanaoka et al reported expression of 
ULBPs on blood cells expressing GPI antigens in patients with PNH but not on blood 
cells from normal controls (Hanaoka et al, 2006). The presence of these ULBPs could 
allow NK cell killing of these cells providing a selective advantage for PNH blood cells 
in these patients. Interestingly, ULBPs were expressed on non-PNH cells in these patients 
for years after their initial diagnosis was made. 
 
1.9.7 The Wilms Tumour Gene 
 
The Wilms Tumour Gene (WT1), located on chromosome 11, is thought to be expressed 
in CD34+ HSCs but not in CD34- progenitors (Shichishima et al, 2002). The WT1 
protein is involved in regulating HSC growth and development. MDS represents a 
qualitative defect in haemopoietic stem cells resulting in underproduction in one or more 
type of blood cells, which may develop into acute leukaemia. WT1 expression in MDS 
appears to correlate with disease progression, indicating that it may be involved in the 
pathophysiology of bone marrow failure syndromes (Tamaki et al, 1999). WT1 mRNA 
expression in patients with PNH is significantly higher in both GPI+ and GPI- cells than 
that found in either AA or in healthy control subjects (Tamaki et al, 1999), with the PNH 
cells also showing significantly higher WTI RNA levels in the PNH cells than the non-
PNH cells. WT1 expression is known to induce a WT1 peptide specific CTL response 
(Oka et al, 2000). In a study by Ikeda et al., PNH patients were shown to have increased 
WT1 peptide specific CTLs and in their cytotoxicity assays there was a greater reduction 
in colony formation from bone marrow normal CD34+CD59+ MNCs (80%) in contrast 
to PNH CD34+ CD59- MNCs (10%). The authors suggested that this may provide a 
relative growth advantage to PNH cells (Ikeda et al, 2007), although why WT1 peptide 
specific CTLs should provide PNH cells with a survival advantage is unclear. 
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1.9.8 Secondary Genetic Mutations – HMGA2 
 
In accord with the two-step model for PIG-A mutant clonal expansion proposed by Inoue 
et al aberrant expression of the high mobility group protein A2 (HMGA2, previously 
known as HMG1-C) in haematological progenitors has been proposed as a mechanism for 
clonal expansion in PNH (Inoue et al, 2006). HMGA2 is an architectural transcription 
factor which attaches to AT-rich regions of DNA by three specific binding domains 
called AT hooks (Reeves, 2001). Upon binding to DNA, both HMGA2 itself and the 
DNA undergo conformational changes. The number and frequency of AT rich sequences 
in the bound DNA determines the effect that HMGA2 will have (Cleynen and Van de 
Ven, 2008). HMGA2 also binds proteins and induces conformational changes in its 
binding partners. As many of these are transcription factors, HMGA2 can influence gene 
expression by this second mechanism (Cleynen and Van de Ven, 2008). 
 
HMGA2 is thought to be involved in growth regulation and development and is expressed 
at very high levels during fetal development (Rogalla et al, 1996). In normal adult blood 
cells, HMGA2 is only present at very low levels (Rogalla et al, 1996). Over-expression of 
HMGA2 has been observed in neoplastic cells including stomach, breast, pancreas, lung, 
oral squamous cell carcinoma and sarcoma (Berner et al, 1997; Rogalla et al, 1997; Abe 
et al, 2003; Miyazawa et al, 2004; Meyer et al, 2007a; Motoyama et al, 2008). In these 
cases, there is an increased expression of normal HMGA2 protein (Cleynen and Van de 
Ven, 2008). Abnormal HMGA2 expression is more commonly seen in benign 
mesenchymal tumours where translocation of HMGA2 leads to expression of aberrant 
fusion genes (Ashar et al, 1995; Schoenmakers et al, 1995; Geurts et al, 1997; 
Kazmierczak et al, 1999; Mine et al, 2001, Nucci et al, 2001).  
 
Increased HMGA2 expression has also been implicated in some cases of haematological 
malignancy. There have only been a small number of cases reported. A high grade 
transformation in CLL, a case of acute myeloid leukaemia and another of acute lymphatic 
leukaemia, all with chromosome 12 translocations affecting the HMGA2 locus (Santulli 
et al, 2000; Pierantoni et al, 2003; Nyquist et al, 2012). Upregulation of HMGA2 
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expression has also been identified at the time of transformation in chronic myeloid 
leukaemia from chronic phase to blast crisis (Meyer et al, 2007b). Similarly, 
translocations affecting the HMGA2 gene have been identified in two patients with 
myelofibrosis with myeloid metaplasia (Andrieux et al, 2004) and in a case series of six 
patients with MDS (Odero et al, 2005). 
 
Increased expression of HMGA2 was initially reported in two individuals with PNH 
(Inoue et al, 2006). These patients had moderate to large granulocyte PNH clones (55-
60% and 88%) with haemolytic PNH. Chromosome 12 abnormalities were detected in 
both patients, with the HMGA2 gene being disrupted at exon 5. The first patient had an 
18.5mbp fragment translocated from one chromosome 12 into the other at the HMGA2 
locus. The second patient had an intra-chromosomal insertion. In both cases there was 
increased expression of HMGA2 mRNA in the bone marrow from the rearranged alleles. 
Murakami et al evaluated HMGA2 expression in blood and bone marrow samples of 25 
patients with PNH (Murakami et al, 2012). HMGA2 mRNA was found to be elevated in 
the peripheral blood but not in the bone marrow. As HMGA2 has been shown to play a 
role in regulation of cell growth and potentially tumourigenesis, it represents a good 
candidate gene responsible for the clonal expansion in PNH.  
 
In idiopathic myelofibrosis abnormal expression of HMGA2 occurs and is dependent on 
the presence of janus kinase 2 (JAK2) mutations (Guglielmelli et al, 2007).  JAK2 is a 
cytoplasmic tyrosine kinase involved in signal transduction in response to haemopoietic 
growth factor receptors, such as erythropoietin. JAK2 mutations have been implicated as 
the causative mutation in myeloproliferative disorders, providing the affected clones with 
a growth advantage (Baxter et al, 2005; James et al, 2005). The occurrence of a JAK2 
mutation as a secondary genetic mutation in PNH could explain HMGA2 expression and 
clonal expansion in the disease.  
 
1.9.9 Apoptosis 
 
One mechanism whereby GPI-deficient cells might receive a relative growth advantage 
over their normal counterparts is by the PIG-A mutation causing increased resistance to 
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apoptosis. This hypothesis is supported by a number of in vitro studies that showed GPI-
deficient myeloid cells are relatively resistant to apoptosis (Brodsky et al, 1997; Chen et 
al, 2000; Chen et al, 2002; Ismail et al, 2003; Kunyaboon et al, 2012). However, further 
studies have failed to confirm this (Ware et al, 1998; Yamamoto et al, 2002). 
 
 
1.10 Haematopoietic Stem Cell Immunophenotype and Long Term Bone Marrow 
Culture (LTBMC) Studies 
 
1.10.1 Early Progenitor Cells 
 
A key question in the pathogenesis of PNH is the stage of haemopoiesis at which the 
PIG-A mutation occurs. This is particularly the case given the suggestion that the 
sporadic PIG-A mutant clones that occur in normal individuals may be derived from 
committed progenitors. Terstappen et al evaluated CD55 and CD59 expression on normal 
blood and bone marrow cells by flow cytometry in the early 1990s (Terstappen et al, 
1992; Terstappen et al, 1993). They looked at CD55 and CD59 expression on different 
cell types including early progenitor cells that they defined as CD34+ CD38- cells. In 
normal subjects, there was a uniform expression of these proteins, which has also been 
confirmed by Maciejewski et al (Maciejewski et al, 1997). This evaluation was also 
performed on bone marrow samples from two patients with PNH (Terstappen et al, 
1993). Their CD34+ CD38- cells showed two distinct populations, one with a normal 
expression and the other with a complete absence of CD55 and CD59. The above studies 
were performed on very limited numbers of patients and to date there have been no other 
reports looking at progenitor cells in PNH.  
 
1.10.2 Long Term Bone Marrow Cultures in PNH and AA 
 
Long Term Bone Marrow Culture (LTBMC) provides an in vitro model for examining 
the underlying aetiology in both PNH and AA. Bone marrow cells, if provided with the 
correct environment (i.e. temperature and growth factors), can be maintained for a 
number of weeks in vitro (Dexter, 1979). The use of LTBMC therefore provides an 
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opportunity to study patterns of growth of bone marrow from patients with PNH 
compared to those without the disease in order to determine the underlying events that 
allow expansion of PNH clones in vivo. Once the underlying cause of the relative 
expansion of the PNH clone is known, future therapies can be directed to stop clonal 
expansion and support re-expansion of normal haemopoiesis. 
 
The first study of AA bone marrow cells in LTBMC demonstrated that both mature and 
committed progenitor cell production declined much quicker than that of normal controls 
(Gibson and Gordon-Smith, 1990). Marsh et al reported that bone marrow from their 
series of patients with AA “showed little or no signs of generating progenitor cells” 
(Marsh et al, 1990). They also performed cross-over studies where cells from a patient 
with AA were inoculated onto normal bone marrow stroma that had been irradiated and 
vice versa. This showed the underlying abnormality in the disease relates to the HSC 
rather than its stromal environment, as AA cells grown on normal stroma failed to 
produce progenitor cells. Conversely, levels of haemopoietic growth factors produced in 
LTBMC of normal and AA bone marrow have been assessed and may show reduced 
production of specific factors (interleukin-3, interleukin-6 and granulocyte-colony 
stimulating factor) (Gibson et al, 1995). This suggests that in some cases of AA there is a 
defect in the bone marrow environment. 
 
In PNH, LTBMC have also been performed and further cross-over experiments show the 
defect is due to the HSCs and not the stroma (Nishimura et al, 2002). There have been 
contrasting reports about the overall number of CD34+ cells in PNH patients’ bone 
marrow with some finding normal amounts (Elebute et al, 2003) and others finding 
reduced numbers of cells (Maciejewski et al, 1997). The potential for these cells to 
produce progenitors is, however, reduced in all previous studies (Maciejewski et al, 1997; 
Elebute et al, 2003). These results again highlight the difference in behaviour between the 
PIG-A deficient progenitor cells in vitro and their apparent advantage in vivo. The defect 
in HSC function of PIG-A mutant cells argues strongly against a cell intrinsic growth 
advantage. The results at the same time suggest that LTBMC culture may provide a tool 
in which to test conditions that favour growth of PIG-A mutant clones relative to normal. 
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2.1 Patients  
 
2.1.1 Patients Treated with Eculizumab 
 
Seventy-nine patients with PNH were treated with eculizumab at the Leeds Teaching 
Hospitals PNH centre between May 2002 and July 2010, including 34 patients from the 
clinical trials and a further 45 treated since then. In the 7 years before the availability of 
eculizumab, 30 patients who fulfilled the English national criteria for eculizumab therapy 
were also cared for in Leeds. The mortality of these 30 patients, up to the point at which 
they went on to receive eculizumab, was evaluated to provide a control group for 
comparison. The follow-up of patients was approved through the Central Research Ethics 
Committee, and all patients gave signed informed consent for entry into the study in 
accordance with the Declaration of Helsinki. 
 
The clinical history for these patients is summarised in Section 3.5. Laboratory results, 
complications of the disease, both before and whilst on eculizumab, as well as the overall 
outcomes of these patients are described in Chapter 3. 
 
2.1.2 Patients Treated during Pregnancy  
 
Eleven patients were treated with eculizumab during pregnancy, at the Leeds Teaching 
Hospitals PNH centre between November 2007 and May 2013. The follow-up of patients 
was approved through the Central Research Ethics Committee, and all patients gave 
signed informed consent for entry into the study in accordance with the Declaration of 
Helsinki. The clinical history, results and the outcomes for these patients are discussed in 
Chapter 4.  
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2.2 Evaluation of HMGA2 in PNH Patients and Normal Subjects 
 
2.2.1 Patient and Control Groups 
 
Patients included in this study were all diagnosed with haemolytic PNH and were 
selected for analysis on the basis that they had very high PNH granulocyte clones to 
reduce the amount of normal cells being evaluated. All patients were attending the PNH 
clinic at St James’s University Hospital and most of these patients were given the 
monoclonal antibody eculizumab to treat the symptoms of their disease. A normal control 
group was also evaluated. 
 
2.2.2 Red Cell Lysis 
 
An 8 millilitre (ml) sample of peripheral blood or a 5ml sample of bone marrow was 
collected in ethylenediaminetetraacetic acid (EDTA) sterile vacuum tubes from patients 
and added to a 50ml Falcon tube, which had 42ml of 10x ammonium chloride lysis 
solution present. 
 
The 10x ammonium chloride lysis solution was prepared by dissolving 8.99 grams of 
ammonium chloride, 1 gram of potassium bicarbonate and 40ml 0.5 Molar (M) EDTA at 
pH 8.0 in 80ml of double distilled water (ddH2O). The pH was then adjusted to 7.3 and 
the solution was made up to 100ml with ddH2O. This solution was stored at 4oC in a 
tightly closed bottle. 
 
Once the blood or bone marrow sample was added, the mixture was inverted several 
times and left at room temperature for 3-5 minutes, occasionally inverting until the 
mixture started to clear. 
 
The sample was centrifuged at 300xg for 5 minutes at room temperature, the supernatant 
was removed and a cell count performed. The cell pellet was resuspended in 1ml TRIzol 
reagent and stored at -20oC, until ribonucleic acid (RNA) extraction was performed. 
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TRIzol is a monophasic solution of phenol and guanidine isothiocyanate and can be used 
to isolate RNA, deoxyribonucleic acid (DNA) and proteins. 
 
2.2.3 RNA Extraction 
 
The cells suspended in TRIzol were thawed. 200 microlitres (µl) of chloroform was 
added and mixed together by inversion and incubated at room temperature for 2-3 
minutes. The sample was centrifuged at 12,000xg for 15 minutes at 4oC. The upper 
aqueous phase was transferred to a fresh tube and the RNA was precipitated using 0.5ml 
of isopropyl alcohol. This was incubated at room temperature for 10 minutes before 
centrifuging at 12,000xg for 10 minutes at 4oC. The supernatant was removed and the 
RNA washed with 1ml of 75% ethanol. A further centrifugation was performed at 
7500xg for 5 minutes at 4oC. The supernatant was removed and the sample underwent a 
quick spin to remove traces of ethanol prior to air drying for 5 minutes. The RNA was 
dissolved in 44µl diethylpyrocarbonate (DEPC) treated water and incubated with this for 
10 minutes at 55oC. The sample then underwent DNase I treatment before nanodrop 
estimation of the RNA quantity. 
 
2.2.4 DNase Treatment  
 
To remove any residual genomic DNA present, a mixture (6µl) of DNase I (1µl per 
sample, concentration 2units/ml)) and 10x buffer (5µl per sample) was added to each 
RNA sample using the Ambion DNA-freeTM kit. DNase I is an enzyme that non-
specifically cleaves DNA to 5’-phosphorylated di-, tri- and oligonucleotide products. 
 
The sample was incubated at 37oC for 1 hour before the addition of a DNase inactivation 
reagent at 5µl per sample. Prior to the adding the inactivation reagent it was mixed by 
vortexing for 3-4 seconds. The sample was incubated at room temperature for 2 minutes 
before centrifuging at 300xg for 1 minute at room temperature. The sample was stored at 
-80oC until complementary DNA (cDNA) synthesis was performed. 
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2.2.5 cDNA Synthesis 
 
All reagents used were supplied by Invitrogen. SuperScriptTM II reverse transcriptase was 
used to synthesise first-strand cDNA using random primers. 5µl RNA, 1µl random 
primers at a concentration of 50ng/ml, 1µl mix deoxynucleotide triphosphates (dNTP, 
containing dATP, dCTP, dGTP, dTTP, 10mM each) were added together with 3µl 
nuclease free water. The mixture was heated to 65oC for 5 minutes and quick chilled back 
on ice to reduce secondary structure. 1µl SuperScriptTM II (200U), was added to 2µl 10x 
first strand buffer, 2µl 0.1M 1,4-dithiothreitol (DTT), 4µl of 25mM magnesium chloride 
(MgCl2) and 1µl RNAseOut (40U/µl), a ribonuclease inhibitor. This was added to the 
initial mixture and resuspended thoroughly before being incubated at 42oC for 50 
minutes. 
 
Inactivation of the reverse transcriptase was performed by heating at 70oC for 15 minutes. 
The mixture was quick chilled on ice for 5 minutes before the addition of 1µl RNAse H 
(2U/µl), an endoribonuclease that degrades the RNA strand of the RNA-DNA hybrid to 
form cDNA and oligoribonucleotides. The mixture was then incubated for 20 minutes at 
37oC. cDNA templates formed by this method were stored at -80oC prior to real-time 
polymerase chain reaction (PCR) experiments. 
 
In order to try to optimise the synthesis of cDNA, an increased concentration of hexamers  
(at a concentration of 1.5µl/ml hexamers instead of 50ng/ml of random primers) and an 
increased concentration of SuperScriptTM II (x 4) was used. The duration of the first-
strand cDNA annealing phase was also lengthened from 50 to 120 minutes.  
 
2.2.6 Quantitative PCR 
 
Primers used for real-time or quantitative PCR (qPCR) were designed with Primer 
Express 3.0 Software (Applied Biosystems) to amplify total HMGA2 and its two 
transcript variants individually. The primers were designed to span one or more introns to 
avoid amplification of genomic DNA and are shown in Table 2.1. The specificity of the 
amplicon was confirmed by both the dissociation curve protocol (Applied Biosystems) 
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and by conventional PCR followed by agarose gel electrophoresis described in Sections 
2.2.7, 2.2.8 and Chapter 5. 
 
The real-time reactions were performed using the ABI 7500 Real-Time PCR System 
(Applied Biosystems) and results obtained were analysed using the Sequence Detection 
System (Applied Biosystems) software. SYBR Green reverse transcription PCR (Applied 
Bisosystems) was used in all the PCR reactions. Synthesised cDNA samples were diluted 
to 60µl with 40µl nuclease free water. 5µl of SYBR Green PCR Master Mix (SYBR 
Green I Dye, AmpliTaq Gold DNA Polymerase, dNTPs with dUTP and buffer 
components), 2.6µl of nuclease free water, 0.4µl of primers (500nm) were added to 2µl 
of the cDNA template. 
The amount of DNA present during the exponential phase of the reaction can be 
determined by plotting fluorescence against cycle number on a logarithmic scale as an 
exponentially increasing quantity will give a straight line on the graph. The amount of 
DNA present during this exponential phase will double with each cycle. The cycle 
threshold (CT) is the PCR cycle number at which the fluorescence crosses the threshold. 
It is possible to determine the amount of DNA present by comparing the results obtained 
with that of a standard curve, which is made up from serial dilutions of a known amount 
of DNA. A housekeeping gene (a gene that is expressed at a similar level between 
different samples) is then needed to qualify the gene expression. The measured amount of 
DNA is divided by the measured amount of the housekeeping gene (β-ACTIN in this 
case) to normalise against variations in the amount of DNA between different samples so 
that sample values can be compared. 
All reactions were performed in duplicate alongside a negative control in EU ABI7500 96 
well plates (BIOplastics) and covered with a MicroAmp optical adhesive film (Applied 
Biosystems). cDNA samples were also evaluated using the primers from the research 
group finding elevated HMGA2 mRNA in patients with PNH (Murakami et al, 2012). 
These primers are shown in Table 2.1. In these PCR reactions levels of full-length 
transcripts were analysed using TaqMan gene expression for HMGA2.  
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Primers used in Experiments (sequence 5’-3’) 
 
Forward Primer 
PIG-M. 724.RT. CACACGCGACGAGTCTTTTC 
Reverse Primer 
PIG-M.895.RT. CCCGATTACACAGCCTTTTCA 
Forward Primer 
HMGA2.990.RT. TCTTGTTTTTGCTGCCTTTGG 
Reverse Primer 
HMGA2.1028.RT. AGTGGCTTCTGCTTTCTTTTGAG 
Forward Primer 
HMGA2 variant 1.1658.RT. TTGGTGTTCTAAACAGAGGATTCA 
Reverse Primer 
HMGA2 variant 1.1200.RT. TCTCCCTTCAAAAGATCCAACTG 
Forward Primer 
HMGA2 variant 2.1504.RT. CAAACCACACCATAGCCACACT 
Reverse Primer 
HMGA2 variant 2.1091.RT. GGAGCTGGTTCTTGGTAGTAGATTG 
Forward Primer 
HMGA2 .RT. TTCAGCCCAGGGACAACCT 
Reverse Primer 
HMGA2 .RT. TCTTGTTTTTGCTGCCTTTGG 
Forward Primer 
ACTB.210.RT. CATCGAGCACGGCATCGTCA 
Reverse Primer 
ACTB.420.RT. TAGCACAGCCTGGATAGCAAC 
Forward Primer 
JAK2 (specific) RT. AGCATTTGGTTTTAAATTATGGAGTATATT 
JAK2 (internal control) RT. ATCTATAGTCATGCTGAAAGTAGGAGAAAG 
Reverse Primer 
JAK2 RT. CTGAATAGTCCTACAGTGTTTTCAGTTTCA3’ 
TaqMan MGB probe 
FAM AGCAAGAACCAACCGGT 
Forward Primer 
HMGA2 RT.TTCAGCCCAGGGACAACCT 
Reverse Primer 
HMGA2 RT. TCTTGTTTTTGCTGCCTTTGG 
 
Table 2.1 Primers used in PCR experiments. 
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2.2.7 Conventional PCR Reactions 
 
Synthesised cDNA samples were diluted to 60µl with 40µl nuclease free water. 
Experiments were undertaken in a GeneAmp PCR 9700 System (Applied Biosystems). 
Reactions were performed in a total volume of 25µl containing 2µl cDNA, 16.125µl 
nuclease free water, 2.5µl 10x buffer, 1.25µl dimethyl sulphoxide (DMSO), 1.5µl 25mM 
MgCl2, 0.5µl 10mM dNTPs, 0.5ml 100µM forward primer, 0.5ml 100µM reverse primer 
and 0.125µl of Taq DNA polymerase (5U/µl). The primers used are shown in Table 2.1.  
The PCR conditions were as follows: 94oC for 5 minutes, followed by 30 cycles of 94oC 
for 30 seconds, annealing temperature of 60oC for 30 seconds and extension of 1 minute 
at 72oC. The amplification was followed by a final extension period of 10 minutes at 
72oC. 
 
2.2.8 Agarose Gel Electrophoresis 
 
The PCR products were separated and visualised by agarose gel electrophoresis. A 2% 
concentration agarose gel in Tris/Borate/EDTA (TBE) buffer (89mM Tris, 2mM EDTA, 
89mM boric acid) was used containing ethidium bromide at a concentration of 0.5µg/ml. 
PCR product samples were mixed with gel loading buffer and loaded onto the gel. The 
electrophoresis was performed at 80 volts for 20 minutes using a Power Pack 300 
(Biorad). The products were visualised using ultra violet light and photographed with a 
Molecular Imager Gel Doc XR System (Biorad). A 100bp ladder was used to assess the 
size of the products detected. This ladder was purchased from New England Biolabs and 
is derived from digestion of proprietary plasmids by specific restriction enzymes, which 
yield 12 bands of standard molecular weights during agarose gel electrophoresis. 
 
2.2.9 CD15 Positive Selection  
 
20ml of peripheral blood was collected in sterile vacuum tubes (EDTA type) from 
patients and healthy volunteers. Samples were centrifuged at 2,400rpm for 5 minutes at 
room temperature and mononuclear cell (MNC) layer removed by pasteur pipette and 
resuspended in 10ml 0.84% ammonium chloride. The cells were incubated at 4oC for 5 
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minutes and then centrifuged with the same settings. The supernatant was discarded and 
the cell pellet transferred to an eppendorf tube. The cell number was determined for each 
sample. 
 
CD15 Dynabeads (Dynal) were pre-washed by resuspending the beads in the vial, 
transferring 20µl to a separate tube and adding an equal volume of buffer (Dynal), 
exposing the beads to a magnet for 1 minute and discarding the wash. After removal from 
the magnetic field, the beads were again resuspended in 20µl buffer and subsequently 
incubated with each sample for 30 minutes at 4oC. Prior to the final wash, the magnet was 
applied for 2 minutes and the supernatant transferred to a new tube. The beads were 
washed 3 times with 20µl buffer, then removed from magnet. 
 
Cell purity was assessed by mixing 50µl sample with 400µl fluorescence activated cell 
sorting (FACS) buffer, staining with anti-CD15, and subsequent analysis by flow 
cytometry (Section 2.4.1). Samples then underwent RNA extraction, DNase Treatment 
and cDNA synthesis prior to qPCR (Sections 2.2.3, 2.2.4, 2.2.5 and 2.2.6). 
 
 
2.3 Evaluation of Prevalence of PIG-M Promoter Site and JAK2 Mutations 
 
2.3.1 Patient Cohort 
 
The inclusion criteria for the selection of patient samples for analysis for PIG-M 
promoter mutations and JAK2 mutations were the same as in 2.2.1. 
 
2.3.2 Genomic DNA Extraction  
 
Genomic DNA was extracted from cell pellets using the QIAamp DNA Mini Kit 
(Quiagen). Two hundred microlitres of sterile phosphate buffered saline (PBS) was added 
to 200µl of the whole blood (the sample). Twenty microlitres of proteinase K (activity of 
600U/mg protein) and 200µl of lysis buffer (buffer AL) was then added in sequential 
order and mixed by pulse-vortexing for 15 seconds before being incubated in a waterbath 
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at 56oC for 10 minutes. The samples were briefly centrifuged to remove droplets from the 
inside of the lid. Two hundred microlitres of 100% ethanol was added, mixed by pulse-
vortexing for 15 seconds and transferred to a 1.5ml micro-column. The samples were 
then transferred to a QIAamp Spin Column and the columns were centrifuged for 1 
minute at 8000rpm at room temperature. The filtrate was discarded and the samples from 
the columns were transferred into a fresh collection tube. Five hundred microliters of 
buffer (buffer AW1) was added and the column was centrifuged for 1 minute at 8000rpm 
at room temperature. The QIAamp Spin Column was placed into a fresh collection tube 
and the filtrate was discarded. Five hundred microliters of buffer (buffer AW2) was 
added to the column, which was then centrifuged for 3 minutes at 14,000rpm at room 
temperature to remove the buffer. The QIAamp Spin Column was transferred into a fresh 
collection tube and 200ml elution buffer (buffer AE) was added. The columns were 
incubated for 2 minutes, then centrifuged for 1 minute at 8000rpm at room temperature 
before being stored (genomic DNA) at-4oC until analysed. 
 
2.3.3 Val617Phe JAK2 Point Mutation Analysis 
 
Reactions were performed in a total volume of 25µl taken from a mastermix consisting of 
100µl of 10 x Reddymix PCR buffer, 5µl 25mM dNTPs, 8µl JAK2 reverse primer (400 
picomols), 4µl JAK2 forward specific primer (200 picomols), 4µl JAK2 forward control 
primer (200 picomols), 879µl nuclease free water. Five hundred nanograns (ng) of the 
sample (genomic DNA) were added to 25µl of the mastermix followed by 0.1µl (0.5 
units) of Thermoprime Taq Polymerase. The primers used are shown in Table 2.1. 
 
PCR experiments were carried out using a GeneAmp PCR 9700 System (Applied 
Biosystems). The PCR conditions were as follows: 95oC for 2 minutes, followed by 35 
cycles of 95oC for 30 seconds, annealing temperature of 58oC for 30 seconds and 
extension of 30 seconds at 72oC. The amplification was followed by a final extension 
period of 10 minutes at 72oC. Reaction products were visualised by agarose gel 
electrophoresis as in 2.2.8. 
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2.3.4 PIG-M Promoter Mutation Analysis 
 
The PCR reaction was performed as in Section 2.2.7. The primers used are shown in 
Table 2.1. Agarose gel electrophoresis was performed on 5µl of PCR product to confirm 
the presence of a single band of the expected size. 
 
Shrimp Alkaline Phosphatase/Exonuclease (SAPEX) was used for purification of the 
samples. In each reaction, 7µl PCR product, 1µl exonuclease (20U/µl), and 2µl Shrimp 
Alkaline Phosphatase (1 U/µl) were used. The PCR plate was covered with optical film 
and vortexed for 15 seconds prior to being centrifuged at room temperature at 400xg for 1 
minute. The PCR 9700 System (Applied Biosystems) was used with the following 
conditions: 37oC 30 minutes followed by 80oC 15 minutes. 
 
Sequencing reactions were all performed in 10µl reactions in a PCR 9700 System 
(Applied Biosystems). In each reaction the following were added: 3µl nuclease free 
water, 2µl big dye terminator 2, 2µl half big dye, 2µl primer (1:100, 1pmol) and 1µl 
SAPEX treated product. The following conditions were used: 25 cycles of 96oC for 10 
seconds, 55oC for 5 seconds and 60oC for 4 minutes. 
 
Ethanol Clean-up: 
1µl 3M Sodium Acetate was added to each well followed by 25µl of 95% ethanol. The 
PCR plate lid was sealed and vortexed for 10 seconds. Samples were left at room 
temperature for 30 minutes to precipitate, prior to being centrifuged at 3200rpm for 45 
minutes at room temperature. The lid was removed and the samples inverted onto tissue 
paper. The samples were then centrifuged at 1980rpm for 1 minute at room temperature. 
Sixty microlitres of 70% ethanol was added and then the samples were centrifuged at 
3200rpm for 15 minutes at room temperature. The plate was again inverted onto tissue 
paper and centrifuged at 1980rpm for 1 minute at room temperature. The resulting pellets 
were dried by placing the plate onto a heat block at 95oC for 1 minute. 
 
 
 
 73 
 
Sequencing: 
Sequencing reactions were analysed on the 3100 Series Genetic Analyser (Applied 
Biosystems). Samples were dissolved in 15µl HiDi formamide, vortexed for 15 seconds 
and a quick spin performed. Samples were transferred to a MicroAmp plate and 
centrifuged at 1000rpm for 1 minute at room temperature. The plate was placed onto a 
heat block at 95oC for 2 minutes and snap-cooled on ice prior to analysis using the ABI 
3130xl gene sequencer. 
 
 
2.4  Long Term Bone Marrow Cultures 
 
2.4.1 Flow Cytometry Analysis of Bone Marrow Samples 
 
All samples were analysed on a FacsCanto or FacsCanto II System (Becton Dickinson 
Biosciences). Table 2.2 shows the antibodies used in labelling cells for analysis on the 
fluorescence activated cell sorting (FACS) machine. The antibodies shown in Table 2.2 
were added, at the concentrations listed therein, to each sample in a FACS tube. They 
were incubated for 20 minutes at room temperature, protected from the light and gently 
mixed every 5 minutes. Two millilitres of FACSLyse (Becton Dickinson Biosciences, 
working dilution 1:10 in distilled water) was then added and the mixture vortexed gently 
before a further 10-minute period of incubation at room temperature, protected from the 
light. Samples were then centrifuged at 400xg for 2 minutes at room temperature. The 
supernant was discarded by rapidly inverting the tube and excess FACSLyse was 
removed by blotting the tube rim on a paper towel. The cell pellet was gently 
resuspended and 2ml of 0.5g bovine serum albumin (Sigma) dissolved in 500ml 
FACSFlow (Becton Dickinson Biosciences) (FACSFlow/BSA). Samples were again 
centrifuged at 400xg for 2 minutes at room temperature with the supernant discarded by 
rapidly inverting the tube and the excess FACSFlow/BSA was removed by blotting the 
tube rim on a paper towel. The cells were resuspended in 300µl of FACSFlow. The cells 
were thoroughly resuspended to break up any aggregates before being processed as soon 
as possible through the flow cytometer. A minimum of 100,000 events were recorded and 
analysed using FACSDiva software (Becton Dickinson Biosciences). 
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CD or 
specificity 
Conjugate Clone 
Name 
Amount 
Used 
Catalogue 
Number 
Manufacturer 
FLAER ALEXA 
488 
n/a 10µl FL25 Pinewood 
Scientific 
CD3 PE SK7 5µl 345765 Beckton 
Dickinson 
CD14 APC-Cy7 M P9 10µl 333951 Beckton 
Dickinson 
CD15 APC HI98 10µl 551376 Beckton 
Dickinson 
Pharmingen 
CD16 PerCpCy5.5 3G8 10µl 338440 Beckton 
Dickinson 
CD24 PE ML5 10µl 555428 Beckton 
Dickinson 
Pharmingen 
CD33 PE-Cy7 P67.6 10µl 333952 Beckton 
Dickinson 
CD34 APC 8G12 2.5µl 345804 Beckton 
Dickinson 
CD38 PerCpCy5.5 HIT2 2.5µl 551400 Beckton 
Dickinson 
Pharmingen 
CD45 APC-H7 2D1 10µl 641417 Beckton 
Dickinson 
CD45 V450 2D1 10µl 642275 Beckton 
Dickinson 
CD117 PEcy7 104D2 10µl 339217 Beckton 
Dickinson 
 
Table 2.2 FACS Antibodies used in the study. 
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2.4.2 Isolation of Bone Marrow Mononuclear Cells 
 
Bone marrow samples (10mls) were diluted in equal volumes of sterile phosphate 
buffered saline (PBS). An equal volume of the density gradient media, lymphoprepTM 
(Axis-Shield), was measured out into a fresh tube and the bone marrow/PBS mix was 
overlaid in a 50ml Falcon tube using a pipette, tilting the Falcon tube at an angle and very 
slowly and smoothly adding the bone marrow/PBS onto the lymphoprep. The samples 
were then centrifuged at 2500rpm at room temperature for 25 minutes with no brake. The 
MNC layer was transferred to a fresh 10ml tube and made up to 10mls with sterile PBS. 
The samples were centrifuged at room temperature for 10 minutes at 300xg. The 
supernatant was removed and a cell count performed. Samples underwent flow cytometry 
analysis using the method described in 2.4.1. 
 
2.4.3 Isolation of Bone Marrow CD34+ Cells 
 
CD34+ selection was performed using a Direct CD34 Progenitor Cell Isolation Kit 
(Miltenyi Biotech). Using MNC up to 108 cells suspended in 300µl rinsing buffer (RB; 
500µl of autoMACSTM rinsing solution (Miltenyi Biotech) diluted 1:25 with sterile PBS), 
the following were added: 100µl FcR blocking reagent to inhibit non-specific Fc 
mediated binding and 100µl CD34 microbeads. These were mixed well and incubated for 
30 minutes at 4oC. Cells were then washed with 5ml sterile PBS and passed through a 
30mm nylon mesh filter. Samples were centrifuged at 300xg for 10 minutes at room 
temperature and resuspended in 1ml RB. 
 
Magnetic Separation 
An LS column (Miltenyi Biotech) was rinsed with 3ml RB and a magnetic field was 
applied to the column before the samples were added. Each column was washed 3 times 
with 3ml RB. The column was removed from the magnetic field and the retained cells 
flushed out with 5ml RB. Samples were then centrifuged at 300xg for 10 minutes at room 
temperature. All but 1ml of supernatant was removed and the cells were resuspended in 
this. An MS column (Miltenyi Biotech) was rinsed with 500µl RB and a magnetic field 
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applied to the column prior to the cells being added. Each column was washed 3 times 
with 500µl RB. The column was then removed from the magnetic field and the retained 
cells flushed out with 1ml RB prior to a cell count being performed. Samples underwent 
flow cytometry analysis using the method described in 2.4.1. 
 
2.4.4 T-cell Depletion of CD15+ Bone Marrow Mononuclear Cells 
 
CD15+ Isolation 
CD15+ selection was performed using CD15 MicroBeads (Miltenyi Biotech). Using 
MNC up to 107 cells suspended in 80µl RB, 20µl of CD15 MicroBeads were added per 
107 cells. These were mixed well and incubated for 15 minutes at 4oC. Cells were then 
washed with 5ml sterile PBS and passed through a 30mm nylon mesh filter. Samples 
were centrifuged at 300xg for 10 minutes at room temperature and resuspended in 1ml 
RB. Magnetic separation was performed using the same method described in 2.4.3. 
 
T-cell Depletion 
T-cell depletion of the CD15+ selected cells was performed using CD3 MicroBeads 
(Miltenyi Biotech). Using MNC up to 107 cells suspended in 80µl RB, 20µl of CD3 
MicroBeads were added per 107 cells. These were mixed well and incubated for 15 
minutes at 4oC. Cells were then washed with 5ml sterile PBS and passed through a 30mm 
nylon mesh filter. Samples were centrifuged at 300xg for 10 minutes at room temperature 
and resuspended in 1ml RB. Magnetic separation was performed using the same method 
described in 2.4.3 but the supernant was not immediately discarded. Along with the T-
cell depleted samples the supernant underwent flow cytometry analysis using the method 
described in 2.4.1. 
 
2.4.5 Isolation of T-cells from Bone Marrow Mononuclear Cells 
 
T-cell isolation was performed using the Pan T-cell Isolation Kit II (Miltenyi Biotech). 
Using MNC up to 107 cells suspended in 40µl RB, 10µl of Biotin-Antibody Cocktail 
were added per 107 cells. These were mixed well and incubated for 10 minutes at 4oC. 
Thirty microliters of RB was added per 107 cells, followed by 20µl of Anti-Biotin 
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MicroBeads per 107 cells. These were mixed well and incubated for 15 minutes at 4oC.  
Cells were then washed with 5ml sterile PBS and passed through a 30mm nylon mesh 
filter. Samples were centrifuged at 300xg for 10 minutes at room temperature and 
resuspended in 500µl RB. 
 
Magnetic Separation 
An LD column (Miltenyi Biotech) was rinsed with 2ml RB and a magnetic field was 
applied to the column before the samples were added. Each column was washed 2 times 
with 1ml RB. The unlabelled cells that passed through the column were collected. 
Samples were then centrifuged at 300xg for 10 minutes at room temperature. All but 1ml 
of supernatant was removed and the cells were resuspended in this. Samples underwent 
flow cytometry analysis using the method described in 2.4.1. 
 
2.4.6 Maintaining Long Term Cultures 
 
Long-term culture experiments were carried out in sterile tissue culture flasks with a 
25cm2 surface area at the bottom of the flask (T25 flasks). Murine bone marrow 
fibroblast cell line cells, M210B4 cells (Cell Lines Service), were used as stroma to 
support the culture experiments. M210B4 cells will support human and murine 
myelopoiesis in long term culture, they express laminin and collagen IV, but do not 
express collagen I or Factor VIII (Lemoine et al, 1988). The mouse stromal cells were 
grown to confluence in RPMI 1640 medium supplemented with 2 mM L-glutamine and 
10% fetal bovine serum and then irradiated them with 80 Grays (Gy) for 57 minutes 
using an X-RAD 350 machine. 1 x 106 irradiated cells were plated in each T25 flasks and 
left either overnight, or for a minimum of 8 hours to allow them to adhere to the flask 
surface.  
 
The RPMI 1640 media was removed and replaced with 10ml of pre-warmed MyelocultTM 
H5100 media (StemCell Technologies).  MyelocultTM H5100 contains 12.5% horse 
serum, 12.5% fetal bovine serum, 2-mercaptoethanol (10-4M) in alpha minimal essential 
medium supplemented with L-glutamine (2mM), I-inositol (0.16mM) and folic acid 
(16mM). It can support long-term myelopoiesis by primitive human hematopoietic cells 
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(Sutherland et al, 1990; Eaves et al, 1991; Sutherland et al, 1991; Petzer et al, 1996; 
Hogge et al, 1996). Immediately prior to use filter sterilised hydrocortisone (StemCell 
Technologies) was added to give a final concentration of 10-6M.  
 
Sample cells were inoculated into 2 separate T25cm2 flasks at a concentration of 106 for 
MNCs and 104 cells for CD34+ selected cells, and kept at 33oC. Half-media changes 
were performed weekly with 5ml media removed and replaced with fresh pre-warmed 
MyelocultTM H5100 media. The harvested media was centrifuged at 400xg for 5 minutes 
at room temperature. The supernatant was discarded, a cell count performed, and a 
proportion of these cells were assayed for colony formation assays (CFAs) and a 
proportion for flow cytometry assessment, using the method described in 2.4.1. 
 
2.4.7 Colony Formation Assays 
 
MethocultTM GF H4434 (StemCell Technologies) was used to support the optimal 
growth of all progenitors (CFU-E, BFU-E, CFU-GM, CFU-G and CFU-M). 
MethocultTM GF H4434 contains 1% methylcellulose, 30% fetal bovine serum, 1% 
bovine serum albumin, 10-4M 2-mercaptoethanol, 2mM L-glutamine, 50ng/ml 
recombinant human (rh) stem cell factor, 10ng/ml rh GM-CSF, 10ng/ml rh IL-3, 3U/ml 
rh erythropoietin in MDM. (Eaves, 1995). 
 
2-5 x 104 cells from LTBMC media were mixed with 1ml of thawed aliquots of 
MethocultTM GF H4434. The mixture was then plated in triplicate in a 24 well plate and 
incubated at 37oC with 5% carbon dioxide and > 95% humidity for 14 days, prior to 
counting of CFU-GM, CFU-G and CFU-Ms. 
 
2.4.8 Colony Analysis 
 
Colonies were examined using a high quality inverted microscope under low 
magnification (X5 and X10). CFU-GM, CFU-G and CFU-Ms numbers were evaluated 
and photographed. Identified colonies then underwent flow cytometric assessment using 
the method described in 2.4.1. 
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3.1 Introduction 
 
In this chapter the clinical features, laboratory findings, and outcomes of 79 consecutive 
patients with PNH who were referred to the Leeds National PNH centre at St James’s 
University Hospital and treated with eculizumab between May 2002 and July 2010 are 
described. The diagnosis was established or confirmed using multicolour flow cytometry 
of the erythrocytes, monocytes and granulocytes in all cases. Data collected for analysis 
include age and symptoms at diagnosis, presence of a history of preceding AA or MDS, 
age at the start of eculizumab, use of other medication to treat PNH, the occurrence of 
thrombosis prior to and during eculizumab treatment, blood transfusion requirement for 
the 12 months prior to starting eculizumab and after its initiation, LDH levels at the start 
of eculizumab and the most recent level (all of which were from May, June or July 2010) 
and documentation of cause and date of death if applicable. Data was collected up until 
the end of July 2010 when this planned analysis was made. All patients were evaluated at 
a minimum of every 12 weeks by the Leeds PNH team. This information provides further 
understanding of the natural history of this illness and the impact that eculizumab has on 
morbidity and the mortality in patients with PNH. 
 
 
3.2 Additional Patient information 
 
Thirty-four of these patients were from the eculizumab clinical trials (Hillmen et al, 
2004; Hillmen et al, 2006, Brodsky et al, 2008) and 45 were treated since then. Funding 
was through the National Health Service either via central commissioning in England or 
via local funding in Wales, Scotland or Northern Ireland. 
 
The information on 30 patients that would have been eligible for treatment with 
eculizumab in the 7 years preceding the availability of this drug was also obtained. 
Twenty-five of these individuals went on to make up part of the 79 patients treated with 
eculizumab and the other 5 patients died. The mortality of these patients up to the point 
that they went on to receive eculizumab was evaluated to provide a control group for 
comparison. 
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3.3 Eculizumab Therapy 
 
The national commissioned indications for treatment with eculizumab were: 
i) Transfusion-dependent haemolysis (4 or more transfusions in 12 months) 
ii) A significant PNH-related complication (i.e. thrombosis or renal failure), 
regardless of transfusion history 
 
Seventy-five patients fulfilled these criteria. Of the four patients who did not their 
treatment was agreed as exceptions, 2 would have fulfilled the standard criteria but for 
religious reasons declined transfusions and 2 were treated due to the severity of their 
symptoms. 
 
The mean duration of eculizumab treatment was 39 months (range 1-98 months). 
Eculizumab has been stopped in 2 patients - one due to predominant aplastic anaemia and 
one with spontaneous remission of his PNH. Seventy-four patients remained on 
eculizumab to end of study date and 3 patients died. 
 
Eculizumab was initially delivered at the approved dosing schedule of 600mg intravenous 
infusions over 30 minutes each week for four doses followed by a 900mg infusion after a 
further week. A 900mg dose was then given every 14 days (+/- 2 days) indefinitely. After 
the initial 2 to 5 doses, all therapy was administered in the patient’s home by homecare 
nurses, (Healthcare-at-Home Limited) under the guidance of the Leeds PNH team. A 
return of a patient’s symptoms (e.g. red or black urine or abdominal discomfort) or an 
increased LDH immediately prior to a dose of eculizumab was indicative of break-
through from complement control and these patients were treated with higher doses 
(usually 1200mg) every 14 days. Seventy-four were treated with a maintenance dose of 
900mg of eculizumab every 14 days with 5 patients requiring higher doses. Four of these 
required 1200mg and 1 required 1500mg every 14 days. 
 
The major potential complication of treatment with eculizumab is an increased risk of 
meningococcal infection with Neisseria meningitidis, as terminal complement appears 
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critical to prevent such infections (Ross and Densen, 1984; Sjoholm, 1990; Daha, 2010). 
All patients were vaccinated with a tetravalent meningococcal vaccine against sub-group 
A, C, W and Y prior to starting eculizumab. Currently there is no vaccine available 
against serogroup B, although one is under development. In January 2010 our policy 
changed to continue with vaccination but to also recommend antibiotic prophylaxis to all 
patients (penicillin V 500mg twice a day or erythromycin 500mg twice a day for patients 
intolerant of penicillins). 
 
 
3.4 Statistical Analysis 
 
Unless otherwise stated, all analysis was generated using SAS software, Version 9.2. 
Survival curves were derived by the Kaplan-Meier method using the log-rank test to 
evaluate the significance of differences between groups.  Patient survival on eculizumab 
was compared with age and sex matched control averages obtained using 2001 UK 
census data from the UK Office of National Statistics. To enable a log-rank comparison 
between this data and the PNH cohort, UK individual survival data was generated to 
match the age and sex control averages derived from the census data. A Cox regression 
model with time-dependent covariates was used to assess whether the introduction of 
eculizumab as a new treatment strategy altered the mortality of patients with PNH. This 
analysis included patients with PNH treated in the 7 years prior to the availability of 
eculizumab; analysis was generated using Stata Statistical Software release 11. When 
drawing the survival curve for this pre-eculizumab cohort, patients were censored at the 
time they first received eculizumab. 
 
Seventy five patients required transfusions prior to eculizumab therapy and 61 of these 
(81%) had been on therapy for at least 12 months. Their transfusion requirements in the 
12 months prior to eculizumab and in the most recent 12 months were compared using 
the Wilcoxon signed rank sum test. The patients within this group who were not 
transfusion independent at the time of analysis were further evaluated using a paired t-test 
to assess whether there was a significant difference in the number of transfusions required 
compared with their transfusion requirements prior to eculizumab. 
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Thrombotic event rates for pre-eculizumab and eculizumab treatment periods were 
calculated as the mean number of thrombotic events per year since diagnosis or start of 
treatment, respectively. Comparison of the occurrence of thrombosis before and after 
starting eculizumab was carried out using the Wilcoxon signed rank sum test. 
 
Platelet counts at the start of eculizumab treatment were compared to those after 12 
months of treatment using a paired t-test. 
 
 
3.5 Individual Patient Data  
 
U.P.N. 1 Female D.O.B. 08.03.1944 
U.P.N. 1 was diagnosed with PNH in 1965 after presenting with menorrhagia.  She had a 
pregnancy complicated by pre-eclampsia and premature delivery in 1968. She required 
occasional transfusions and had intermittent haemoglobinuria and abdominal pain until 
2000. In 2000 she suffered multiple pulmonary emboli and was anticoagulated with 
warfarin. She became transfusion dependent in 2000, requiring 6-8 transfusions a year. 
She started eculizumab in November 2008. Her PNH symptoms resolved but she 
continued to need blood transfusions every 6 weeks. 
 
U.P.N. 2 Male  D.O.B. 18.07.1940 
U.P.N. 2 presented in June 1991 with a six month history of haemoglobinuria, tiredness 
and breathlessness.  He was first transfused in May 1992 and required a 4 unit transfusion 
every eight weeks until 2004. Since 2004 he has needed 2-3 units of blood every 3 weeks. 
He had a total of ~490 units of blood prior to eculizumab therapy. He suffered paroxysms 
every month with symptoms including severe lethargy and haemoglobinuria. He has had 
erectile dysfunction since 1992. He has not suffered any thrombotic complications. He 
started eculizumab in November 2008. Since starting eculizumab he has required 
occasional transfusions associated with infections and his PNH symptoms have resolved. 
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U.P.N. 3  Male  D.O.B. 30.03.1968 
U.P.N. 3 was diagnosed with PNH in 1992 after presenting with haemoglobinuria, fatigue 
and blurred vision. He was initially transfused twice a year but this increased to 5-6 times 
a year in 1993. In 1995 he developed abdominal pain and loose motions. Chron’s disease 
was diagnosed and he had a resection of his terminal ileum and part of his small intestine. 
In 1997 he had a portal vein thrombosis and he was anticoagulated with warfarin. He 
started eculizumab in June 2005 and since this he has needed approximately 1 transfusion 
a year associated with infections. His other PNH symptoms have resolved. 
 
U.P.N. 4 Female D.O.B 06.11.1957  
U.P.N. 4 was diagnosed in September 1999 having presented to hospital with anaemia. 
Although she was found to have haemolytic PNH she declined blood transfusions due to 
religious beliefs. She was treated with low dose corticosteroids with little symptomatic 
benefit. In January 2009 she experienced a right popliteal deep vein thrombosis. 
Anticoagulation with warfarin was considered but not commenced due to concerns as to 
how this could be managed, as she also has learning difficulties. She commenced 
eculizumab in February 2009 but the dose was increased to 1200mg every 2 weeks in 
July 2009 as she was experiencing clinically significant breakthrough haemolysis. Since 
starting eculizumab her haemoglobin has been stable between 9.0 – 10.5g/dl and she has 
remained well. 
 
U.P.N. 5 Female D.O.B. 02.04.1958  
U.P.N. 5 was diagnosed with tuberous sclerosis when she was in her 20’s. She has had 
bilateral renal angiomyolipomas presenting with haematuria. These have been 
intermittently treated with embolisation. She was diagnosed with PNH in May 2008 
whilst being investigated for anaemia. She has had attacks of PNH since 2002 with 
dysphagia and haemoglobinuria. Typically these paroxysms lasted for a week and 
occurred approximately every 6 weeks. She has never suffered with a thrombosis. Since 
2002 she has been transfusion dependent requiring 3-4 units of blood every 2-3 months. 
In total prior to starting eculizumab she had 90 units of blood in 6 years. She started 
eculizumab in July 2008 and has continued to require blood 2-3 times a year, usually at 
times of infections. Her other PNH symptoms have resolved. 
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U.P.N. 6 Female D.O.B. 31.01.1976  
U.P.N. 6 was diagnosed with PNH in July 2001 whilst being investigated for anaemia. 
She was breathless on minimal exertion and had haemoglobinuria daily. She remained 
severely anaemic (haemoglobin level between 5-8g/dl) but chose to only be transfused 
intermittently before starting eculizumab in June 2005. She has never suffered with a 
thrombosis. She has not been transfused since starting eculizumab and has no PNH 
symptoms.  Her haemoglobin is consistently around 10g/dl. 
 
U.P.N. 7 Female D.O.B. 15.02.1956  
U.P.N. 7 became anaemic in 2000 and was initially investigated for “haematuria” as she 
had dark brown urine and intermittent loin pain. She was diagnosed with PNH in 
February 2001. She had disease paroxysms around every 6 weeks with a typical episode 
consisting of haemoglobinuria, abdominal discomfort and dysphagia. She started to have 
regular transfusions in 2001, having 3-4 units of blood every 6-8 weeks. She suffered a 
stroke in May 2002, which presented as a left-sided hemiplegia. Prior to developing PNH 
she had colorectal cancer, which was surgically resected in 1996. Eculizumab was started 
in November 2004 and she has had no PNH symptoms or transfusions since. 
 
U.P.N. 8 Female D.O.B. 27.07.1947  
U.P.N. 8 presented with chest pain and severe anaemia (haemoglobin 6.2g/dl) in January 
2008. She was initially investigated for blood loss without any cause identified. In July 
2008 she developed dark urine and was thought to have autoimmune haemolytic anaemia. 
A trial of steroids was given. In March 2009 a diagnosis of PNH was established. She 
required 10 units of blood in the 7 months before starting eculizumab in June 2009. She 
has only required 1 transfusion of 2 units of blood since starting eculizumab and has had 
no PNH symptoms. 
 
U.P.N. 9 Male  D.O.B. 14.02.1935  
U.P.N. 9 was diagnosed with PNH in 1999 after having symptoms of anaemia for the 
preceding 12 months. He started with regular transfusions in March 1999, requiring 2-3 
units of blood every 6-8 weeks. He suffered with lethargy and dark urine for 2-3 days 
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prior to each transfusion. He started eculizumab in September 2002 with a dramatic 
reduction in his transfusion requirement, needing around 4 units a year. His other PNH 
symptoms resolved. In 2008 his transfusion requirement increased and he became 
pancytopaenic. A bone marrow examination confirmed that his disease had transformed 
to MDS (refractory anaemia with excess blasts). He continued to receive 2-3 units of 
blood every 2-3 weeks. 
 
U.P.N. 10 Female D.O.B. 07.01.1969  
U.P.N. 10 was diagnosed with aplastic anaemia and PNH in 1994. She was treated with 
ciclosporin and had a haematological response with her blood count normalising. Her 
blood count remained normal until 1997 when she again became pancytopaenic. Danazol 
was commenced and a good haematological response again occurred with her blood 
count remaining normal until August 2001. She was anticoagulated with warfarin as  
primary prophylaxis in October 2001 but stopped this due to side effects in April 2002. In 
August 2002 she was found to have a cerebral vein thrombosis after developing severe 
headaches and was anticoagulated with phenindione. She required 2 transfusions before 
starting eculizumab in June 2005. She has had no PNH symptoms and has not required a 
transfusion sine being on eculizumab. 
 
U.P.N. 11 Female D.O.B. 03.06.1957 
U.P.N. 11 was diagnosed with PNH in April 2002 after developing acute renal failure 
from a severe haemolytic episode. She required haemodialysis for a 2 week period but 
her kidney function gradually improved. In September 2001 she had suffered a subdural 
haematoma. She has had several thrombotic events including bilateral pulmonary emboli 
in December 2001, a portal vein thrombosis in June 2003 and a mesenteric thrombosis in 
September 2003. Eculizumab was started in May 2005. She has been transfusion 
independent since 2006. In November 2008 she developed right leg weakness and slurred 
speech. A subdural haematoma was found and she was treated conservatively with a full 
recovery. Her anticoagulation was stopped.  
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U.P.N. 12 Male  D.O.B. 08.08.1961  
U.P.N. 12 presented with pancytopaenia and was diagnosed with hypoplastic anaemia 
and PNH in July 1986. Initially he was transfused with blood every 2-3 months but this 
increased in frequency to every month. In the 15 years prior to starting eculizumab he 
received around 600 units of blood. He had erectile dysfunction and haemoglobinuria for 
3-4 days preceding each transfusion. He started anticoagulation to prevent thrombosis in 
1990 and has not had a thrombotic event. Eculizumab was commenced in October 2008 
and although he remains transfusion dependent, his requirement for blood has reduced to 
around every 16 weeks. He now has no other PNH symptoms. 
 
U.P.N. 13 Female D.O.B. 27.09.1934 
U.P.N. 13 initially suffered with dizziness and was found to be severely anaemic. She 
was found to have AA and was treated with ciclosporin. Haemoglobinuria started in 
September 2008 and occurred daily until starting eculizumab in December 2008. She 
became transfusion dependent in June 2007 and has continued to require the same level 
of transfusion support despite eculizumab therapy. Her other PNH symptoms have 
resolved.  
 
U.P.N. 14 Female D.O.B. 05.03.1954  
U.P.N. 14 initially presented with haemoglobinuria in 1964, aged 12. She has had 
haemoglobinuria every 2-3 weeks lasting 3-4 days since 1966. She had 5 miscarriages 
before being sterilised in 1987. She has required transfusions with 2-3 units of blood 
every 6 weeks since around 1970. She started eculizumab in May 2002 and her 
haemolytic parameters improved but her transfusion requirement remained the same. It 
was felt that her transfusion need was due to her aplasia and her eculizumab was stopped 
in June 2003. She continues to require transfusions every 6 weeks. 
 
U.P.N. 15 Female D.O.B. 17.10.1929  
U.P.N. 15 suffered a myocardial infarction in August 2008. She was found to have an 
asymptomatic portal vein thrombosis and anaemia. She was diagnosed with PNH whilst 
on the coronary care unit and was transfused with 7 units of blood. She had a preceding 
history of haemoglobinuria prior to her admission. She commenced eculizumab in 
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October 2008 and has not had any PNH symptoms sine. She remains transfusion 
independent. 
 
U.P.N. 16 Female D.O.B. 28.09.1962   
U.P.N. 16 presented in February 2005 with a sudden visual disturbance affecting her left 
eye. No retinal vein thrombosis was identified but she was anaemic and PNH was 
diagnosed. She had been breathless on exertion for the previous 6 months but had no 
other PNH symptoms. In 1993 she had had severe anaemia associated with pregnancy. A 
bone marrow at the time was suggestive of MDS but her blood count recovered 
spontaneously. She declined transfusions for religious reasons. Eculizumab was started in 
July 2005 and since this therapy her haemoglobin has remained stable around 10g/dl. 
 
U.P.N. 17 Female D.O.B. 31.01.1968  
U.P.N. 17 was found to be pancytopaenic in October 2006 whilst being assessed as a 
blood donor. She remained well until she suffered gastroenteritis whilst on holiday. She 
developed haemoglobinuria, which lasted for 6 days. She then had haemoglobinuria for 2 
days prior to her periods and in August 2008 when her haemoglobin had fallen to 7g/dl a 
diagnosis of PNH was made. From October 2008 she had daily haemoglobinuria and she 
was treated with a five day course of steroids every 2 weeks. She has never had a 
thrombosis and was started on warfarin as primary prophylaxis. On days when she had 
severe haemolysis she had dysphagia especially for liquids. She was transfused with 6 
units of blood before eculizumab was initiated in December 2009. Since being on 
eculizumab she has had no further PNH symptoms and has not needed a transfusion. She 
stopped her warfarin in March 2010. 
 
U.P.N. 18 Female D.O.B. 14.05.1968 
U.P.N. 18 was diagnosed with aplastic anaemia in 1980 at the age of 12. She was initially 
treated with steroids with an improvement in her blood parameters. She still required 
regular blood transfusions for a further 4 years before her blood count recovered. In 1988 
she again became anaemic and a diagnosis of PNH was made. She again became 
transfusion dependent, requiring 2-3 units of blood every 6 weeks. She had episodes of 
disease paroxysms roughly every 2 months with each episode lasting 1-3 days in 
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duration. With each of these attacks she would have haemoglobinuria, jaundice, lethargy, 
dysphagia and aching in her elbows, knees and shoulders. In October 1997 she was 
admitted with abdominal pain and was thought to have had splenic infarcts. She was 
started on warfarin at this time. She received over 220 units of blood between 2002 and 
starting eculizumab in November 2008. Since starting eculizumab she has been 
transfusion independent and has not had symptoms due to her PNH. 
 
U.P.N. 19 Male  D.O.B. 19.01.1963  
U.P.N. 19 became unwell in February 1994 when he developed severe abdominal pain 
requiring opiates. An initial diagnosis of Chron’s disease was made. He continued to have 
severe attacks of abdominal pain around 4-6 times a year. In December 1998 he started 
with haemoglobinuria and since then each episode of abdominal pain has been associated 
with dark urine. His diagnosis of Chron’s disease was re-evaluated and changed to PNH. 
In 2000 he was a hospital inpatient for 8 months due to abdominal pain and became 
opioid dependent. By 2001 he was getting painful exacerbations of his disease around 
every 2-3 weeks, with severe central abdominal pain, nausea and vomiting, marked 
weight loss and haemoglobinuria. In 2002 he became transfusion dependent requiring 2-3 
units of blood every 4 weeks. He started eculizumab in January 2005. Since then he has 
been transfusion independent and not had symptoms of PNH. He has also returned to 
work. 
 
U.P.N. 20 Female D.O.B. 03.10.1933  
U.P.N. 20 presented with a flu-like illness in 1985 with associated haemoglobinuria and a 
diagnosis of PNH was made. Between 1985 and 2007 she has been transfused with 3 
units of blood approximately every 4 weeks. During this time she has had daily 
haemoglobinuria and jaundice. She also suffered from frequent headaches and lower 
respiratory tract and urinary tract infections. At the time she commenced eculizumab in 
June 2009 she was requiring 3 units of blood every week. Although she felt better 
symptomatically on eculizumab, she still required extremely regular transfusions (2 units 
every week). She was also treated with deferasirox for iron overload. She died in March 
2010 with bronchopneumonia. 
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U.P.N. 21 Male  D.O.B. 22.09.1974  
U.P.N. 21 presented in 1991 with very severe AA and was treated with anti-lymphocyte 
globulin, ciclosporin and androgens. He was heavily transfusion dependent for 2-3 years 
before developing PNH when his transfusion requirement reduced to 2 units of blood 
every 3-4 weeks. He had daily haemoglobinuria with his urine being dark in the mornings 
but clearing during the day. He has never experienced any thrombotic complications. He 
started eculizumab in February 2005 and apart from 2-3 episodes of breakthrough 
haemolysis, had no further PNH symptoms during the study period. 
 
U.P.N. 22 Male  D.O.B. 19.02.1939  
U.P.N. 22 was found to be anaemic when he was admitted for a left total hip replacement 
in January 2005. He was given a 2 unit transfusion prior to the operation but remained 
tired and anaemic post-op. He started with haemoglobinuria and “indigestion” during an 
episode of diarrhoea and vomiting in May 2005. PNH was diagnosed in June and he 
started eculizumab in September 2005. He received 7 units of blood in the 12 months 
preceding starting eculizumab. He continued to require intermittent transfusions (2 units 
every 6 weeks). In April 2009 he developed a seronegative arthropathy, which affected 
his spine, hands, elbows, shoulders, hips and knees. This became progressively worse and 
his eculizumab was stopped in March to see if it the arthropathy would improve. 
Unfortunately he developed ischaemic colitis with evidence of small vessel thrombosis 
and restarted eculizumab. His arthropathy did not improve on discontinuing eculizumab. 
His transfusion requirement increased gradually from early 2009 with him needing 3 
units of blood every 2-3 weeks by January 2010. A bone marrow examination in January 
2009 revealed he had developed refractory anaemia with multilineage dysplasia. He 
continued to deteriorate and died from his MDS in September 2010. 
 
U.P.N. 23 Female D.O.B. 18.05.1945  
U.P.N. 23 became unwell in early 2008 with bruising and blood blisters in her mouth. 
She then had several episodes of collapse and severe lethargy over the following 6 
months. She received a transfusion in May 2008 and was found to be pancytopenic 
(haemoglobin 10.5g/dl, neutrophils 1 x 109/l, platelets 30 x 109/l). Since this initial 
transfusion she was transfused every 4-5 weeks. In May 2009 a diagnosis of aplastic 
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anaemia was made and she was treated with ciclosporin for 6 weeks. This was 
discontinued due to renal dysfunction, (creatinine 375mmol/l) which resolved on 
stopping immunosuppression. PNH was diagnosed in August 2009. Since her diagnosis 
she needed 2 units of blood every 3 weeks as she is very symptomatic with anaemia when 
her haemoglobin is below 11g/dl. In the week leading up to her transfusions she would 
have haemoglobinuria, oesophageal spasm, abdominal pain and lethargy. She has not had 
any thrombotic complications. She had a low grade non-Hodgkins lymphoma diagnosed 
in 1999. This was treated with surgery followed by radiotherapy. She commenced 
eculizumab in June 2010. 
 
U.P.N. 24 Male  D.O.B. 31.12.1961  
U.P.N. 24 presented with symptoms in 1977, at the age of 15, when he suddenly 
developed breathlessness and black urine. He was diagnosed with PNH and continued to 
have intermittent episodes of haemoglobinuria. Over time these episodes increased in 
both their frequency and severity. He was first reviewed in Leeds in March 2004 and at 
this stage he was having these episodes every 4-6 weeks. He started to require blood 
transfusions in 1996 and since then he has received 2-3 units of blood every 2 months. 
During severe episodes of haemolysis he also experienced dysphagia, abdominal pain, 
erectile dysfunction and severe lethargy. He has never had a thrombosis. He commenced 
eculizumab in November 2004, which has stopped his PNH symptoms. He has also 
become transfusion independent. 
 
U.P.N. 25 Male  D.O.B. 26.10.1988 
U.P.N. 25 was diagnosed with severe aplastic anaemia in June 2009 whilst being 
investigated for tiredness, loss of appetite and easy bruising. He was treated with rabbit 
antithymocyte globulin (ATG) and ciclosporin and his counts gradually improved. He 
remained well and transfusion independent until October 2008 when his blood count 
deteriorated and he started needing regular transfusions. In September 2009 PNH was 
diagnosed after an episode where he passed black urine. He was transfused 12 units of 
red blood cells in 2009. He has never had a thrombosis. Eculizumab was started in 
January 2010. Although his symptoms due to PNH improved on eculizumab, he still 
required regular transfusions up to the end of the study period (July 2010). 
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U.P.N. 26 Male  D.O.B. 31.10.1960  
U.P.N. 26 developed abdominal discomfort in March 2003. This discomfort, 
haemoglobinuria, dysphagia and a feeling of being “bloated” recurred periodically with 
typical episodes lasting 3-5 days. He underwent a normal colonoscopy and gastroscopy. 
Over time his symptoms became more severe and in September 2004 he was found to be 
pancytopenic and was diagnosed with PNH. He has never had a thrombosis but a repeat 
abdominal ultrasound scan in 2004, revealed splenomegaly, which may have been due to 
a prior intra-abdominal thrombosis. He started eculizumab therapy in the SHEPHERD 
trial in September 2005.  
 
U.P.N. 27  Male  D.O.B. 10.12.1951  
U.P.N. 27 first developed symptoms in 1965 with jaundice, anaemia and dark urine. In 
1970 he began to need regular transfusions, initially 5 times a year but by 2000 he needed 
monthly transfusions. He suffered with monthly “paroxysms” with dysphagia, 
haemoglobinuria, back pain and lethargy. He also experienced erectile dysfunction. He 
has never had a thrombosis. He started eculizumab in the pilot study in 2002 and has 
generally remained well since, requiring only 7 transfusions between 2002 and 2010. 
 
U.P.N. 28  Male  D.O.B. 29.01.1962  
U.P.N. 27 was diagnosed with PNH in June 2000. He had previously been a regular blood 
donor but failed screening in 1998 due to anaemia. He remained well until December 
1999 when he suffered with a viral infection and severe fatigue. This led to the diagnosis 
being made. Since his diagnosis he has had dark urine most days with occasional 
episodes of black urine, lethargy and abdominal and chest pain. He also had erectile 
dysfunction. He started to require transfusions in July 2003. Eculizumab was started in 
December 2004. His symptoms have resolved and he has not required a transfusion since 
2004. 
 
U.P.N. 29  Male  D.O.B. 01.12.1953 
U.P.N. 29 presented in 1977 with a flu-like illness. He was found to be pale and had 
severe anaemia. He was diagnosed with a haemolytic anaemia and was treated with 
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corticosteroids from 1977 until 1989. PNH was diagnosed in 1980 and he had his first 
blood transfusion in 1981. He did not need further transfusions until 1987 and between 
1987 and 2006 he received approximately one transfusion a year. In 2006 his transfusion 
requirement increased significantly to every 2-3 weeks. He has never had a thrombosis. 
He was diagnosed with adenocarcinoma of the colon in 2008, which was treated with 
surgery and capecitabine chemotherapy. He subsequently commenced eculizumab in 
August 2008. In March 2009 his adenocarcinoma recurred with metastases and he died. 
 
U.P.N. 30  Female D.O.B. 10.12.1951 
U.P.N. 30 presented in May 1998 with bruising and bleeding. She was diagnosed with 
severe aplastic anaemia and went on to receive equine ATG and ciclosporin in 1998. Her 
counts had normalised by October 2000. In July 2002 she moved to Belfast and whilst 
undergoing in vitro fertilisation she developed jaundice, black urine and was diagnosed 
with PNH. Between December 2003 and June 2005 she received approximately 10 
transfusions and was entered into the TRIUMPH study. She received placebo for 6 
months before commencing eculizumab in the extension study. She stopped eculizumab 
in October 2007 as she wished to become pregnant. She became pregnant with twins and 
due to concerns about her PNH she restarted eculizumab 26 weeks into the pregnancy. 
She underwent an elective caesarean section but had severe post-partum bleeding 
resulting in uterine artery embolisation and the administration of a prothrombin complex 
concentrate. Her eculizumab was stopped 3 months after the delivery due to funding 
restrictions but was re-commenced in August 2009 due to the development of a portal 
vein thrombosis. She did not receive a further transfusion from restarting eculizumab and 
the end of the study period. 
 
U.P.N. 31 Female D.O.B. 12.02.1937  
U.P.N. 31 was diagnosed with PNH in December 2004 after presenting with dark urine, 
severe lethargy, jaundice and dysphagia. She was started on prophylactic warfarin at the 
time of diagnosis and has never had a thrombosis. She was diagnosed with chronic renal 
failure in May 2007 and started to require regular transfusions in June 2007. She had an 
arterial venous fistula created as it was felt she would need haemodialysis. Eculizumab 
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was commenced in November 2008. She has not been transfused since the drug was 
started and her renal function improved without the need for haemodialysis. 
 
U.P.N. 32 Male  D.O.B. 15.07.1957  
U.P.N. 32 first presented in May 2005 with a 3 month history of tiredness and 
breathlessness. This was associated with abdominal and back pain and he was found to be 
anaemic. He was diagnosed with PNH and he suffered paroxysms of his disease every 2-
3 weeks with severe abdominal pain, lethargy and haemoglobinuria. In August 2006 he 
lost consciousness and when he came round he had a dense left hemiparesis, which lasted 
for 15 minutes. He required 2 units of blood transfused every 4-6 weeks from March 
2006. He has had no previous thrombosis. He commenced eculizumab in October 2008 
and has been transfusion independent since starting this treatment. 
 
U.P.N. 33 Male  D.O.B. 04.10.1930  
U.P.N. 33 started with symptoms in 2000, initially with abdominal pain and fatigue. He 
was found to be pancytopaenic and was diagnosed with PNH when he developed 
haemoglobinuria a few weeks later. He required 2-3 units of blood every month from the 
time of his diagnosis. He had significant other medical conditions including ischaemic 
heat disease, left ventricular failure and renal stones. He started eculizumab in April 
2009. His dosage was increased to 1200mg every 2 weeks in June 2009 as he had 
developed breakthrough haemolysis. He did experience symptomatic benefit from 
eculizumab treatment but died due to cardiac failure in January 2010. 
 
U.P.N. 34 Female D.O.B. 22.09.1937 
U.P.N. 34 was diagnosed as having severe aplastic anaemia in 2001 after collapsing at 
home. She was treated with ATG and ciclosporin with a haematological response. In 
November 2002 PNH was diagnosed whilst she was investigated for nausea and 
weakness. She began to need transfusions in December 2002 and was transfused 
approximately every 2 months. She entered the TRIUMPH study in 2005 and did not 
require a further transfusion from starting this treatment during the study period. She has 
never had a thrombosis. 
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U.P.N. 35 Male  D.O.B. 12.05.1926  
U.P.N. 35 was initially thought to have immune thrombocytopenic purpura in 1999 as he 
presented with bruising and thrombocytopaenia. PNH was diagnosed after he experienced 
dark urine in 2003. He was initially treated with corticosteroids and intermittent 
transfusions (approximately every 6 weeks). He suffered with severe dysphagia during 
acute episodes. He started eculizumab in July 2005 and has been transfusion independent 
since October 2005. He has never had a thrombosis. 
 
U.P.N. 36 Female D.O.B. 28.04.1985 
U.P.N. 36 presented in May 2006 with 3-4 months of increasing tiredness. She was 
diagnosed with aplastic anaemia and treated with ATG and ciclosporin. She had severe 
serum sickness including pulmonary haemorrhage, requiring a stay in the intensive care 
unit. The ciclosporin was stopped in December 2007 as she had had a haematological 
response. In February 2008 she became pancytopaenic and was diagnosed with PNH and 
AA. She was treated with corticosteroids but became cuishingoid. She recommenced 
ciclosporin in January 2009. Her PNH clone size increased significantly from a 
granulocyte clone of 2.55% in May 2006 to 93.5% in November 2010. She became 
transfusion dependent in September 2009 and commenced eculizumab in June 2010. She 
has never had a thrombosis. 
 
U.P.N. 37 Male  D.O.B. 16.04.1942  
U.P.N. 37 started with symptoms in December 2003 when he noticed intermittent black 
urine. He was initially investigated for urinary tract problems. He became symptomatic 
with fatigue, daily haemoglobinuria, abdominal pain and dysphagia. A diagnosis of PNH 
was made in June 2006. In 2008 he spent over 3 months in hospital in 5-6 separate 
admissions due to severe dysphagia and abdominal pain requiring opiates. He was 
transfused regularly from 2010, requiring 2 units of blood every 2-4 weeks. He started 
eculizumab in November 2008 with a resolution of his dysphagia and abdominal pain. He 
has continued to need 1-2 transfusions a year since starting eculizumab. 
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U.P.N. 38 Male  D.O.B. 02.05.1953  
U.P.N. 38 was diagnosed with aplastic anaemia in May 1988 after a 3 week history of 
breathlessness and spontaneous bruising. He was treated with ATG in June and again in 
December 1988 as well as with oxymethalone in 1988 and danazol and cyclosporin from 
1989 to 1993 and 2011, respectively. He became transfusion dependent in 1993 needing 
2-4 units of blood every 4-6 weeks. He was diagnosed with PNH in September 1993. He 
suffered acute episodes of PNH every 4-5 weeks, experiencing haemoglobinuria, fatigue 
and severe dysphagia especially to liquids. He commenced eculizumab in the pilot study 
in May 2002 with marked symptomatic improvement. His last transfusion whilst on 
eculizumab in the study period was in July 2008. He has never had a thrombotic event. 
 
U.P.N. 39 Male  D.O.B. 20.05.1958  
U.P.N. 39 was diagnosed with PNH whilst being investigated for abdominal pain and 
“haematuria” in 1994. He suffered with haemolytic episodes initially every 2-3 months 
where the main symptoms were abdominal pain and haemoglobinuria. These attacks 
became more frequent and he started on regular transfusions in 1999, having 3 units of 
red cells every 3 weeks. In 2001 he had a severe haemolytic episode where he developed 
acute renal failure requiring 2 weeks of haemodialysis. He has never had a thrombosis. 
He started eculizumab in the SHEPHERD trial in August 2005. He has received 3 red cell 
transfusions from starting eculizumab to the end of the study period. These transfusions 
were needed as he had increased haemolysis associated with infections. 
 
U.P.N. 40 Female D.O.B. 04.11.1974  
U.P.N. 40 initially had red urine in April 2002. This recurred in September 2002 after a 
viral infection. PNH was diagnosed in November 2003 when she was found to be 
anaemic and was symptomatic with haemoglobinuria and dysphagia. She was treated 
with corticosteroids until August 2004 with no clinical improvement. In September 2004 
she experienced a dermal vein thrombosis and in December 2004 she developed a portal 
vein thrombosis. She had a transjugular intrahepatic portosystemic shunt (TIPPS) inserted 
in August 2005 and started eculizumab in September 2005. Since starting eculizumab she 
has continued to need intermittent transfusions but has not had a further thrombosis. 
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U.P.N. 41 Male  D.O.B. 05.11.1965  
U.P.N. 41 was diagnosed with severe AA in November 1997 and treated with ATG and 
ciclosporin. He had a good response to this and the ciclosporin was stopped in October 
1998. He remained well until January 2001 when he was diagnosed with PNH after 
experiencing recurrent episodes of haemoglobinuria, dysphagia and abdominal pain 
during the previous 6 months. He required monthly transfusions usually with 2 units of 
red cells from the time of his diagnosis. In September 2001 he had a length of infarcted 
ileum removed due to thrombosis. He started eculizumab in September 2002. The 
frequency of dosing was increased to every 12 days in March 2003 due to breakthrough 
haemolysis. This was altered to an increased dose of 1200mg every 14 days in October 
2007 for convenience. Since being treated with eculizumab he has required only 
occasional transfusions. 
 
U.P.N. 42 Male  D.O.B. 05.10.1989  
U.P.N. 42 was diagnosed with severe AA in April 2005 after presenting with epistaxis 
and pancytopenia. He was treated with equine ATG and ciclosporin in June 2006. He 
became transfusion independent within 2 months. In March 2007 he was diagnosed with 
PNH after developing haemoglobinuria and abdominal pain. He continued these 
symptoms intermittently and became transfusion dependent in 2007 requiring 2-3 units of 
red cells every 4-6 weeks. Ciclosporin was restarted in November 2009 without benefit. 
He started eculizumab in June 2010. He has never had a thrombosis. 
 
U.P.N. 43 Male  D.O.B. 26.06.1962  
U.P.N. 43 was diagnosed with found to be anaemic in June 1997. An initial diagnosis of 
pyruvate kinase deficiency was made in 1999. In May 2000 he was diagnosed with PNH 
and he began to be regularly transfused, having 40-50 units of red cells a year. He 
experienced severe fatigue and daily haemoglobinuria. He has never had a thrombosis. 
He commenced eculizumab in November 2008. He has had a symptomatic improvement 
but has still needed intermittent red cell transfusions, approximately 2 units every 8 
weeks. 
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U.P.N. 44 Female D.O.B. 14.12.1967  
U.P.N. 44 presented with severe anaemia and haemoglobinuria and was diagnosed with 
PNH in October 2006. She was extremely symptomatic with fatigue/lethargy, which 
affected her quality of life. She received 15 units of red cells from the time of her 
diagnosis to starting eculizumab in May 2008. She has only required 1 transfusion since 
starting this drug, which was only a few weeks after starting eculizumab. She has never 
had a thrombosis. 
 
U.P.N. 45 Female D.O.B. 21.10.1980    
U.P.N. 45 was admitted to hospital after an episode where she collapsed in October 2003. 
She was found to be anaemic and further investigations lead to a diagnosis of PNH in 
February 2004. The main symptoms she experienced were fatigue and haemoglobinuria. 
She had a single transfusion in October 2003 and has never had a thrombosis. She 
commenced eculizumab in July 2005 in the SHEPHERD trial. She has not required a 
further transfusion since 2003. 
 
U.P.N. 46 Male  D.O.B.  11.05.1939  
U.P.N. 46 was diagnosed with PNH in 1991 after being investigated for anaemia. He 
developed haemoglobinuria and started to require regular transfusions in 1994, initially 
only every 3 months but this increased to four units of red cells every 5 weeks by 2004. 
He started eculizumab in July 2005. He had a marked improvement in his overall 
condition but continued to need intermittent transfusions related to concurrent infections. 
He has never had a thrombosis. 
 
U.P.N. 47 Female D.O.B. 25.06.1987    
U.P.N. 47 presented in June 2006 with abdominal pain and anaemia. She was thought to 
have atypical Still’s disease and started on corticosteroids, which were stopped in 
September 2007. She started with haemoglobinuria in November 2006 and was 
diagnosed with PNH in January 2007. In May 2007 she was admitted to hospital with 
headaches and found to have both a cerebral vein thrombosis and a portal vein 
thrombosis, despite anticoagulation with warfarin. She had an extension of the cerebral 
vein thrombosis and subsequently commenced eculizumab in July 2007. She was 
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transfused 9 units of red blood cells prior to starting eculizumab and has not required 
further transfusions since July 2007. She has not experienced any further thromboses. 
 
U.P.N. 48 Female D.O.B. 03.09.1922 
U.P.N. 48 was diagnosed with PNH in 1997 having had intermittent episodes including 
haemoglobinuria, abdominal pain, dysphagia and lethargy for approximately 36 months. 
In 2002 she became transfusion dependent requiring 2 units of red cells every 8 weeks. 
She has not had a thrombosis. She started eculizumab in July 2009. She has continued to 
feel tired and require intermittent transfusions whilst on eculizumab but has not had any 
of her other PNH related symptoms. 
 
U.P.N. 49 Male  D.O.B. 06.09.1971  
U.P.N. 49 was found to be anaemic (haemoglobin 5.7g/dl) when he was screened as a 
blood donor in December 2008. Initially he had no other symptoms but started with an 
episode of haemoglobinuria, abdominal pain and severe lethargy in January 2009. He 
searched his symptoms on the internet and thought they fitted with a diagnosis of PNH 
which was confirmed in February 2009. He had further paroxysms of PNH in March and 
May, the latter requiring a blood transfusion. He developed a hepatic vein thrombosis the 
week before he started eculizumab in May 2009. He has not required a transfusion or had 
further thrombotic complications since starting eculizumab. 
 
U.P.N. 50 Male  D.O.B. 25.01.1988  
U.P.N. 50 developed breathlessness and lethargy in 2004 whilst at College. He lost 1 and 
a half stone in weight due to dysphagia and was initially referred to an eating disorder 
clinic. He was diagnosed with PNH in April 2005 after becoming anaemic in February of 
that year. Since August 2005 he experienced daily haemoglobinuria with his urine colour 
clearing during the day. In December 2005 he was admitted with acute kidney failure due 
to a severe disease paroxysm. This resolved with conservative treatment. Towards the 
end of 2007 he became transfusion dependent, requiring 3 units of blood every 6 weeks. 
He was also having recurrent abdominal pains. He commenced eculizumab in August 
2008 with a marked clinical response. In October 2008 he became unwell with 
meningococcal septicaemia. He had a further serious septic episode in July 2009, 
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although meningococcus was not identified during the second illness. In July 2009 his 
eculizumab was stopped due to concerns about the infections and because his granulocyte 
clone had fallen to around 30%. Eculizumab was restarted in April 2010 as his PNH 
clone had risen and he was again requiring regular transfusions. He has never had a 
thrombosis. 
 
U.P.N. 51 Male  D.O.B. 19.01.1960  
U.P.N. 51 was initially diagnosed with PNH in 1981, having progressive tiredness, severe 
lethargy and haemoglobinuria. He began regular transfusions in 1981 and between 1981 
and 2007 he received 3 units of blood every 12 weeks. Since 2007 his transfusion 
requirement increased to 2 units of blood every 4 weeks. He has never had a thrombosis. 
He started treatment with eculizumab in April 2010, 2 months before the end of the study 
period. 
 
U.P.N. 52 Female D.O.B. 01.01.1962  
U.P.N. 52 was diagnosed with AA in 1994. She was treated with equine ATG and 
ciclosporin with normalisation of her blood counts. The ciclosporin was stopped in July 
1996. In July 2003 she was diagnosed with PNH after becoming anaemic. She required 
regular blood transfusions every 6 weeks from 2004 and commenced eculizumab in 
January 2005. She has never had a thrombosis and has not received a transfusion since 
starting eculizumab. 
 
U.P.N. 53 Male  D.O.B. 10.03.1976  
U.P.N. 53 was diagnosed with PNH in March 1999 and suffered a portal vein thrombosis 
in April 1999. He began to require regular transfusions in 2000 with the frequency of 
these gradually increasing. He experienced regular episodes of abdominal pain and daily 
haemoglobinuria with his urine never really clearing. He started eculizumab in June 2005 
and although he stopped requiring transfusions he remained anaemic with a haemoglobin 
level between 7-9g/dl. In April 2007 his eculizumab dose was increased to 1200mg every 
14 days due to breakthrough intravascular haemolysis. In November 2009 his dose was 
again increased due to breakthrough haemolysis, up to 1500mg every 14 days. Since then 
he has remained well and his haemoglobin has become normal. 
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U.P.N. 54 Male  D.O.B. 2.11.1963  
In 1977 U.P.N. 54 was found to be anaemic but a cause for this was not determined. This 
anaemia persisted and PNH was diagnosed in 1995 after he developed haemoglobinuria 
and abdominal pain. He became transfusion dependent in 1995, initially only requiring 1-
2 transfusions a year, although this increased in frequency to 2 units of blood every 2 
months by 2002. He has never had a thrombosis. Prior to starting eculizumab in May 
2005 he was also suffering with recurrent dysphagia and erectile dysfunction. Since 
starting eculizumab he has not required a transfusion and his other symptoms have 
resolved. 
 
U.P.N. 55 Male  D.O.B. 27.09.1979  
U.P.N. 55 initially presented with jaundice in December 2006. At the time he was 
drinking around 50 units of alcohol a week. During 2007 and 2008 he had intermittent 
blurred vision, nausea, vomiting, abdominal pain and difficulty swallowing. These 
symptoms were all put down to be due to his high alcohol intake. In February 2009 he 
had a stroke with right-sided paralysis. He commenced eculizumab in July 2009 but 4 
days before starting eculizumab he became blind in his left eye due to a central retinal 
vein thrombosis. He has not had any further thromboses since starting eculizumab and 
has never needed a transfusion. 
 
U.P.N. 56 Female D.O.B. 26.12.1975  
U.P.N. 56 became ill after her first pregnancy in 1998. One month after she gave birth 
she developed dark urine, dysphagia and intermittent temperatures. Within a month PNH 
was diagnosed and she was given regular transfusions every 4 months. She became 
pregnant again and delivered a second baby in January 2000. A week after the delivery 
she had a haemolytic episode, which was complicated by acute renal failure and a hepatic 
vein thrombosis. She began eculizumab therapy in September 2005; at this time she was 
being transfused every 8 weeks. She has not required a transfusion since starting 
eculizumab. 
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U.P.N. 57 Female D.O.B. 08.01.1981  
U.P.N. 57 was diagnosed with both AA and PNH in 1997 when she was being 
investigated for anaemia. From 1997 she was transfusion dependent, needing 4 units of 
blood every 6-8 weeks. She had frequent episodes of dark urine, severe lethargy and 
abdominal pain. She started eculizumab in the pilot study in May 2002. Her transfusion 
requirements reduced on eculizumab, but she still needed 3-4 transfusions a year. She has 
had 2 pregnancies during the study period and elected to remain on eculizumab whilst 
pregnant. Her transfusion requirement increased when she was pregnant. 
 
U.P.N. 58 Female D.O.B. 23.08.1978  
U.P.N. 58 was well until February 2001 when she presented with abdominal pain and 
ascites. She was found to have a portal vein thrombosis and underwent angioplasty and a 
TIPPS. At this time she was diagnosed with PNH. She had needed regular transfusions 
since August 2003, having 2 units every 6 weeks. She started eculizumab in June 2005. 
She has not needed a transfusion since 2007. 
 
U.P.N. 59 Female D.O.B. 18.07.1967  
U.P.N. 59 was diagnosed with PNH in February 2001 having been unwell for the 
preceding 8 months. Since her diagnosis she has had intermittent haemoglobinuria every 
3 weeks, which was associated with severe lethargy and back pain. She had a possible 
DVT in August 2000, but this was not proven by imaging. She had 3 separate 
transfusions prior to starting eculizumab in June 2005. Since being on eculizumab she has 
had occasional transfusions, usually associated with infections, with the last one in the 
study period being in August 2009. 
 
U.P.N. 60 Male  D.O.B. 17.04.1956  
U.P.N. 60 was diagnosed with PNH in October 2005 after presenting with a swollen left 
leg thought to be a DVT, although this was not imaged at the time. Since his diagnosis he 
has needed to be transfused with 2-3 units of blood every month. He started eculizumab 
in November 2008 and his PNH symptoms have resolved. His last transfusion in the 
study period was in March 2009. 
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U.P.N. 61 Male  D.O.B. 04.07.1951  
U.P.N. 61 was diagnosed with AA and PNH in 1996. He was treated with 2 courses of 
ATG and ciclosporin, in February 1998 and in March 1999. From 1998 onwards, he was 
transfused 2 units of blood every 8 weeks. He became blind in his left eye in September 
1998, which was thought to be due to a thrombosis. He commenced eculizumab in June 
2002 and has not required a transfusion since November 2003. In January 2009 he 
stopped eculizumab as his PNH granulocyte clone had fallen to 10%. 
 
U.P.N. 62 Male  D.O.B. 05.12.1952  
U.P.N. 62 was diagnosed with PNH in October 2001 with a 4 month history of 
progressive anaemia, erectile dysfunction, intermittent jaundice and dark urine. Since 
2002 he required regular transfusions, having 2 units of blood approximately every 4 
weeks. He commenced eculizumab in December 2004. He underwent a cholecystectomy 
in December 2007, which is the last time he required a blood transfusion. 
 
U.P.N. 63 Male  D.O.B. 11.09.1979  
U.P.N. 63 first presented in February 2006 with abdominal discomfort, haemoglobinuria 
and pancytopaenia and a diagnosis of PNH was established. Since his diagnosis he has 
needed approximately 4 transfusions a year and has continued to experience dark urine, 
abdominal pain and bloating and fatigue. He started eculizumab in November 2008 and 
remained transfusion independent and symptom-free during the study period. He has 
never had a thrombosis. 
 
U.P.N. 64 Female D.O.B. 03.12.1976  
U.P.N. 64 was diagnosed with severe AA in March 1995 and was treated twice with ATG 
and ciclosporin in May 1995 and July 1996. She first noticed dark urine in August 1998. 
She had paroxysms of PNH at least every month lasting for 3-5 days at a time. During 
these episodes she would experience haemoglobinuria, dysphagia and fatigue. She 
needed 4 transfusions in the 12 months preceding the start of eculizumab in June 2002. 
She became pregnant and delivered a pre-term infant in April 2009. She remained on 
eculizumab throughout the pregnancy. Other than during the pregnancy she has remained 
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free from PNH symptoms and transfusion independent during the study period. She has 
never had a thrombosis. 
 
U.P.N. 65 Male  D.O.B. 13.09.1938  
U.P.N. 65 was diagnosed with PNH in Holland in 1975 when he presented with 
abdominal pain and dark urine. Since 1975 he has had haemoglobinuria most mornings 
with more severe haemolytic episodes, including abdominal pain and dysphagia, 
occurring on average once a month. In 2003 he commenced regular transfusions, having 
2 units of blood every 2-3 months. He started eculizumab in May 2005 and since then he 
has only required 2 transfusions, with the last one being in January 2009. There was a 
progressive deterioration in his renal function in 2003 and in July 2006 he began regular 
haemodialysis. In October 2007 he was found to have a thrombosis in his arterio-venous 
fistula and another one was fashioned.  
 
U.P.N. 66 Female D.O.B. 28.03.1944 
U.P.N. 66 presented in 2001 with AA after a 6 month history of bruising, breathlessness 
and palpitations. She was treated with supportive care and was transfusion dependent 
from 2001, having 2-3 units of blood every 6-8 weeks up until she started eculizumab in 
June 2009. She was symptomatic with fatigue, haemoglobinuria, abdominal pain, 
dysphagia, diarrhoea and breathlessness. She did not become transfusion independent on 
eculizumab, still requiring occasional transfusions, but her other symptoms resolved. 
 
U.P.N. 67 Male  D.O.B. 26.09.196  
U.P.N. 67 was diagnosed with PNH in August 1991 when he was being investigated for 
anaemia and abdominal pain. He was treated with corticosteroids continuously between 
1992 and 2010 with a subsequent Cuishingoid appearance and diabetes. He continued to 
have intermittent abdominal pain and was transfused 1-2 times a year between 1994 and 
1999. He suffered a portal vein thrombosis in 1998. Eculizumab was started in 
September, which has enabled his corticosteroid treatment to be stopped in May 2010.  
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U.P.N. 68 Male  D.O.B. 07.02.1943  
U.P.N. 68 was diagnosed with AA in March 1984 after a six week history of 
breathlessness, spontaneous bruising and recurrent sore throats. In 1984 he was given 
oxymethalone but was intolerant of this. Danazol was commenced in 1985 prior to ATG 
later the same year. PNH was diagnosed in February 1987 after he developed 
haemoglobinuria. He experienced regular disease paroxysms every 5-6 weeks including 
abdominal pain, severe fatigue and haemoglobinuria. He also experienced erectile 
dysfunction. He required regular transfusions approximately every 6-8 weeks from the 
time of his diagnosis up until starting eculizumab in May 2002. Sine starting eculizumab 
he has not required a transfusion and has not had symptoms attributable to PNH. He has 
never had a thrombosis. 
  
U.P.N. 69 Female D.O.B. 31.03.1968  
U.P.N. 69 presented with numbness of her foot in September 2007. She was diagnosed 
with PNH that month after being found to be pancytopaenic. In March 2008 she was had 
a suspected pulmonary embolus but this was not proven. She first experienced 
haemoglobinuria at this time. She remained relatively well until May 2010 when she 
developed pneumonia associated with associated severe haemolysis. She had 3 blood 
transfusions during this hospital admission. Two weeks later she was again admitted to 
hospital with abdominal pain due to small bowel ischaemia. She also had 3 further 
transfusions in this period. She began eculizumab in June 2010 just before the end of the 
study period. 
 
U.P.N. 70 Male  D.O.B. 19.03.1994  
U.P.N. 70 was diagnosed with severe AA in October 1999. He was treated with ATG and 
ciclosporin in April 2000, with an initial improvement in his blood counts. Ciclosporin 
was stopped in November 2004. His blood count deteriorated and a diagnosis of PNH 
was made in February 2005. He became transfusion dependent in 2005, receiving blood 
every 5-6 weeks. He also experienced fatigue, recurrent abdominal pain, 
haemoglobinuria, headaches and dizziness prior to his transfusions. He commenced 
eculizumab in November 2008 but continued to require transfusions due to underlying 
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aplasia. Ciclosporin was restarted in November 2009. He did not experience a thrombosis 
during the study period. 
 
U.P.N. 71 Female D.O.B. 25.08.1926  
U.P.N. 71 initially presented in January 2003 with dark urine and anaemia. She suffered a 
stroke in January 2004, which affected her vision. Initially she did not require 
transfusions but continued to experience 2-3 disease paroxysms a year, which included 
haemoglobinuria, abdominal pain and fatigue. She started eculizumab in August 2005 
with an improvement in her symptoms but she had a retinal vein thrombosis in May 
2007, despite eculizumab therapy and therapeutic anticoagulation. 
 
U.P.N. 72 Female D.O.B. 21.07.1966  
U.P.N. 72 presented in 1984 with pancytopaenia and was diagnosed with aplastic 
anaemia. She received 2 courses of ATG, the first in 1984 and the second in 1985. She 
partially responded to the second course. In 1986 she was diagnosed with PNH, at this 
stage she was requiring blood transfusions every 6 weeks. In December 1996 she was still 
needing the same level of transfusion support but she developed black lesions on her left 
hand, side and foot which were thromboses originating from her heart. She had 2 cardiac 
arrests but made a gradual recovery. Since 1997 she has needed 3 monthly blood 
transfusions and only experienced haemoglobinuria at times of concurrent infection. 
Eculizumab was started in October 2008 and she has not required a transfusion or 
experienced a further thrombosis since then. 
 
U.P.N. 73 Female D.O.B. 23.04.1935  
U.P.N. 73 was diagnosed with PNH in 2001 after developing pancytopenia and easy 
bruising. She initially required blood transfusions every 7 weeks but this gradually 
increased in frequency to every 5 weeks. She has had occasional episodes of abdominal 
pain and haemoglobinuria. She has never had a thrombosis. She started eculizumab in 
November 2009 but continued to need regular transfusions, 2 units every 4 weeks, during 
the study period. 
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U.P.N. 74 Female D.O.B. 17.07.1991  
U.P.N. 74 was found to be severely anaemic in September 2005 and required a blood 
transfusion. PNH was diagnosed in January 2006 when she developed acute renal failure. 
She required dialysis and further transfusions before her kidney dysfunction resolved. 
Since this episode she experienced daily haemoglobinuria and 4 weekly transfusions. She 
has never had a thrombosis. She started eculizumab in November 2008 and has not 
required a transfusion since. She also no longer has haemoglobinuria. 
 
U.P.N. 75 Male  D.O.B. 29.12.1952  
U.P.N. 75 was diagnosed with hypoplastic MDS in August 2006 after being unwell for 3 
months. He received ATG and subsequent ciclosporin in June 2007 but remained 
transfusion dependent, receiving 3 units of blood every 4 weeks. He has had occasional 
haemoglobinuria since September 2008 when PNH was diagnosed. He received a further 
course of ATG in February 2009 before starting eculizumab in September 2009. He 
continued to require regular transfusions in the study period, having 2 units of blood 
every 5 weeks. 
 
U.P.N. 76 Male  D.O.B. 31.05.1986  
U.P.N. 76 was diagnosed with PNH in March 2007 whilst being investigated for anaemia. 
He had had intermittent haemoglobinuria since December 2006. In 2009 his symptoms 
became more severe, having daily haemoglobinuria, severe fatigue, abdominal pain and 
erectile dysfunction. He started to require regular transfusions every 4 weeks in August 
2009. He started eculizumab in May 2010, a month before the end of the study period. He 
has never had a thrombosis. 
 
U.P.N. 77 Female D.O.B. 06.03.1938  
U.P.N. 77 presented with leg weakness in January 2005. Imaging revealed a prior stroke 
and her symptoms resolved in 48 hours. At the time she was found to be anaemic and was 
diagnosed with MDS and PNH. Since January 2005 she required 2-3 units of blood 
transfused every 6-8 weeks. She did not have other PNH symptoms and has never had a 
thrombosis. She started eculizumab in April 2009 and she has not needed a transfusion 
sine then.  
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U.P.N. 78 Male  D.O.B. 01.03.1940  
U.P.N. 78 was diagnosed with PNH in October 2007 having been previously thought to 
have had immune thrombocytopenic purpura since 1993. PNH was suspected when he 
became pancytopenic. He began to require transfusions in 2008 and was also 
symptomatic with angina, which was felt to be in part due to his anaemia. Eculizumab 
was started in October 2009, but he still required regular transfusions during the study 
period. He has never had a thrombosis. 
 
U.P.N. 79 Female D.O.B. 27.01.1981  
U.P.N. 79 was diagnosed with severe AA and PNH in August 2005 after a 3 month 
history of fatigue and spontaneous bruising. In October 2005 her counts recovered 
without treatment coinciding with her PNH clone increasing significantly. She began to 
require regular transfusions in 2009 and at the time she began to experience 
haemoglobinuria. She has never had a thrombosis. She started eculizumab in July 2009 
and has not needed a blood transfusion since then. 
 
 
3.6 Patient data at diagnosis and prior to starting eculizumab 
 
3.6.1 Sex 
 
The proportion of males to females with PNH was equal (40 males and 39 females). 
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Figure 3.1 The age at diagnosis of 79 patients. 
 
 
3.6.2 Age 
 
The age at diagnosis is shown in Figure 3.1. The median age at diagnosis was 37 years 
old. The youngest patient was 12 years old at the time of diagnosis and the oldest was 78 
years old. 
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Figure 3.2 Symptoms experienced by 79 PNH patients at the time the disease was 
diagnosed. 
 
 
3.6.3 Symptoms at Diagnosis 
 
The symptoms experienced by patients with PNH can be very varied with the commonest 
features often being non-specific in nature. The symptoms observed in these individuals, 
when their disease was diagnosed is shown in Figure 3.2. Most patients were anaemic at 
diagnosis (96%).  
 
3.6.4 Cytopenias in PNH 
 
The relationship between aplastic anaemia and PNH is well known and was a prominent 
feature in this patient cohort. A third of patients had previously had a documented history 
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of bone marrow failure (30%). The majority of these were AA but there was 1 case of 
MDS.  
 
3.6.5 Haemolysis as a Complication of PNH 
 
Chronic intravascular haemolysis is the underlying cause of many of the symptoms 
experienced by patients with PNH. Anaemia is an extremely common finding (see 
Section 3.6.3). As a consequence of their haemolysis many patients with PNH need 
regular transfusions to try to reduce the degree of lethargy/fatigue experienced. Seventy–
five of the 79 patients (94%) required transfusions prior to commencing eculizumab, with 
the number of transfusions in the year preceding eculizumab treatment varying from 2 
units to 156 units of red cells.  
 
3.6.6 Thrombosis as a Complication of PNH 
 
Venous thrombosis accounts for around half of the deaths attributable to PNH (Hillmen et 
al, 1995; Socié G et al, 1996; de Latour et al, 2008). It is also a significant cause of 
morbidity in patients with PNH. Thrombosis occurred in 21 of the 79 patients (27%) from 
the time PNH was diagnosed to the time the patient started eculizumab. Some patients 
experienced more than 1 thrombotic event, with a total of 34 separate thrombotic events 
occurring in these 21 patients. The sites of these thromboses are shown in Figure 3.3. The 
thromboses described were all proven by direct imaging, thus the incidence calculated are 
likely to be an underestimate of the true figure.  
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Figure 3.3 Sites of thrombosis experienced. 
 
 
3.7 Patient Data at the Start of Eculizumab Treatment  
 
3.7.1 Laboratory Findings 
 
The haematology laboratory findings for the patients when they began therapy with 
eculizumab are shown in Table 3.1.  
 
The haemoglobin was decreased in 74 out of the 77 patients (96%) where the 
haemoglobin level was known at the start of anti-complement therapy. The haemoglobin 
value was unknown in 2 cases as both these patients started therapy in a different country 
before moving to the United Kingdom. Out of the 4 cases where the haemoglobin was 
within the normal range at the start of therapy (haemoglobin >13.5g/dl in men and 
>11.5g/dl in women), 3 of these were due to blood transfusion support.  
 
 
 
 
12#
4#3#3#4#
3# 3# 2# Budd-Chiari Mesenteric Cerebral 
Pulmonary embolus 
Deep veins 
Other 
Stroke 
Myocardial infarction 
Arterial 
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UPN Haemoglobin WCC Neutrophils Platelets Reticulocytes LDH 
1 10.4 1.9 1 45 127 3691 
2 12.2 9.3 6.9 180 221 2990 
3 10.4 2.1 1.39 76 218 4762 
4 Unavailable Unavailable Unavailable Unavailable Unavailable 6811 
5 8.6 1.9 0.6 197 101 2403 
6 5.6 3.8 2.2 148 271 4671 
7 10.5 2.82 1.6 208 354 5262 
8 7.9 4.1 2.8 183 210 5269 
9 10.3 5.3 3.9 223 Unavailable 3308 
10 7.3 2.5 1.3 157 191 2142 
11 9.8 2.7 2 43 141 3982 
12 9.3 2.3 1.8 146 363 1707 
13 10.8 3.6 2.3 114 108 2298 
14 8.1 2.6 1.1 36 160 2042 
15 9.5 3 1.5 150 59 904 
16 7.3 3.7 2.4 100 104 1828 
17 11.6 5.4 3.8 259 286 4117 
18 12 5.5 4.1 58 148 2266 
19 12.4 14.96 11.9 439 254 1448 
20 8.3 6.4 3.8 28 392 5417 
21 9.9 3.2 2.1 151 415 8723 
22 9 8.1 5.9 383 140 2235 
23 12.6 3.7 1.8 164 124 1609 
24 9.4 1.7 0.61 85 288 5021 
25 6.8 5.7 3.9 176 183 2546 
26 8.5 2 1.21 43 95 4335 
27 13.5 7 4.6 501 120 2733 
28 10.2 4.5 2.88 216 Unavailable 7050 
29 9.1 3.1 2.1 46 158 1972 
30 10.9 3.4 1.59 241 170 1537 
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UPN Haemoglobin WCC Neutrophils Platelets Reticulocytes LDH 
31 8.7 4.8 3.7 159 200 5566 
32 9.2 4.9 2.9 268 268 6788 
33 8.7 7.3 5.8 153 355 4259 
34 10.2 4.7 3.5 215 152 3208 
35 7.3 7.8 5.94 125 91 2192 
36 9.6 3.8 2.4 135 171 2433 
37 10.3 6.2 3 235 158 2791 
38 10.3 4.2 2.9 130 Unavailable 2044 
39 13.4 3.7 2.5 165 151 905 
40 4.9 2.3 1.6 80 262 5724 
41 12.9 5.3 4.2 182 138 587 
42 9.7 2.8 1.6 111 111 3799 
43 11.9 6 4.6 176 99 4107 
44 9.1 4.1 2.2 122 145 1166 
45 9.6 3.3 2.2 186 175 3637 
46 9.9 3.5 0.97 98 213 2943 
47 9.8 9.8 6.9 114 158 4312 
48 10.6 3.3 1.7 110 124 5017 
49 12.7 5.37 3.4 159 184 2916 
50 8.1 2.9 1.4 102 262 2072 
51 11.1 2.1 1 84 107 1928 
52 9.7 2.5 1.02 155 283 5225 
53 7.7 2.4 1.8 63 303 9130 
54 6.8 4.5 3.6 210 221 5124 
55 10.5 3.4 2.1 109 133 1374 
56 Unavailable Unavailable Unavailable Unavailable 164 Unavailable 
57 7.6 3.7 2.1 219 191 10300 
58 10.9 2.9 1.9 71 135 1857 
59 10.6 4.1 2.6 215 336 5666 
60 11.2 3.1 1.9 191 316 1486 
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UPN Haemoglobin WCC Neutrophils Platelets Reticulocytes LDH 
61 10.6 2.4 0.8 74 98 2745 
62 9.9 4.3 1.8 257 261 5424 
63 11.5 3.9 1.6 151 113 2572 
64 10.9 2.1 0.8 198 238 2642 
65 8.1 3.9 2.7 108 78 2075 
66 11.7 5.8 3.6 240 280 
Not 
performed 
67 8.9 8.4 7.3 85 206 1346 
68 11.6 4.2 2.52 233 154 2833 
69 9.1 3.9 0.9 91 271 2872 
70 8.1 2.9 1.2 107 328 4974 
71 10.1 4.8 3.6 295 194 3256 
72 10.4 3.3 2 235 134 2741 
73 9.8 8.2 6.1 80 57 1550 
74 9.3 5.8 4.2 144 287 4151 
75 13 3.7 1.8 11 109 1815 
76 11.9 4.5 2.9 156 233 6724 
77 10.8 3.6 2.5 119 88 2082 
78 9.8 3.8 2.1 81 99 1842 
79 10.2 5.7 3.7 149 171 3150 
 
Table 3.1 Laboratory values at the time of starting eculizumab. (Units – Hb g/dl, 
normal range 13.5- 18g/dl in men 11.5-16g/dl in women, white cell count (WCC) x 
109/L, normal range 4-11 x 109/L, neutrophils x 109/L, normal range 2-7.5 x 109/L, 
platelets x 10/9L, normal range 150-400 x 109/L, reticulocytes x 109/L, normal range 
20-80 x 109/L, LDH IU/L normal range 160-430IU/L). 
 
The range of neutrophil counts was between 0.6 and 11.9 x 109/L with the median level 
being 2.2 x 109/L. Twenty nine patients (38%) were neutropaenic with 6 of these having 
marked neutropaenia (<1.0 x 109/L). Thirty-seven patients (47%) were 
thrombocytopaenic at the start of eculizumab therapy with the range being between 11 
 117 
 
and 507 x 109/L. The median platelet count was 149 x 109/L. Reticulocyte counts were 
not performed/unavailable in 4 patients at the start of their eculizumab therapy. In those 
where it was performed the range varied between 57 and 415 x 109/L with the median 
level being 171 x 109/L. 
 
3.7.2 Clone Evaluation 
 
PNH clones were determined by 6 colour flow cytometry. Antibodies against CD55, 
CD59 and CD235a were used to assess the erythrocytes and CD15, CD33, CD14, CD16, 
CD24 and FLAER were used to assess the monocytes and granulocytes. The granulocyte, 
monocyte and erythrocyte clones at the start of eculizumab treatment are shown in table 
3.2. The granulocyte clones ranged between 41.8% and 100% with the median being 
96.4%. The erythrocyte clones ranged between 2.9% and 100% with the median being 
34%. The median level for type II and type III PNH erythrocytes was 3.8% and 25% 
respectively. 
 
3.7.3 Other Lab Tests 
 
Serum LDH levels at initiation on eculizumab treatment were available in 77 patients. 
LDH levels varied from 587 to 10300IU/L with the median value being 2872IU/L. In all 
cases the LDH was raised before eculizumab was commenced and in 76 of the 77 patients 
it was greater than 1.5 times the upper limit of normal. 
 
 
3.8 Patient Data on Eculizumab Treatment 
 
3.8.1 PNH Complications  
 
3.8.1.1 Intravascular Haemolysis and Transfusion Requirements 
 
As seen in Figure 3.4, there is a decrease in LDH values from those at the start of 
eculizumab therapy. The median LDH value was initially 2872 IU/L (range 587- 
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10300, upper limit of normal 430), which then fell to the most recent average recording 
of 477 IU/L (range 177-1793) (p<0.0001). 
 
 
UPN Granulocyte clone Total RBC clone RBC type II clone RBC type III clone 
1 99.49 33.41 11.39 22.02 
2 99.91 15.37 0.49 14.88 
3 99.9 82.94 27.57 57.37 
4 97.57 63.83 0.27 63.56 
5 66.99 40.86 0.35 40.51 
6 99.4 53.57 3.96 49.61 
7 99.91 16.59 4.69 11.9 
8 99.91 43.44 8.52 34.92 
9 97 37.24 0.25 36.99 
10 98.2 80.6 1 79.6 
11 90.8 46.2 0.9 45.3 
12 99.61 18.12 0.63 17.49 
13 95.58 22.67 2.4 20.27 
14 99.96 46.52 2.47 44.05 
15 96.5 68.35 50.92 17.43 
16 86.89 30.95 6.74 24.21 
17 99.92 21.65 0.85 20.8 
18 93.85 8.13 0.49 7.64 
19 75.58 43.37 12.73 30.64 
20 98.89 16.3 1.17 15.13 
21 99.88 40.26 1.25 39.01 
22 92.9 27.76 0.11 27.65 
23 87.3 unavailable unavailable unavailable 
24 96.38 42.13 8.68 33.45 
25 97.19 56.13 7.85 48.28 
26 83.39 20.05 3.64 16.41 
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27 93.27 38.45 8.04 30.41 
28 91.29 24.19 0 24.19 
29 96.88 26.97 24.57 2.4 
30 93.97 60.23 4.18 56.05 
31 99.88 60.82 26.77 34.05 
32 99.56 24.83 4.08 20.75 
33 99.98 35.8 10.83 24.97 
34 87.53 43.35 2.43 40.92 
35 98.8 21.19 6.72 14.47 
36 52.91 31.18 6.98 24.2 
37 97.38 41.17 4.98 36.19 
38 99.82 27.48 0.86 26.62 
39 96.05 27.65 7.94 19.71 
40 99.8 7.48 1.07 6.41 
41 96.98 50.69 1.39 49.3 
42 96.55 37.18 16.62 20.56 
43 96.83 2.97 0.15 2.82 
44 92.45 30.88 11.86 19.02 
45 99.95 100 77.35 22.65 
46 99.07 15.97 0.65 15.32 
47 95.5 31.08 20.32 10.76 
48 99.45 50.21 0.28 49.93 
49 99.58 36.9 27.82 9.08 
50 61.75 30.55 2.99 27.56 
51 99.48 33.8 4.11 29.69 
52 85.26 23.4 2.06 21.34 
53 98.2 57.17 22.56 34.61 
54 99.93 69.29 47.1 22.19 
55 84.09 48.36 3.82 44.54 
56 unavailable unavailable unavailable unavailable 
57 99.83 34.1 4.37 29.73 
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58 88.3 38.7 19.2 19.5 
59 99.7 42.82 0 42.82 
60 99.94 25.2 0.05 24.97 
61 47.78 39.72 25.07 14.65 
62 96.11 19.07 5.23 13.84 
63 89.71 41.08 0.45 40.63 
64 80.6 49.18 2.16 47.02 
65 93.68 12.9 0.4 12.5 
66 99.51 53.71 0.23 53.48 
67 47.76 28.34 20.58 7.6 
68 98.38 55.92 7.9 48.02 
69 99.4 unavailable unavailable unavailable 
70 99.61 47.09 16.66 30.43 
71 92.33 52 0 52 
72 53.12 51.72 1.26 50.46 
73 99.73 31.9 4.6 27.3 
74 96.23 57.71 5.68 52.03 
75 99.82 16.14 0.58 15.56 
76 63.6 28.5 1.64 26.86 
77 85.29 31.27 3.86 27.41 
78 64.05 15.93 1.13 14.8 
79 86.66 11.14 0.57 10.57 
 
Table 3.2 PNH clone (%) at the time of starting eculizumab. (RBC – Red Blood 
Cell). 
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Figure 3.4 LDH levels taken both at the start of eculizumab treatment and at the 
most recent clinical review. 
 
Eculizumab therapy also has an effect on transfusion requirements. Sixty-one of the 75 
patients (81%) both needed transfusions prior to commencing treatment and have now 
been on eculizumab for 12 months or greater. The mean number of units of blood 
transfused in the year prior to starting eculizumab was 19.9 units. When comparing units 
transfused over the most recent 12 months on eculizumab therapy with those over the 
same timescale prior to starting treatment, the number of units needed fell by 74%. 
 
As seen in Figure 3.5 a mean of 19.3 units (range 2-52) fell to 5.0 units (range 0-50) 
(p<0.001). Indeed, 40 of the 61 patients (66%) became transfusion independent, no 
longer requiring supplemental blood. Of the remaining 21 patients still needing 
transfusions in the most recent 12 months, the mean number of units required fell from 
24.6 units (range 4-52) to 14.6 units (range 2-50). This represents a significant reduction 
(p = 0.028). 
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Figure 3.5 Blood transfusion requirements in the 12 months before eculizumab 
therapy and the most recent 12 months on eculizumab treatment in 61 patients. 
 
 
3.8.1.2 Thrombosis 
 
Twenty-one of the 79 patients (27%) experienced thrombotic episodes prior to 
eculizumab. There were 34 thromboses in total - 16 of these (47%) occurred despite the 
patients being on anticoagulation therapy. Seven of the 21 patients had thromboses in the 
12 months prior to commencing eculizumab. 
 
There were 2 patients who temporarily stopped eculizumab and also needed to stop 
prophylactic anticoagulation. Both developed thromboses within 5 months of stopping 
the eculizumab therapy. One had experienced funding problems and the other developed 
a seronegative arthropathy of uncertain origin. Eculizumab was stopped to investigate 
whether the arthropathy would improve, but unfortunately it did not. Anticoagulation had 
also caused serious bleeding problems and was therefore discontinued. As a result neither 
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of these episodes is included in the statistical analysis as the thromboses occurred whilst 
off treatment. 
 
Two patients experienced thrombotic events whilst taking eculizumab. The first had a 
stroke before she started therapy and then developed retinal vein thrombosis despite both 
eculizumab and warfarin treatment. The second had a thrombosis in his arteriovenous 
fistula created for haemodialysis. He has end-stage renal failure but no previous 
thromboses. 
 
Comparisons can be made between the number of thrombotic events which occurred 
during the period from diagnosis to starting eculizumab therapy with the number 
occurring whilst on the treatment. The mean length of time between PNH diagnosis and 
starting eculizumab was 7.7 years (range 0-44) and the mean length of time on 
eculizumab was 3.3 years (range 0-8). There was a reduction in the rate of thrombotic 
events, from 5.6 per 100 patient years prior to starting eculizumab to 0.8 events per 100 
patient years whilst on therapy (p<0.001 by the Wilcoxon signed rank sum test). 
 
Due to the apparent protection against thromboses offered by eculizumab, the traditional 
prophylaxis with warfarin appears unnecessary. Prior to eculizumab, warfarin was 
commenced before patients experienced any thrombotic events. However, primary 
prophylaxis was stopped in 21 patients and secondary prophylaxis in another patient due 
to severe bleeding. Overall anticoagulation in patients on eculizumab has been stopped 
for a mean duration of 10.8 months (range 1-60) and a cumulative total of > 19 years 
during the study period. There have been no thrombotic events. If patients had a prior 
history of thrombosis then warfarin was not routinely stopped. 
 
3.8.1.3 Clonal Evolution 
 
Clonal change occurred in 3 patients (4%). MDS developed in 2 of these patients (71 and 
75 years old) 58 and 76 months respectively after eculizumab was started. Although in 
both patients the MDS occurred within the GPI-negative cells, almost the entirety of the 
myeloid series originated from the PNH clone (granulocyte clone 100% and 99.4% 
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respectively). The third patient, aged 50 years, developed acute myeloid leukaemia 
(AML) 27 years after his PNH was diagnosed. Again, although this occurred in GPI-
deficient cells, the myeloid series was derived from the PNH population (granulocyte 
clone 97.9%). Additionally, monosomy 7 had been found in his baseline bone marrow 
prior to starting eculizumab. He was treated with intensive chemotherapy. All 3 of these 
patients were treated with eculizumab until the end of the study period in July 2010. 
 
3.8.2 Effects of Eculizumab 
 
3.8.2.1 Platelets 
 
Platelet values can be compared in the 61 patients who have been on eculizumab 
treatment for 12 months. Individual platelet counts at this time were compared with levels 
at the time when eculizumab was started. No significant difference was found, with the 
mean platelet count being 161 x109/L as treatment was commenced and 163 x109/L after 
12 months. There were as many patients whose levels had increased as had decreased. 
Twelve patients were thrombocytopaenic (platelets <100 x109/L) when eculizumab was 
commenced and again, after treatment, no significant difference in values was found 
(mean platelet counts: 67 x109/L initially and 66 x109/L after 12 months of treatment). 
 
3.8.2.2 Meningococcal Infection 
 
Two patients (U.P.N. 10 and U.P.N. 51) developed meningococcal sepsis. Both made a 
rapid recovery after prompt treatment. Within the study period, this equates to an 
infection rate of 0.9 events per 100 patient years on eculizumab. 
 
3.8.2.3 Survival 
 
Figure 3.6 represents the survival curve for the study patients. They are compared with 
age and sex matched controls from within the UK population. As shown, there is no 
significant difference between the groups (p = 0.46). At 5 years after starting eculizumab 
treatment, there is a 0.8% (95% CI -4.2% to +5.8%) difference between the patient group 
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and the control. The difference then at 8 years on treatment is -0.8% (95% CI -5.8% to 
+4.2%). All 45 patients who were started on eculizumab prior to the age of 50 years are 
still alive. Figure 3.7 shows the survival curves for different age groups.  
 
 
 
 
Figure 3.6 Overall survival of the 79 patients from initiation of eculizumab 
treatment compared to age- and sex-matched controls. 
 
There were 3 deaths (4%) in the study population whilst on eculizumab, but no causes 
were related to PNH. One 55 year old patient had been diagnosed with disseminated 
metastatic caecal carcinoma before eculizumab was started. One 76 year old patient had a 
long history of recurrent bronchopneumonia, from which she died. And a 79 year old 
patient died from congestive cardiac failure secondary to long standing ischaemic heart 
disease. 
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Figure 3.7 Overall survival of the 79 patients from initiation of eculizumab 
treatment according to age. 
 
 
Another 30 PNH patients were assessed between 1997 and 2004. These patients fulfilled 
the criteria for eculizumab therapy but were not eligible for the trial at the time so their 
survival can be compared with the treatment group, as seen in Figure 3.8. This shows that 
the risk of death is significantly lower when on eculizumab. The p-value obtained from 
the time-dependent Cox model is 0.030, with a corresponding hazard ratio of 0.21 (95% 
CI 0.05-0.88). The 5 year survival for the group not on eculizumab is 66.8% (95% CI 
41.4%-85.1%), significantly lower than the eculizumab group, at 95.5% (95% CI 87.6%-
98.5%). 
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Figure 3.8 Overall survival of patients before and after eculizumab. 
 
 
3.9 Discussion 
 
Prior to the availability of eculizumab there was little other than supportive care available 
to patients with PNH. Due to the rarity of the condition there are only 3 papers published 
that have looked at the mortality in this disease. Hillmen et al reported a significantly 
worse survival for patients, seen between 1940 and 1970 in the United Kingdom, with 
PNH compared with matched controls, with ~ 50% of patients dying as a result of their 
PNH (Hillmen et al, 1995). Nishimura et al compared the clinical course of Caucasian 
and Asian patients, from North America and Japan respectively, and observed a similar 
median survival in the Caucasian population with a mean survival of 19.4 years from 
diagnosis (Nishimura et al, 2004). The mean survival in the Japanese patients was 32.1 
years and the difference was speculated to be due to a reduced proportion of Asian 
patients experiencing thromboses. The most recent cohort of patients where mortality was 
evaluated comes from a French group (de Latour et al, 2008). de Latour et al looked at 
mortality in patients between 1950 and 2005 with a PNH clone. Overall the median 
survival was 22 years but this also includes patients with aplastic anaemia with small 
PNH clones. If you look specifically at the patients with classical PNH, like our cohort of 
patients, this is reduced to 19 years. 
prot ctive against thrombosis in PNH, primary prophylaxis with
warfarin has now been stopped in 21 patients and secondary
prophylaxis stopped in a further patient because of an episode of
life-threatening bleeding. Overall, anticoagulation in patients on
eculizumab has been stopped for a mean duration of 10.8 months
(range, 1-60 months) and a cumulative total of more than 19 years.
No thrombotic complications have been seen in these patients.
Anticoagulation of patients with a previous history of thrombosis
was not routinely stopped.
Two patients had proven meningococcal infection both with
N meningitidis serogroup B, which translated to a risk of 0.9 events
per 100 patient-years on eculizumab. With advice from the United
Kingdom Meningococcal Reference Unit, our policy was altered in
January 2010 to include a recommendation for patients to have
routine antibiotic prophylaxis.
Intravascular hemolysis and transfusion requirements
The median LDH value fell from 2872 IU/L (range, 587-
10 300 IU/L, upper limit of normal 430 IU/L) at the start of
eculizumab treatment to the most recent average recording of
477 IU/L (range, 177-1793 IU/L).
In the 12 months before starting eculizumab, the mean number
of units of blood transfused was 19.9. Sixty-one of the 75 patients
(81%) required transfusions before eculizumab and have been on
eculizumab for 12 months. We compared the transfusion require-
ments for the 12 months before eculizumab therapy with the most
recent 12 months on therapy. The mean number of transfusions
required fell by 74% from 19.3 units (range, 2-52 units) to 5.0 units
(range, 0-50 units, P ! .001; Figure 4), with 40 of the 61 patients
(66%) becoming transfusion independent.
Looking specifically at the 21 patients of this group of 61 who
still needed a transfusion in the last 12 months, there was a
significant reduction in the number of transfusions needed
(P " .028). The mean number of units transfused fell from
24.6 units (range, 4-52 units) to 14.6 units (range, 2-50 units).
Two of these patients continued to require transfusions as they
had developed MDS, 4 patients were transfused as they had
breakthrough hemolysis and their eculizumab maintenance dose
was increased to 1200 mg every 14 days, 5 patients had 2 or
fewer transfusions in the 12-month period (and these were associ-
ated with infections usually viral in nature), 2 patients were
transfused as they had developed aplasia, and 8 patients continued
Figure 3. Overall survival of patients before and after
eculizumab.
Figure 4. Blood transfusion requirements in the
12 months before eculizumab therapy and the most
recent 12 months on eculizumab treatment in
64 patients.
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This is the first study to show dramatically improved survival in patients with PNH 
treated with eculizumab. There was no difference in mortality between patients on 
eculizumab and the normal population (P=0.46; Figure 3.6). Three of the 79 patients 
(4%) treated with eculizumab at our centre during the study period have died, all from 
non-PNH related causes. There were no deaths in the 45 patients commencing 
eculizumab under the age of 50 years old which is a significant finding as the median age 
at diagnosis in PNH is in the 4th decade of life (Figure 3.7). Two of the 11 patients over 
70 years old died as a result of co-morbidities and not as a direct result of their PNH. 
 
Three patients (4%) developed either MDS or acute leukaemia. This incidence is similar 
to that seen in previous trials (Hillmen et al, 1995; Nishimura et al, 2004; de Latour et al, 
2008). There were 2 instances of MDS in the 8th decade and one patient with AML 
developing at the age of 50. The latter occurred 27 years after his PNH was diagnosed. In 
all cases, the MDS or AML developed in the GPI-negative clone of cells. In the patient 
who developed AML, his baseline bone marrow showed monosomy 7, which is usually 
associated with MDS, despite no features suggestive of MDS. It is not surprising that 
clonal myeloid evolution occurred from the PNH clone as the vast majority of 
haematopoiesis in these three patients was derived from PNH stem cells. 
 
This study population is typical of patients with PNH. Age at diagnosis, history of 
aplastic anaemia and symptoms experienced are all representative, as is the most common 
feature at diagnosis - anaemia. However, there was a far higher proportion of patients 
with haemoglobinuria at diagnosis (63%) than seen previously (Dacie and Lewis, 1972) 
although it s not found in all patients with PNH. Its absence often contributes to the delay 
in PNH diagnosis. 
 
The main cause of mortality in PNH is thromboembolism, which accounts for around 
40% of deaths. After the first thrombotic event, there is a far higher risk of reoccurrence 
and mortality then increases 5-10 fold (Nishimura et al, 2004; de Latour et al, 2008). If 
anticoagulation is commenced prior to the first thrombosis, it is usually effective (Hall et 
al, 2003), but once a thrombotic event has occurred, then anticoagulation alone is often 
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insufficient in preventing further clots (Moyo et al, 2004; Audebert et al, 2005). 
Additionally, there are the recognised risks of anticoagulation in patients prone to liver 
problems and thrombocytopaenia (Palareti et al, 1996). 
 
Twenty-one patients (27%) had thrombotic events prior to starting eculizumab therapy. 
This group demonstrated 34 thromboses, 16 (47%) of which occurred whilst on 
anticoagulation. This shows that anticoagulation alone will not always prevent 
thromboses developing. There was then a dramatic reduction in thrombotic events once 
eculizumab therapy was started with only 2 episodes reported. There was a highly 
significant reduction in the rate of thrombosis: from 5.6 events to 0.8 events per 100 
patient years once eculizumab was started (p<0.001). This is despite the shorter duration 
of follow-up after commencing eculizumab. 
 
Of the 7 patients who had a thrombosis in the year prior to starting eculizumab treatment, 
there have been no further thrombotic events whilst on eculizumab. These patients remain 
on a combination of both eculizumab and anticoagulation. But for those who have never 
had a thrombotic episode, primary prophylaxis was stopped (21 patients). No thromboses 
were seen (cumulative time period > 19 years). Therefore if a patient has never had a 
thrombosis, we now recommend there is no need to anticoagulate, which is highly 
advantageous in terms of the small but significant risk of severe bleeding when on long-
term anticoagulation (Palareti et al, 1996). Should there be a prior history of thrombosis 
however, anticoagulation is not routinely stopped. 
 
There were 2 patients with large PNH clones who had to both stop eculizumab 
temporarily and also cease anticoagulation due to significant bleeding problems. In less 
than 6 months, both patients had developed a thrombosis and were then restarted on 
eculizumab. This has only occurred in 2 patients, but anticoagulation should be 
considered in any patients who stop eculizumab, but still have a significant disease 
burden. Additionally, in order to dilute the PNH red cell population and thus reduce the 
likelihood of haemolysis, red cell transfusions should be considered if eculizumab is 
stopped. 
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Eculizumab therapy in PNH causes a rapid reduction in intravascular haemolysis with a 
corresponding reduction in LDH levels. The information here shows that LDH remains 
low beyond 8 years on eculizumab treatment. Once on therapy for at least a year, two-
thirds of patients on eculizumab remain transfusion independent, which is better than the 
proportion of transfusion independent patients in the clinical trials. Only 51% of patients 
were transfusion independent in the 6 month period of the TRIUMPH study and the 12 
month period of the SHEPHERD study (Hillmen et al, 2006; Brodsky et al, 2008). This 
may be explained in that the patients in our study are more homogenous due to the strict 
criteria for eculizumab therapy and/or our patients are clinically improving on long-term 
eculizumab after presenting acutely unwell. Even the 21 patients who still needed 
transfusions had a significant reduction in the amount of blood required after starting 
eculizumab (p=0.03). This even holds true after taking into account that 2 of these 
patients needed far more blood after developing MDS. The patients who did still need 
transfusions had a variety of reasons: breakthrough haemolysis, aplasia and extravascular 
haemolysis. Extravascular haemolysis has been reported in two studies on patients with 
PNH receiving eculizumab (Risitano et al, 2009; Hill et al, 2010a). However, in our 
series there was a dramatic reduction in transfusion requirement, indicating that the 
phenomenon of extravascular haemolysis is of limited clinical importance for most 
patients. 
 
It has been reported previously that patients with thrombocytopaenia have an increase in 
platelet count directly because of the eculizumab treatment (Socie et al, 2009). One 
hypothesis is that the terminal complement activation of PNH platelets contributes to on-
going platelet activation, which is then reflected by platelet consumption, and contributes 
to thrombocytopaenia. However we did not observe any increase in platelet count in this 
population, either looking at all study patients or just those with thrombocytopaenia. 
 
As with all medication there are potentially adverse effects in being on eculizumab 
treatment. It can only be given as an intravenous infusion, it has to be given every 2 
weeks and it is a long-term and in many cases a lifelong treatment. There are very few 
infusional related side effects observed. The main concern with eculizumab therapy is the 
increase in incidence of meningococcal sepsis. In our study there were 2 cases of proven 
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meningococcal infection. Although the likelihood of meningococcal infection is low both 
preventative measures to reduce its incidence and enhanced education of patients and 
their carers as to symptoms to be aware of are important to keep this risk to a minimum. 
 
Anti-complement therapy has transformed treatment for patients with PNH. By blocking 
terminal complement activation, eculizumab has been shown to be the first effective 
therapy for patients with PNH, not only in alleviating symptoms, but for the first time 
altering the natural course of the disease to such an extent that survival in the patient 
group was the same as age and sex matched controls. 
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4.1 Introduction 
 
In this chapter, the clinical features, laboratory findings, and outcomes of 11 female 
patients with PNH who were cared for by the Leeds National PNH centre at St James’s 
University Hospital and treated with eculizumab during 15 separate pregnancies are 
described. The diagnosis of PNH was established or confirmed using multicolour flow 
cytometry of the erythrocytes, monocytes and granulocytes in all cases. Data collected for 
analysis include age and symptoms at diagnosis, age at the start of eculizumab, 
complications occurring both during the gestation and the postpartum periods. Data was 
collected up until the end of May 2013. All patients were evaluated at a minimum of 
every 12 weeks by the Leeds PNH team. This information provides an understanding into 
the clinical management of pregnancy in PNH in the era of monoclonal antibody therapy. 
 
 
4.2 Additional Patient information 
 
Five of these patients have been described in Chapter 3 and make up part of the cohort of 
79 patients whose response to eculizumab was evaluated. Funding during pregnancy was 
through the National Health Service either via central commissioning in England or via 
local funding in Wales, Scotland or Northern Ireland. 
 
 
4.3 Individual Patient Data 
 
U.P.N. 30  Female D.O.B. 03.02.1973  
U.P.N. 30 is described in Chapter 3. She became pregnant with twins after IVF treatment 
in February 2008. She commenced therapeutic low molecular weight heparin (LMWH) 
as soon as her pregnancy was confirmed and started eculizumab treatment at 26 weeks 
gestation, when she was first seen in Leeds. She developed evidence of breakthrough 
haemolysis with haemoglobinuria and a raised LDH whilst on the standard maintenance 
dose. Weekly infusions of 900mg of eculizumab were then given, up until her delivery. 
An elective caesarean section was performed at 35 weeks gestation, as it was a twin 
pregnancy. This was complicated by severe postpartum bleeding, resulting in uterine 
 134 
 
artery embolisation and the administration of a prothrombin complex concentrate. She 
required 9 units of blood during the pregnancy prior to starting eculizumab and 5 units 
during the 9 weeks of her pregnancy on eculizumab. Eculizumab therapy was stopped 3 
months after the delivery due to funding restrictions.  
 
U.P.N. 56 Female D.O.B. 26.12.1975  
U.P.N. 56 is described in Chapter 3. She began eculizumab therapy in September 2005 
and became pregnant in March 2012. Her warfarin was converted to therapeutic dose 
LMWH at diagnosis and she elected to continue eculizumab during her pregnancy. 
During the pregnancy she was troubled with recurrent epistaxis, which required nasal 
cautery. She also had persistently high IgM anti-beta-2 glycoprotein 1 antibodies, which 
are associated with thrombosis and pregnancy loss, for which she was treated with low 
dose aspirin. Labour was induced at 38 weeks gestation in November 2012. She did not 
require transfusions during the pregnancy but did receive 2 units of blood soon after 
delivery. 
 
U.P.N. 57 Female D.O.B. 08.01.1981  
U.P.N. 57 is described in Chapter 3. She has had 3 consecutive pregnancies whilst on 
eculizumab. She was treated with therapeutic LMWH as soon as pregnancy was 
confirmed on each occasion. She also has an inherited thrombophilia, being heterozygous 
for the prothrombin gene mutation (Prothrombin G20210A). At 26 weeks gestation in her 
first pregnancy she developed breakthrough intravascular haemolysis and was given 
eculizumab infusions more frequently (every 12 days). She had no further breakthrough 
episodes and had a vaginal delivery at term in July 2008. She again developed 
breakthrough haemolysis in her second and third pregnancies, but instead of increasing 
the frequency of eculizumab infusions the dose was increased to 1200mg. In these 
subsequent pregnancies the breakthroughs occurred earlier, in both cases at 18 weeks. 
She delivered at term in March 2010 and again in October 2012. Her transfusion 
requirement increased dramatically in pregnancy with her needing 25, 20 and 21 units of 
red cells in each of her pregnancies, respectively. 
 
 
 
 135 
 
U.P.N. 64 Female  D.O.B. 03.12.1976  
U.P.N. 64 is described in Chapter 3. Her warfarin was converted to therapeutic dose 
LMWH and her atenolol switched to labetolol 6 weeks prior to her becoming pregnant in 
September 2008. Her pregnancy progressed normally until week 28 when she developed 
pre-eclampsia and required an emergency Caesarean section in April 2009. Prior to her 
diagnosis of PNH she had been diagnosed with hypertension, which was thought to be 
related to previous ciclosporin therapy. Her baby had meconium plug syndrome, also 
known as toxic megacolon, a functional colonic obstruction associated with premature 
birth. The baby required a temporary ileostomy to treat this. She required 4 units of blood 
during her pregnancy whereas both before and after her pregnancy she was transfusion 
independent. 
 
U.P.N. 74 Female D.O.B. 17.07.1991  
U.P.N. 74 is described in Chapter 3. She became pregnant in August 2012 and 
commenced treatment with therapeutic LMWH. She had evidence of intravascular 
haemolysis with a raised LDH, haemoglobinuria and began to need blood transfusions at 
week 18 of her pregnancy and her eculizumab dose was increased to 1200mg every 14 
days. This was increased further at 24 weeks gestation and again at 35 weeks to 1500mg 
every 14 days and then to 900mg every 7 days, as her eculizumab trough level remained 
sub-therapeutic. The baby was delivered vaginally after induction. Prior to becoming 
pregnant she was transfusion independent but she needed 14 units of blood during the 
pregnancy.   
 
U.P.N. 80 Female D.O.B. 21.10.1981  
U.P.N. 80’s initial PNH symptoms began in 2001 with haemoglobinuria, chest pain and 
breathlessness. She experienced these symptoms, as well as intermittent fatigue and 
dysphagia, up until a diagnosis of PNH was made in July 2011. At this time she was 
already 8 weeks pregnant. She commenced therapeutic LMWH as soon as the pregnancy 
was confirmed and eculizumab at 12 weeks of gestation. Her dose of eculizumab was 
increased to 1200mg every 14 days at week 38 of the pregnancy due to signs of 
intravascular haemolysis. She was delivered by a planned caesarean section a week later. 
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Eculizumab was continued for 12 weeks postpartum. Her transfusion requirement 
increased in pregnancy with her requiring 11 units of blood. 
 
U.P.N. 81 Female D.O.B. 23.02.1990  
U.P.N. 81 was diagnosed with aplastic anaemia in 2001 having developed spontaneous 
bruising, lethargy and breathlessness. She was treated with immunosuppressive therapy, 
initially with rabbit ATG but had an adverse reaction to this and subsequently received 
equine ATG followed by ciclosporin in 2005. She remained dependent on red cell and 
platelet transfusions until 2007. She was diagnosed with PNH whilst pregnant in 2010. 
She required 4 units of blood to be transfused during the pregnancy. She had a vaginal 
delivery at term but subsequently developed vulval breakdown requiring six corrective 
operations. She was relatively asymptomatic with a compensated haemolysis with her 
only on going symptom being persistent fatigue. She became pregnant for a second time 
in January 2012 and her anticoagulation was changed to LMWH. She commenced 
eculizumab at 13 weeks gestation. She required 2 units of blood during her pregnancy 
and she had a vaginal delivery at term. Her eculizumab was discontinued 12 weeks after 
the birth. 
 
U.P.N. 82 Female D.O.B. 29.09.1974  
U.P.N. 82 was diagnosed with aplastic anaemia in June 2006 after the onset of 
spontaneous bruising. She was treated with rabbit ATG in November 2006. This was 
complicated by septicaemia and an intracranial haemorrhage. She remained transfusion 
dependent until August 2007 when she started with haemoglobinuria and PNH was 
diagnosed. She remained relatively symptom free with a compensated haemolysis before 
becoming pregnant in February 2011. Her anticoagulation was converted to LMWH and 
she commenced eculizumab at 18 weeks gestation. She underwent an emergency 
caesarean section at 37 weeks for foetal distress, which was thought to be secondary to 
placental abruption. She received 11 units of blood during her pregnancy. She stopped 
eculizumab 12 weeks after delivery but restarted it in September 2012 due to worsening 
symptoms and the need for recurrent transfusions. 
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U.P.N. 83 Female D.O.B. 10.07.1984  
U.P.N. 83 was diagnosed with PNH in March 2010 after being found to be severely 
anaemic and jaundiced. She was symptomatic with haemoglobinuria and had noticed 
increasing tiredness over the previous 3 years. She was relatively asymptomatic with a 
compensated haemolysis until she became pregnant in November 2011. She commenced 
therapeutic LMWH in November 2011 and eculizumab at 13 weeks gestation. She 
experienced breakthrough haemolysis at week 32 and her eculizumab dose was increased 
to 1200mg every 14 days. She was transfused 9 units of blood during the pregnancy. She 
had an induced labour at 38 weeks. She elected to continue long-term eculizumab after 
her pregnancy ended. 
 
U.P.N. 84 Female D.O.B. 16.06.1975  
U.P.N. 84 was diagnosed with PNH in January 1999 after having haemoglobinuria and 
being found to be anaemic. Since her diagnosis she had disease paroxysms approximately 
every 4 weeks. Her symptoms included dysphagia, abdominal, chest and back pain, 
jaundice and haemoglobinuria. She became transfusion dependent in 2000, initially 
requiring 2-3 units of blood every 12 weeks but since 2008 this has increased to every 6 
weeks. She has never had a thrombosis. She commenced eculizumab in March 2010 and 
did not require a transfusion before becoming pregnant in September 2010. During this 
pregnancy she experienced breakthrough haemolysis at week 22 gestation and her 
eculizumab dose was increased to 1200mg every 14 days. She developed pre-eclampsia 
and required an emergency Caesarean section at 35 weeks gestation. She became 
pregnant again in March 2012 but had a miscarriage at 9 weeks gestation. She became 
pregnant for the third time whilst on eculizumab in June 2012 and was delivered by 
Caesarean section at 35 weeks gestation. The dose of eculizumab was also increased to 
1200mg every 14 days in this pregnancy due to breakthrough haemolysis at 23 weeks 
gestation. She required 6 units of blood to be transfused during the first pregnancy but 
needed no transfusions in the second pregnancy. 
 
 
 138 
 
U.P.N. 85 Female D.O.B. 24.03.1981  
U.P.N. 85 presented with a deep vein thrombosis in January 2008. She was found to be 
pancytopaenic and was diagnosed with PNH. She experienced intermittent 
haemoglobinuria but did not require transfusions. She became pregnant in April 2010 and 
commenced eculizumab at week 28 of her pregnancy. During the pregnancy she was 
transfused with 9 units of blood before and 2 units after starting eculizumab. She was 
induced at 39 weeks gestation and stopped eculizumab after the postpartum period in 
April 2011. 
 
 
4.4 Complications during Pregnancy 
 
There were 14 live births from the 15 pregnancies evaluated in which eculizumab was 
administered to the mother. Two patients had more than 1 pregnancy (U.P.N. 57 and 
U.P.N. 84) and 1 patient had a twin delivery (U.P.N. 30). The patient characteristics and 
the complications observed during the pregnancies are shown in Table 4.1. The median 
age at diagnosis was 24 years old and at conception was 30 years old. The median PNH 
granulocyte clone at conception was 95.4% (range, 69.7 – 99.7%). 
 
All patients commenced therapeutic LMWH as soon as the pregnancies were confirmed 
and remained on it during the pregnancy and postpartum period. Symptomatic anaemia 
was a common finding with transfusion requirements increasing in 12 of the 15 
pregnancies (80%). Significant thrombocytopaenia was only seen in 1 case (7%). The 
main other complication observed during the pregnancies was that of breakthrough from 
complement blockade. This occurred in 10 of the 14 pregnancies (71%) that continued 
past the first trimester. In each case the dose of eculizumab had to be increased to control 
the symptoms of intravascular haemolysis observed. 
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Table 4.1 Patient characteristics and complications observed during the pregnancy 
(TD LMWH –therapeutic dose low molecular weight heparin). 
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Table 4.2 Pregnancy complications at delivery and postpartum. 
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4.5 Delivery and the Postpartum Period 
 
A summary of the complications observed at the time of delivery and in the postpartum 
period is shown in Table 4.2. One pregnancy (U.P.N. 84) miscarried at 9 weeks and the 
other 14 pregnancies ended with live births. Five of the deliveries resulted in the birth of 
a premature infant, defined as being born prior to 37 weeks gestation. 
 
The births were managed by a number of different delivery strategies. Four pregnancies 
were delivered vaginally without intervention, 4 were induced labours, 2 were elective 
Caesarean sections and 4 emergency Caesarean sections were performed. The emergency 
sections were undertaken for pre-eclampsia in 3 instances and for 1 case of foetal distress 
with a reduced foetal heart rate due to placental abruption. 
 
The presence of eculizumab in the placenta was assessed at 11 of the births. Eculizumab 
levels were tested by the Cambridge Biomedical laboratory in Boston. Eculizumab was 
found at low levels in 4 out of 12 (33%) placental cord samples, but at low levels (range, 
11.8 – 19.2%µg/l). Breast-feeding was undertaken in 5 cases and in all 5, samples of breast 
milk were not found to contain eculizumab. 
 
Significant postpartum haemorrhage was seen in 2 patients, with 1 (U.P.N. 30) requiring 
treatment with both uterine artery embolisation and prothrombin complex concentrate. 
Three patients were only funded to receive eculizumab during the pregnancy and for 12 
weeks after delivery. Two of these 3 had complications related to stopping eculizumab. 
U.P.N. 30 developed a portal vein thrombosis after stopping eculizumab and U.P.N. 82 
was admitted to hospital twice with severe haemolysis. This resolved once her 
erythrocyte PNH clone had reduced to its pre-pregnancy level. There were no foetal 
anomalies observed, but a complication of prematurity was present in the infant of U.P.N. 
64. She was born with toxic megacolon, a functional abnormality of the bowel and 
required an ileostomy, which was reversed a few months later. 
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4.6 Discussion 
 
This is the first group of patients evaluated during pregnancy whilst on eculizumab. It is 
still common for physicians to advise patients with PNH from becoming pregnant due to 
it being a time of heightened risk of disease complications and mortality. Although the 
number of pregnancies is small, it appears that eculizumab is safe to use in pregnancy. It 
is not clear if it crosses the placenta. Low levels of eculizumab were found in 4 out of 12 
cord blood samples (median, 15.4µg/l). These levels are not high enough to block 
terminal complement, a level of at least 30µg/l is needed, and they are within the 
background levels for the assay. Eculizumab is comprised of both human IgG2 and IgG4 
heavy chain regions, and whilst IgG4 crosses the placenta, IgG2 does not. It does not 
appear to be excreted in breast milk, but again the sample number is very low.  
 
Pregnancy in PNH remains a period of increased risk of disease complications. All of our 
patients were monitored closely by both obstetric and haematology specialists. 
Anticoagulation with heparin was commenced as soon as the pregnancies were 
confirmed, to try to prevent the most feared complication, thrombosis. A high proportion 
of these women (71%) had breakthrough haemolysis in their pregnancies, usually in the 
third trimester and required higher or more frequent eculizumab infusions to block 
terminal complement activation. Eculizumab is metabolised to small peptides and amino-
acids by lysosomal enzymes (Dmytrijuk et al, 2008). Increased activity of lysosomal 
enzyme activation in pregnancy, causing increased drug metabolism may account for the 
higher doses required. It is also possible that the need for higher doses in the latter stages 
of pregnancy is due to physiological changes, as maternal fat and water content increases 
which can increase the volume of distribution of drugs.  
 
Even with anti-complement therapy, the management of these patients is challenging, 
with over a third of the infants still being born prematurely. However as more young 
adult women are treated with eculizumab and their PNH symptoms resolve, it is likely 
that more and more they will consider the prospect of starting a family. This data 
provides the first evidence that eculizumab has a vital role in the management of 
pregnancy in those with PNH. 
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5.1 Rationale 
 
There have been marked improvements in the treatment of PNH in the last 10 years (see 
Chapter 3) but in comparison there has been little progress in understanding why the 
illness develops. Somatic mutations of the PIG-A gene are thought to account for all 
cases where PNH develops but these mutations are not looked for in routine practise. This 
is largely due to the advent of high sensitivity diagnostic flow cytometry but also to both 
the practical difficulty and cost of analysis of the PIG-A gene for each suspected case. In 
2006 Almeida et al (Almeida et al, 2006) described a disorder occurring in co-
sanguineous families characterised by venous thrombosis that was attributable to 
mutations in the promoter of PIG-M leading to loss of GPI expression. It is not known 
whether PIG-M mutations also occur in a proportion of PNH patients. If PIG-M 
mutations were common occurrences, it would provide an alternative aetiology for 
disease pathogenesis. Therefore the PIG-M promoter region was sequenced in 35 patients 
with PNH to assess the impact of PIG-M mutations in the disease. 
 
Clonal selection in PNH has been well described and is thought to be due to the 
development of a somatic mutation of the PIG-A gene. The occurrence of a PIG-A 
mutation itself does not appear to provide a growth advantage for the mutated stem cell. 
It is unknown whether an intrinsic or extrinsic effect is responsible for the expansion of 
the PNH clone and both of these have been proposed. In order to evaluate whether a 
second separate genetic event provides an intrinsic growth advantage for PNH cells the 
deregulation of 2 potential genes, HMGA2 and JAK2, was examined in 42 patients with 
PNH. HMGA2 was expressed at low levels and both cDNA synthesis and the PCR of the 
cDNA was optimised to show expression of HMGA2. These findings were also 
confirmed using the primers and technique employed by Murakami et al (Murakami et al, 
2012) who found elevated HMGA2 mRNA levels in Japanese patients. The possibility of 
an extrinsic growth advantage is discussed in Chapter 6. 
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5.2 PIG-M Promoter Mutations 
 
The only reported cases of PIG-M promoter mutations have been in 2 co-sanguineous 
families, with all affected individuals having the same C-G point mutation at position -
270 from translational start site of the PIG-M gene shown below in Figure 5.1. This is the 
binding site for the transcription factor SP1 and this mutation disrupts SP1 binding and 
leads to a partial but severe GPI deficiency on affected cells. 
 
 
 
 
Figure 5.1 Diagrammatic representation showing the positions of the forward and 
reverse primers used to sequence the SP1 site in the PIG-M promoter. 
 
 
5.2.1 PCR Amplification of the SP1 Binding Site 
 
To ascertain whether any patients in our cohort also harboured this mutation, 35 PNH 
samples (median age 45, range: 18-81) were obtained for promoter sequencing with a 
median granulocyte clone size of 97.81%. The samples tested for this mutation are part of 
those making up the group in Table 5.1 but only include the 1st 35 patients shown in the 
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table. Figure 5.1 shows the position of the SP1 binding site and the primer pairs chosen to 
amplify this region. Figure 5.2 shows examples of the PCR product obtained using this 
method.  
 
 
 
 
Figure 5.2 Agarose gel electrophoresis showing an example of PCR products 
obtained prior to sequencing. Lane 1 is a negative control, 2-6 are patient samples 
(U.P.N. 6,7,10,11,16) and lane 7 is a 100 base pair ladder (New England Biolabs). 
 
 
In order to address the possibility of a PIG-M promoter mutation, a PCR and direct 
sequencing approach was taken. Primers were chosen to amplify a 452 base pair region of 
the PIG-M promoter, which encompasses the previously identified mutation site at 
position -270 in the promoter. Amplification was optimised to generate a single PCR 
product of the expected size (See Figure 5.2). 
 
 
5.2.2 SAPEX Purification and Sequencing 
 
These PCR products underwent SAPEX purification prior to sequence analysis using the 
ABI 3130xl genetic analyser. The ABI analyser employs the “dye terminator” sequencing 
method with the four standard deoxynucleotides and dideoxynucleotide chain 
terminators. 
  1        2         3        4         5         6        7 
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U.P.N. Gender Age Granulocyte Clone % Monocyte Clone % Erythrocyte Clone % Minimum % of PNH cells  in sample 
6 Female 32 99.4 97.9 95.5 55.9 
7 Female 52 99.9 99.9 99.0 66.8 
10 Female 39 90.8 82.6 71.4 64.1 
11 Female 51 81.6 89.9 83.6 68.5 
16 Female 46 71.1 65.4 32.5 43.2 
19 Male 45 80.3 76.9 31.3 61.6 
21 Male 34 99.8 99.5 99.8 63.7 
22 Male 68 99.5 99.8 82.5 67.3 
24 Male 37 92.6 89.1 78.1 54.7 
28 Male 46 94.7 93.8 61.1 72.4 
30 Female 33 98.5 98.0 12.0 77.2 
34 Female 69 95.2 94.2 75.7 75.9 
39 Male 50 95.3 93.8 48.4 64.8 
40 Female 34 99.6 98.4 36.3 68.3 
41 Male 43 99.1 98.7 66.4 53.5 
42 Male 18 93.2 94.3 27.4 67.3 
44 Female 41 95.0 95.1 30.6 60.2 
45 Female 28 99.9 99.7 99.2 60.9 
46 Male 69 98.5 99.5 97.6 23.5 
47 Female 21 95.5 95.6 31.1 75.4 
53 Male 32 99.2 96.9 87.2 70.5 
54 Male 45 99.9 95.1 99.2 70.0 
56 Female 33 99.3 96.4 66.5 81.1 
57 Female 27 99.8 99.2 87.1 58.5 
58 Female 30 78.3 69.0 69.4 61.2 
59 Female 41 99.7 97.1 99.9 70.9 
62 Female 56 97.8 98.0 90.7 61.7 
63 Male 27 91.9 90.9 39.9 54.9 
64 Female 32 87.1 89.4 85.2 41.2 
65 Male 70 93.5 91.3 35.9 65.6 
68 Male 65 97.5 96.5 93.2 62.5 
71 Female 82 92.7 95.0 87.2 78.0 
86 Female 24 71.3 71.3 32.6 34.0 
87 Male 40 80.7 81.6 17.7 45.9 
88 Male 29 97.0 93.6 42.2 77.0 
3 Male 40 99.9 99.7 93.8 71.3 
32 Male 51 99.2 98.8 15.6 67.6 
35 Male 81 99.6 99.4 99.2 64.4 
38 Male 55 100 100 100 52.3 
60 Male 52 99.9 99.8 27.2 72.2 
89 Female 60 81.4 91.8 53.3 70.2 
90 Male 45 98.2 98.1 79.4 59.6 
 
Table 5.1 Clone size and minimum proportion of GPI deficient cells present in PNH 
samples undergoing evaluation of PIG-M promoter mutations, JAK2 mutations and 
HMGA2 mRNA levels. 
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This results in the formation of DNA fragments of varying lengths determined by the 
inclusion of the terminating dideoxynucleotide. The dideoxynucleotides are added at 
lower concentration than the standard deoxynucleotides to allow strand elongation 
sufficient for sequence analysis.  
 
 
Figure 5.3 Sequencing read out showing an example of the nucleotides of the PIG-M 
promoter region. 
 
 
Figure 5.4 Closer view of the sequencing read out of each nucleotide around -270 in 
the PIG-M promoter region. 
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The chain terminators are each labelled with different fluorescent dyes that are detected at 
distinct wavelengths corresponding to the different nucleotides. These are conventionally 
displayed as sequence traces as seen in Figures 5.3 and 5.4. 
 
Figure 5.5 shows the nucleotide sequence of the part of the PIG-M promoter that includes 
position -270 and part of the forward and reverse sequences from one of the patients 
evaluated for the point mutation. 
 
Given that the PNH clone sizes were substantial, the PCR product was subject to direct 
sequencing and a heterozygous mutation would be expected to be visible both as a 
decrease in peak height for the expected nucleotide and with the presence of an alternate 
peak representing the mutated allele. No mutations were identified either at -270 or in the 
rest of the amplified sequence. These data indicate that neither inactivation of the PIG-M 
gene via the C-G point mutation at -270 or alternative mutations of the promoter region 
are a common event in the pathogenesis of sporadic PNH. 
 
 
 
Figure 5.5 Sequence readout of the PIG-M promoter region with the forward and 
reverse sequences from a patient alongside.  
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5.3 JAK2 Mutation Analysis 
 
Given the previously described role for JAK2 in driving cell growth in myeloproliferative 
disorders (Baxter et al, 2005; Guglielmelli et al, 2007), and the link with HMGA2 
expression it was reasonable to suggest that abnormal activation of this protein could 
have a similar function in PNH. Therefore, the possibility that JAK2 mutations are 
present in PNH clones was examined in the same 35 patients that were evaluated for PIG-
M promoter mutations (shown in Table 5.1) and a further patient U.P.N. 91. To address 
this question an assay used in the clinical diagnosis of JAK2 mutations was employed 
(Campbell et al, 2005). This assay incorporates three primers that amplify both the 
V617F mutation as well as a control product generated from the mutated and the wild 
type allele. In all PNH cases a band corresponding to control product was detected. A 
V617F mutation was identified in 1 of the 36 samples evaluated, U.P.N. 91 (see Figure 
5.6). 
 
A further sample from UPN 91 was evaluated to determine whether the PNH clone arose 
from cells with the V617F mutation. The granulocytes underwent a cell sort using 
FLAER and the FLAER negative sorted cells were assayed for the V617F mutation. 
Unfortunately there was not enough DNA from the sort and the patient died before the 
experiment could be repeated. 
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Figure 5.6 V617F JAK2 mutation analysis of PNH patients. 
 
Figure legend: 
Lane 1, 15, 26 and 40 - ladder. 
Lane 2 - U.P.N. 6, lane 3 - U.P.N. 7, lane 4 - U.P.N. 10, lane 5 - U.P.N. 11, lane 6 - 
U.P.N. 16, lane 7 - U.P.N. 19, lane 8 - U.P.N. 21, lane 9 - U.P.N. 22, lane 10 - U.P.N. 24, 
lane 11 - U.P.N. 28, lane 12 - U.P.N. 30, lane 13 - U.P.N. 34, lane 14 - U.P.N. 39, lane 16 
- U.P.N. 40, lane 17 - U.P.N. 41, lane 18 - U.P.N. 42, lane 19 - U.P.N. 44, lane 20 - 
U.P.N. 45, lane 21 - U.P.N. 46, lane 22 - U.P.N. 47, lane 23 - U.P.N. 53, lane 27 - U.P.N. 
54, lane 28 - U.P.N. 56, lane 29 - U.P.N. 57, lane 30 - U.P.N. 58, lane 31 - U.P.N. 59, 
lane 32 - U.P.N. 62, lane 33 - U.P.N. 63, lane 34 - U.P.N. 64, lane 35 - U.P.N. 65, lane 36 
- U.P.N. 68, lane 37 - U.P.N. 71, lane 38 - U.P.N. 86, lane 39 - U.P.N. 87, lane 41 - 
U.P.N. 88, lane 42 - U.P.N. 91. 
Lane 24 and 43 - positive controls. 
Lane 25 and 45 - blank. 
1   2   3   4   5   6   7   8   9  10 11 12 13 14    15 16 17 18 19 20 21 22 23 24 25 
 26 27 28 29 30 31 32 33 34 35 36 37 38 39         40 41 42      43      44  
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5.4 HMGA2 Expression 
 
Aberrant expression of HMGA2 has been proposed as one potential molecular 
abnormality that allows expanded growth of a PNH clone (Inoue et al, 2006). These 
findings were based on detection of HMGA2 over-expression resulting from HMGA2 
translocations in two PNH patients. These results, while important, do not provide an 
indication of the frequency of this event in the general PNH patient population. 
 
To determine the proportion of patients who exhibit this abnormality, the levels of 
HMGA2 were assessed in a larger cohort. The cells obtained from any given patient with 
PNH are a mosaic of normal and PNH cells. In order to maximise the proportion of PNH 
cells assessed, only those patients with large granulocyte clones were selected for 
evaluation. This selection criterion was used to minimise the amount of non-PNH 
material examined, which might skew the results observed. A percentage was determined 
for each PNH patient, which denotes the minimum amount of PNH cells present. A 
proportion of the cells included in the experiments are lymphocytes, however, the relative 
number of these that are PNH cells is not routinely evaluated. In determining the PNH 
percentage in these patients all the lymphocytes were presumed to be non-PNH cells, 
which will give an underestimate of the amount of PNH material present. This percentage 
is shown in Table 5.1.  
 
42 patients with PNH were enrolled and compared to 10 normal controls. The mean age 
of the PNH group was 44 years and 7 months old (range, 18 to 81). It consisted of 22 men 
and 20 women. The control group had a mean age of 34 years old (range, 26 to 39). This 
group had 5 men and 5 women. The mean PNH granulocyte clone size was 93.9% (range, 
71.1 to 100%). The average minimum percentage of PNH cells in the samples was 63.5% 
(range, 34 to 81.1%). Table 5.1 displays the details of the patients evaluated.  
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The level of HMGA2 expression in PNH patients was compared to that of the mean from 
the control group (Figure 5.7). The mean of the control group is taken as 1.00. All 
samples were expressed relative to the level of β-ACTIN. A positive control for detection 
of HMGA2 was provided by the U2OS osteosarcoma cell line, in which HMGA2 is 
known to be highly expressed. In contrast HMGA2 is expressed at a very low level in 
adult blood cells and it was initially difficult to obtain consistent results from the control 
group mRNA samples.  In order to attain consistent results for HMGA2 expression both 
the synthesis of cDNA and the PCR reactions were optimised. This was achieved by 
increasing the amount of hexamers and the amount of reverse transcriptase used (x 4) as 
well as increasing the elongation phase of the reaction from 50 minutes to 2 hours. In the 
PCR reaction the concentration of the primers used was optimised increasing the 
concentration of the forward and reverse primers by 15 times. Primers were also selected 
for the two HMGA2 splice variants, which were readily detected in the positive control 
U2OS cell line. However despite the optimisation of the cDNA synthesis and the PCR 
reactions, which was effective for total HMGA2 expression, it was not possible to obtain 
consistent results for splice variants. This reflects the overall very low level of HMGA2 
expression in mature blood cells. Interestingly the results displayed in Figure 5.6 showed 
reduced HMGA2 expression in the PNH patients when compared to the control group by 
greater than 50% in the majority of cases.  
 
In patients with PNH, the level of the granulocyte and monocyte PNH clone size is 
usually very similar, but the proportion of lymphocytes that lack the GPI-anchor is 
generally lower. A proportion of patient samples underwent CD15 positive selection to 
try to eliminate potential bias from non-PNH cDNA within the sample material. This 
preferentially selects granulocytes, which were known to be almost completely PNH 
cells. 8 of the 42 patients therefore had repeat blood samples that underwent CD15 
positive selection and the level of HMGA2 expression relative to the level of β-ACTIN 
from these samples was compared to the samples from the same patients without CD15 
positive selection relative to the normal control samples (Figure 5.8). 
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Figure 5.7 HMGA2 expression in PNH patients compared to the median of the 
normal control group. 
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Figure 5.8 Level of HMGA2 expression in those with and without CD15 positive 
selection. 
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In 5 out of 8 patients the level of HMGA2 expression in the samples that underwent 
CD15+ selection was both lower than that of the unmanipulated samples and the control 
group. In 3 patients there was an apparent increase in the amount of detectable HMGA2, 
however, the levels never reached above 0.5 of the control. Overall expression data from 
CD15 positive selection provided more consistent results (0.30 +/-0.18, vs 0.54+/-0.57). 
Together, these data suggest an overall trend of lower than normal levels of HMGA2 
expression in PNH peripheral blood leukocytes, rather than the overexpression that would 
be predicted if HMGA2 was consistently deregulated by translocation. 
 
 
5.5 Further Assessment of HMGA2 expression using TaqMan Assay 
 
Since this work was undertaken, Murakami et al evaluated HMGA2 expression in both 
blood and bone marrow samples of 25 patients with PNH (Murakami et al, 2012). Unlike 
the initial 2 patients described by Inoue et al, these 25 patients did not exhibit a 
chromosomal rearrangement affecting the HMGA2 gene on chromosome 12. HMGA2 
mRNA levels were reported to be elevated in the peripheral blood of 18 of these 25 
patients when compared to levels from 11 normal control samples. There was no increase 
in HMGA2 expression in the bone marrow of these patients compared to normal control 
samples. 
 
Further analysis of samples from both the 10 normal controls and the 42 patients, shown 
in Table 5.1, was undertaken to evaluate this contrasting finding from these Japanese 
patients (Murakami et al, 2012).  This was performed using a TaqMan assay to evaluate 
total HMGA2 mRNA levels. GUSB was used as the internal control gene. The primers 
used for this analysis were the same as those used in the experiments by Murakami et al. 
Similar to the initial work on HMGA2 expression in the normal group, HMGA2 
expression was consistently considerably lower with a mean CT value of 34.1 as 
compared to a mean CT value of 28.7 for the internal control gene, GUSB. In 
comparison, although GUSB was detected in all the patient samples, the levels of 
HMGA2 were too low to be accurately quantified. These findings are consistent with the 
initial analysis of HMGA2 mRNA expression in these 42 patients. 
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5.6 Discussion 
 
Since the description of somatic mutations of the PIG-A gene by Takeda et al in 1993, 
there have been a number of different hypotheses suggested to provide an explanation for 
clonal expansion in PNH (Takeda et al, 1993). In broad terms these can be categorised 
into effects acting from within PNH cells or external factor/factors acting upon them. The 
close link between PNH and AA, and the likely association with AA and an immune 
mediated attack on the bone marrow, point towards an immune mediated mechanism that 
provides relative clonal expansion in PNH (Young et al, 2008). This is discussed further 
in Chapter 6. 
 
It does appear that the development of a significant PNH clone relies on 2 separate stages 
(Inoue et al, 2003). In the first instance, clonal selection, the occurrence of a PIG-A 
mutation is the initiating event. The second stage, clonal expansion, then provides the 
clone with a relative growth advantage over normal stem cells within the bone marrow. A 
plausible explanation for this clonal expansion is the occurrence of a completely separate 
genetic mutation. In this chapter, 3 potential genetic processes have been evaluated, PIG-
M promoter mutations, JAK2 mutations and the increased expression of HMGA2. 
 
Almedia et al identified two consanguineous families with an illness that is characterised 
by an autosomal recessive inheritance of a point mutation in the PIG-M promoter region  
(Almedia et al, 2006). The possibility that a proportion of patients with PNH have an 
underlying inactivation of PIG-M was evaluated in 35 patients with PNH. No mutations 
were identified, either at -270, described by Almedia et al, or in any other part of the 
amplified region. Although this was only carried out in 35 cases, PIG-M inactivation 
through disruption of the region immediately surrounding the transcriptional start site is 
unlikely to be a common event in the pathogenesis of PNH. 
 
The majority of myeloproliferative disorders are caused by mutations that activate the 
tyrosine kinase, JAK2 (Baxter et al, 2005; James et al, 2005). JAK2 is a tyrosine kinase, 
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which when activated, causes activation of the JAK-STAT signalling pathway. Once 
phosphorylated, JAK2 activates downstream signalling via other transcription factors, 
STAT3, STAT5, MAP kinases, PI3K and AKT ultimately causing the initiation of gene 
transcription responsible for cell growth and differentiation in the cell nucleus (Kota et al, 
2008). The JAK2 mutation is a guanine to thymidine substitution at codon 617 (V617F 
mutation) and underlies clonal expansion in these disorders. The possibility that JAK2 
V617F mutations could drive clonal expansion in PNH was examined in 36 patients with 
PNH. Only 1 patient had both PNH and a JAK2 mutation. Unfortunately the patient died 
before it was possible to demonstrate whether the mutation arose from within the PNH 
clone.  At the time of this work Sugimori et al also described 3 patients with both PNH 
and JAK2 mutations (Sugimori et al, 2012). It is unlikely that JAK2 mutations play a 
major role in the pathogenesis of PNH. It is feasible that in this small number of cases the 
coexistence of JAK2 mutations and PNH is a chance occurrence rather than a causative 
one. 
 
The report by Inoue et al describes 2 patients with chromosomal abnormalities disrupting 
the HMGA2 locus on chromosome 12. In both cases there was a consequent increase in 
ectopic production of HMGA2 mRNA with a greater than ten-fold increase in HMGA2 
mRNA identified (Inoue et al, 2006). This initial report led to the evaluation of HMGA2 
mRNA expression relative to the level of β-ACTIN in 42 PNH patients and 10 control 
samples. Although HMGA2 was expressed at very low levels in all the samples evaluated, 
it could be consistently identified and was reduced in the patient group when compared to 
the control group, even on evaluation of CD15 positively selected MNCs. Further work 
on HMGA2 expression has been undertaken on 25 patients with PNH without 
chromosomal abnormalities (Murakami et al, 2012). This work was performed by the 
same group as the initial report on the 2 patients with chromosome 12 rearrangements. In 
these patients they describe no increase in HMGA2 mRNA expression in the bone 
marrow but increased expression in peripheral blood in 18 out of 24 patients. This 
discrepancy in HMGA2 mRNA expression was examined further in the cohort of 42 
patients by using the same primers in a TaqMan assay as used by the group from Osaka. 
The results failed to show any increase in HMGA2 expression in the PNH patient samples 
compared to the control group. 
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HMGA2 expression is regulated by the microRNA (miRNA), let-7 (Lee and Dutta, 2007; 
Mayr et al, 2007). The 3’untranslated region (UTR) of HMGA2, contains complementary 
sequences to let-7 and there is an inverse correlation between the level of let-7 miRNA 
and the expression of HMGA2, with high levels of HMGA2 mRNA and low levels of let-
7 miRNA in embryonic cells but very low levels of HMGA2 mRNA and high levels of 
let-7 miRNA in adult cells (Tzatsos and Bardeesy, 2008; Ikeda et al, 2012). The 2 
patients described by Inoue et al both had chromosomal rearrangements of the 3’UTR 
potentially leading to disruption of let-7 binding and subsequent increased production of 
HMGA2 protein in PNH cells (Inoue et al, 2006). HMGA2 has been shown to be a 
developmental regulator of stem cell self-renewal and as such increased expression of 
HMGA2 in PNH cells could therefore provide the growth advantage for the PNH clone 
(Nishino et al, 2008; Hammond and Sharpless, 2008). Reduced expression of HMGA2, as 
seen in this work, is likely to reduce self-renewal of PNH cells. Whilst this is at odds with 
the concept that increased HMGA2 occurs in PNH to provide clonal expansion, it may be 
implicated in spontaneous remissions observed in the disease. 
 
Overall these experiments did not support the hypothesis that PIG-M promoter mutations 
are prevalent in PNH. There was also no evidence that JAK2 mutations are prevalent or 
that increased expression of HMGA2 occurs to provide PNH stem cells with a 
proliferative advantage over normal stem cells. 
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6.1 Rationale 
 
PNH stem cells have displayed no increased propensity to divide in in vitro experiments. 
In all in vitro LTBMC experiments reported using bone marrow cells from individuals 
with PNH there has been a reduction in the ability of these cells to produce progenitors 
(Maciejewski et al, 1997; Elebute et al, 2003). This might be due to the relationship 
between AA and PNH and there being a reduced number of stem cells present in samples 
evaluated from PNH bone marrow (Maciejewski et al, 1997). Certainly in LTBM 
cultures using bone marrow from AA patients there has been a marked reduction in 
progenitor cells produced (Marsh et al, 1990). 
 
The possibility of an intrinsic cell effect driving expansion of the PNH clone is discussed 
in Chapter 5. In order to evaluate whether a cell extrinsic factor might cause clonal 
expansion in PNH we have developed an in vitro LTBMC model to mimic the in vivo 
conditions in the bone marrow. This model provides a means of examining environmental 
conditions that favour both normal and PIG-A mutated stem cells. Overall 18 PNH bone 
marrow samples that were collected after informed consent were compared to 10 normal 
controls. Bone marrow MNCs, selected CD34+ cells, T-cell depleted MNCs and T-cell 
depleted MNCs with the T cells added back to the cultures were all assessed using this in 
vitro model. 
 
 
6.2 Normal Control Samples and Initial Results Using PNH Samples 
 
Normal bone marrow samples were obtained from individuals that were undergoing a 
bone marrow biopsy as part of their investigation for suspected lymphoma. Only 
individuals whose blood count (haemoglobin, white cell and platelet parameters) and 
formal bone marrow evaluation was normal were used as control samples. If the bone 
marrow report demonstrated any abnormality of bone marrow function either by flow 
cytometry or by immunohistochemistry the samples were discarded. 
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Ten milliliters of bone marrow were collected by bone marrow aspiration and MNCs and 
CD34+ selected cells were isolated using the methods described in Chapter 2. Table 6.1 
shows the subjects age and amount of MNCs collected from them. The mean age of the 
control group was 48 years and 5 months (range 25-71 years). The mean number of 
MNCs collected from the control group was 3.65 x 107/ml (range 1.02-8.8 x 107/ml).  
 
Initial experiments were carried out in sterile tissue culture flasks with a 25cm2 surface 
area at the bottom of the flask (T25 flasks). Irradiated M210B4 cells were added to the 
flasks (1 x 106 cells) with RPMI media supplemented with 2mM L-glutamine and 10% 
fetal bovine serum least 8 hours prior to in RPMI 1640 medium to a confluence of ~80% 
of the flask surface. Amounts of M210B4 cells were titrated to determine the optimum 
density to provide stromal support to a constant number of CD34+ cells from a single 
normal donor.   
 
UPN Age MNC (x 107/ml) 
N1 71 1.13 
N2 60 1.4 
N3 25 2.5 
N4 52 8.8 
N5 37 8.12 
N6 35 2.16 
N7 64 2.78 
N8 66 1.02 
N9 50 3.58 
N10 24 4.98 
 
Table 6.1 Normal control sample MNCs and CD34+ cells collected. 
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Figure 6.1 Variations in M210B4 stromal cell concentrations and their effect on the 
quantity of progenitor cells. 
 
 
Paradoxically the highest concentration of M210B4 cells resulted in the poorest recovery 
of cells from donor; however the higher confluence level of M210B4 cells lead to 
sloughing off of the stromal layer when the media replaced each week. Lower levels of 
M210B4 cells resulted in reduced levels of progeny cells produced and for the remaining 
concentrations there was a dose-dependent increase in cell viability. This is shown in 
Figure 6.1 where different M210B4 concentrations were used to support MNCs from a 
normal bone marrow sample.  
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Figure 6.2 Flow cytometry of MNCs from a normal bone marrow sample. (A) Cells 
evaluated using forward and side scatter. (B) CD34+ cells selected in gate P2 and 
shown in green. (C) Further gating (P3, blue) of CD34+ selected cells using CD45 
and side scatter. (D) Expression of FLAER on CD34+ cells. 
 
Figures 6.2 and 6.3 show an example of flow cytometry plots of a normal bone marrow 
MNCs and CD34+ selected cells, respectively, used in the LTBMC experiments. 3.6% of 
the MNCs shown in Figure 6.2 are CD34+ cells. 
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Figure 6.3 Flow cytometry of CD34+ selected cells from a normal bone marrow 
sample. (A) Cells evaluated using forward and side scatter. (B) CD34+ cells selected 
in gate P2 and shown in green. (C) Further gating (P3, blue) of CD34+ selected cells 
using CD45 and side scatter. (D) Expression of FLAER on CD34+ cells. 
 
MNCs and CD34+ selected cells were inoculated into 2 separate T25cm2 flasks at a 
concentration of 106 per ml for MNCs and 104 cells per ml for CD34+ selected cells. The 
stromal layer of irradiated M210B4 cells keeps the haemopoietic cells together where 
they can be seen as a classical “cobblestone” appearance by light microscopy (Figure 
6.4). These cobblestone areas represent a population of pluripotent progenitor cells with a 
long-term marrow-repopulating ability (Schrezenmeier et al, 1996). The cells produced 
by these cobblestone areas are released into the media and are mostly myeloid in nature, 
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expressing CD117. The cells collected from the supernatant were assayed in CFAs using 
a methylcellulose-based medium and colonies counted after 14 days. Colony forming 
unit-granulocyte, macrophage (CFU-GM) and colony forming unit-granulocyte, 
erythrocyte, monocyte, megakaryocyte (CFU-GEMM) colonies were both included in the 
numbers of colonies produced. Although there were only a small number of burst 
forming unit-erythroid (BFU-E) identified, these were not included in the results shown, 
as the LTBMC media is predominantly able to support myeloid cells. Figure 6.5 shows a 
typical CFU-GM colony. 
 
 
 
Figure 6.4 Light microscopy (magnification x 40) of stromal layer showing 
haemopoietic cells clustered under the stromal layer. 
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Figure 6.5 Light microscopy (magnification x 40) view of a CFU-GM colony. 
 
 
 
 
Figure 6.6 Mean number of cells from the supernant of the control group using 
MNCs and CD34+ selected cells. 
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Figure 6.6 shows the number of progeny cells produced from the control samples using 
either MNCs or selected CD34+ selected cells. The myeloid long-term cultures were 
similarly maintained for up to 10 weeks using either of these input cells. These progeny 
cells were then added to Methocult media at a concentration of 5 x 104 cells per ml. The 
number of colonies present after the 14 day incubation period is shown in Figure 6.7. 
 
 
 
 
 
Figure 6.7 Mean number of colonies formed in the CFAs from the cells in the 
supernant of the LTBMCs of the control group using MNCs and CD34+ selected 
cells. 
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6.3 Initial LTBMC Findings with PNH Samples 
 
The proportions of MNCs obtained from patients with PNH were variable and are shown 
in Table 6.2. This table includes all PNH samples that were used in the long-term culture 
experiments.  
 
UPN Age Granulocyte 
clone size (%) 
MNC (x 107/ml) 
5 52 98.6 1.13 
21 34 92.9 2.33 
22 68 100 1.4 
24 48 92.6 2.5 
43 49 95 2.16 
46 68 98.9 1.03 
65 69 99 3.6 
74 20 98.6 1.29 
92 58 84.4 2.55 
93 22 49 1.6 
94 67 56.2 1.14 
32 53 99.7 1.22 
49 40 99.6 1.34 
55 32 84.1 1.49 
95 27 58.5 3 
19 49 70.5 2.67 
79 32 92.2 1.46 
96 67 97.2 2.4 
 
Table 6.2 Bone marrow samples from patients with PNH showing the age and PNH 
granulocyte clone size as well as the number of bone marrow MNCs collected.  
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Figure 6.8 Flow cytometry of MNCs from a PNH bone marrow sample (U.P.N. 24). 
(A) Cells evaluated using forward and side scatter. (B) CD34+ cells selected in gate 
P2 (green). (C and D) Further gating (P3, blue and P4, red) of CD34+ selected cells 
using CD45 (red), forward and side scatter (blue). (E) Expression of FLAER on 
CD34+ cells (97.8% GPI deficient). 
 
The first 11 samples in Table 6.2 were the patient samples used in the initial experiments 
and the PNH MNCs and selected CD34+ cells were compared to the control group 
discussed in Section 6.2. The mean age of the whole patient group was 47 years and 6 
months (range 20-69 years) and the mean granulocyte clone size was 87.1% (range 49-
100). The mean number of MNCs collected was 1.91 x 107/ml (range 1.03-3.6 x 107/ml). 
 
The PNH samples where the number of MNCs collected was less 1 x 107 cells per 
millilitre were not used in the LTBMC experiments as this was the minimum amount of 
cells consistently required when manipulation of the sample was required (i.e. CD34+ 
selection, T-cell removal). 
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Figure 6.9 Flow cytometry of CD34+ selected cells from a PNH bone marrow sample 
(U.P.N. 24). (A) Cells evaluated using forward and side scatter. (B) CD34+ cells 
selected in gate P2 (green). (C) Further gating (P3, blue and P4, red) of CD34+ 
selected cells using CD45 (red, not shown), forward and side scatter (blue). (E) 
Expression of FLAER on CD34+ cells (97.8% GPI deficient). 
 
Figures 6.8 and 6.9 show an example of flow cytometry plots of MNCs and CD34+ 
selected cells, respectively, from a PNH bone marrow sample used in the LTBMC 
experiments. 1.4% of the MNCs shown in Figure 6.2 are CD34+ cells and 80.1% of the 
CD34+ selected cells express CD34. 97.8% of both the MNCs and the selected CD34+ 
cells were GPI deficient. 
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Figure 6.10 Mean number of cells from the supernant of both the control and PNH 
samples using MNCs and CD34+ selected cells. 
 
 
Figure 6.10 shows the number of progeny cells produced in the long-term cultures for 
both the PNH and control groups. Both the PNH and control cells are maintained for up 
to 9 weeks. This is the first time long-term culture of PNH cells have been maintained for 
a similar duration to that of normal cells. 
 
These progeny cells were then added to Methocult media at a concentration of 5 x 104 
cells per ml. The number of colonies present after the 14 day incubation period is shown 
in Figure 6.11. In all but 1 case the ability of the progeny from PNH MNCs to form 
colonies is greatly reduced. On selecting out the CD34+ cells from the PNH bone marrow 
samples the progeny formed in the long-term culture model are able to form colonies to a 
similar degree to that of the normal control group. This indicates that it is likely that an 
extrinsic factor is responsible for the inability of these cells to form colonies. 
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Figure 6.11 Number of colonies formed in the CFAs from the cells in the supernant 
of the LTBMCs of the initial PNH samples using MNCs compared to the mean 
number of colonies from the PNH CD34+ selected samples and the MNCs from the 
control group. 
 
It is unclear why the MNCs from U.P.N. 65 continued to produce progeny capable of 
forming colonies unlike the other MNCs from patients with PNH that all stopped 
producing colonies by week 4 or 5. The case of U.P.N. 65 is unusual amongst patients 
with PNH in that he has had the condition for over 35 years. It may be that the 
mechanism preventing colony formation had reduced over time in this case. 
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6.4 Difficulties with the Stromal Layer 
 
After the initial experiments, which showed that PNH cells could be maintained in long-
term culture, further work was undertaken to try to elucidate the reason the PNH MNCs 
progeny did not maintain colony formation beyond 4-5 weeks. Unfortunately in further 
experiments using six PNH bone marrow samples large holes developed in the irradiated 
M210B4 stromal layer (shown in Figure 6.12).  
 
 
Figure 6.12 Light microscopy (magnification x 5) images of the stromal layer. 
 
This caused disruption to the seeded cells and a subsequent reduction in the numbers of 
progeny produced and a failure of the in vitro model. Initially it was unclear why the 
disruption to the stromal layer was occurring and a number of different possibilities were 
assessed. The same method for maintaining the cultures was followed. Fresh batches of 
M210B4 cells were thawed and used as the stromal cells in case either there was an 
infective cause for the disruption, or a problem with the cell line itself, but the disruption 
of the stromal layer continued. The amount of M210B4 cells used to make the stromal 
layer is important (shown in Figure 6.1) as sloughing off of the stromal layer occurs when 
there are too many M210B4 cells present, but this did not appear to be the cause. Finally 
after excluding all other possibilities the cause for the problem was identified as the 
irradiator itself, which was not irradiating the stromal layer correctly and lead to 
continued growth. Repair of the irradiator resolved the disruption to the stromal layer. 
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6.5 Minimisation Experiments 
 
One of the main difficulties in working with PNH bone marrow samples is the finite 
amount of material available from each sample with the average MNC count from the 
initial PNH samples being 1.91 x 107/ml. In order to maximise the potential experiments 
for each sample a scaling-down of the LTBMC model was attempted. Four bone marrow 
samples from the control group were used to ascertain if the model could be successfully 
repeated using a smaller surface area. 
 
 
Figure 6.13 Flow cytometry from a control bone marrow sample used in the 
minimisation experiments. (A) Unmanipulated bone marrow (CD34+ proportion 
0.9% in red). (B) MNCs (CD34+ proportion 2.2% in red). 
 
A reduction in both the number of MNCs and selected CD34+ cells seeded into the 
culture system was tried. The MNCs were seeded into T25 flasks at 1 x 106, 5 x 105 and 
2.5 x 105 cells. Six well plates were also used for the minimisation experiments. These 
plates have a third of the surface area of the T25 flasks and MNCs were seeded into these 
at 3.33 x 105, 1.67 x 105 and 8.33 x 104 cells to reflect the same proportions that were 
seeded into the T25 flasks. Flow cytometry from 1 of the bone marrow samples used 
showing the CD34+ proportion of cells is shown in Figure 6.13. 
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Figure 6.14 Mean number of cells from the supernant of the control group using 
MNCs. 
 
Figure 6.15 Mean number of colonies formed in the CFAs from the cells in the 
supernant of the LTBMCs of the control group using MNCs. 
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The mean number of cells produced in the minimisation experiments from normal MNCs 
is shown in Figure 6.14. The experiments show a reduction in the duration the cultures 
were maintained when either 5 x 105 or 2.5 x 105 MNCs were put into the T25 flasks. 
This is also reflected in the number and duration of colonies that were formed with a 
dramatic reduction observed at 3 and 2 weeks, respectively (shown in Figure 6.15). In the 
case of the 6 well plate experiments there was very little in both the number of cells 
produced and in their ability to produce colonies in CFAs (Figure 6.14 and Figure 6.15). 
The same methods were carried out using CD34+ selected cells from control samples. 
These experiments also failed to maintain the cultures beyond a few weeks using the 
smaller sample numbers. 
 
Although the work using 6 well plates was unsuccessful, the reduction of input cells into 
the T25 flasks could potentially be of use if the culture model could be maintained for a 
few weeks longer. In order to try to optimise this, alterations in both the volume of 
MyelocultTM H5100 media and the concentration of input MNCs was evaluated in a 
control sample (Figures 6.16 and 6.17). 
 
 
Figure 6.16 The number of cells from the supernant of a control group sample using 
different amounts of input MNCs and different volumes of MyelocultTM H5100 
media. 
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Figure 6.17 The number of colonies formed in the CFAs from the cells in the 
supernant of a control group sample using different amounts of input MNCs and 
different volumes of MyelocultTM H5100 media. 
 
At the same time as the above minimisation experiments were performed, increasing 
dilutions of input MNCs from a control sample were seeded into different plates in a 24 
well plate. The amount of MNCs seeded were 1 x 106, 5 x 105, 2.5 x 105, 1.25 x 105, 6.25 
x 104, 3.13 x 104, 1.56 x 104, 7.81 x 103 per well. These experiments also failed to 
maintain long-term myeloid cultures beyond 3-4 weeks. 
 
As the attempts to scale down the long term culture model were unsuccessful, the amount 
of material collected from PNH bone marrow samples continued to be the determining 
step in deciding the number of different experiments in which the samples could be used. 
Routine CD34+ cell selection was omitted and the model using T25 flasks and 1 x 106 
input MNCs was continued. The next focus for manipulating the bone marrow MNCs 
was the effect of T-cell removal. 
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6.6 T-Cell Removal at Different Stages 
 
6.61 T-cell Removal before MNCs Are Added to the Culture Model 
 
To determine if T-cells exert an extrinsic effect on PNH stem cells in the bone marrow, 
T-cells were removed first from control bone marrow MNCs and later PNH ones. 
Initially T-cell removal was performed just using anti-CD3 MicroBeads and the T-cells 
were removed prior to the addition of the sample cells to the culture model.  
 
 
Figure 6.18 Flow cytometry of MNCs from a PNH bone marrow sample (U.P.N. 74). 
(A) P1 gating (red) of the CD34+ cells (1.5% of MNCs). (B) Further gating (P2, 
blue) of cells using forward and side scatter. (C) Gating of CD3+ cells (P3, green, 
60.3% of MNCs). (D) Expression of FLAER on CD34+ CD38+ cells (80.6% GPI 
deficient). 
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Although this greatly reduced the number of cells T-cells present there were still a 
significant number of T-cells present in a number of samples, as shown in Figure 6.18 
and 6.19 where the proportion of CD3+ cells present was only reduced from 60.3% to 
5.4%. 
 
 
 
Figure 6.19 Flow cytometry of MNCs from a PNH bone marrow sample (U.P.N. 74) 
with T-cells removed using anti-CD3 MicroBeads. (A) P1 gating (red) of the CD34+ 
cells (2.9% of MNCs). (B) Further gating (P2, blue) of cells using forward and side 
scatter. (C) Gating of CD3+ cells (P3, green, 5.4% of MNCs). (D) Expression of 
FLAER on CD34+ CD38+ cells (97.3% GPI deficient). 
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Three different methods were assessed to improve the efficiency of removal of T-cells 
from the bone marrow MNCs: 
1. Red cell lysis followed by T-cell depletion using anti-CD3 MicroBeads. 
2. CD15 selection followed by T-cell depletion using anti-CD3 MicroBeads. 
3. Red cell lysis followed by CD15 selection followed by T-cell depletion using 
anti-CD3 MicroBeads. 
 
 
Figure 6.20 Flow cytometry of MNCs from a PNH bone marrow sample prior to T-
cell removal (U.P.N. 19). (A) P1 gating (red) of the CD34+ cells (1.4% of MNCs). (B) 
Further gating (P2, blue) of cells using forward and side scatter. (C) Gating of CD3+ 
cells (P3, green, 35% of MNCs). (D) Expression of FLAER on CD34+ CD38+ cells 
(77.1% GPI deficient). 
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All 3 techniques produced very similar results but as later experiments would include 
adding back T-cells to T-cell depleted samples, CD15+ selection followed by either T-
cell depletion using CD3 MicroBeads (to obtain T-cell depleted samples) or pan T-cell 
removal (to obtain T-cells to add back to T-cell depleted samples) was less likely to 
activate T-cells while the samples were being manipulated. Figures 6.20 and 6.21 show a 
PNH sample before and after the CD15+ selection and CD3 depletion. 
 
 
Figure 6.21 Flow cytometry of MNCs from a PNH bone marrow sample with T-cells 
removed using CD15 selection followed by CD3 depletion. (A) P1 gating (red) of the 
CD34+ cells (1.6% of MNCs). (B) Further gating (P2, blue) of cells using forward 
and side scatter. (C) Gating of CD3+ cells (P3, green, 0.1% of MNCs). (D) 
Expression of FLAER on CD34+ CD38+ cells (73.4% GPI deficient). 
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The T-cell depleted samples were seeded into T25 flasks at a concentration of 1 x 106 
cells per ml and the number of progeny cells produced from the culture experiments are 
shown in comparison to both all the unmanipulated PNH MNCs evaluated using the 
culture system and the MNCs from the normal control group (Figure 6.22). All the input 
cells produced a similar amount of progeny cells for CFA analysis.  
 
 
Figure 6.22 Mean number of cells from the supernant of MNCs from the control 
group, MNCs, T-cell depleted MNCs and T-cell depleted MNCs with the T-cells 
added back to them from PNH samples. 
 
The number of colonies produced from these LTBMC experiments is shown in Figure 
6.23. There is a marked difference in colony formation between the control group and the 
PNH MNC group. This difference is more evident if U.P.N. 65 is excluded from the 
analysis as it is the only PNH MNC sample that produced colonies beyond 4 weeks in a 
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pattern similar to that of the control samples. The T-cell depleted samples were able to 
produce colonies to similar extent as the normal MNCs.   
 
 
 
Figure 6.23 Number of colonies formed in the CFAs from the control group, MNCs, 
T-cell depleted MNCs and T-cell depleted MNCs with the T-cells added back to 
them from PNH samples. 
 
The colonies formed by of 2 of the 6 initial PNH bone marrow samples that were T-cell 
depleted underwent flow cytometry analysis to determine whether the cells forming the 
colonies were GPI deficient or not. These are shown in Figures 6.24 and 6.25.  
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Figure 6.24 Flow cytometry of colonies formed from a PNH sample (U.P.N. 32). (A 
and B) PNH MNCs at week 1 and 2, respectively. (C, D, E and F) T-cell depleted 
PNH MNCs at weeks 1-4, respectively. 
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Figure 6.25 Flow cytometry of colonies formed from a PNH sample (U.P.N. 55). (A 
and B) PNH MNCs at week 1 and 2, respectively. (C, D and E) T-cell depleted PNH 
MNCs at weeks 1-3, respectively. 
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The T-cell depleted colonies from PNH bone marrow appear to have an increased 
proportion of normal cells (FLAER or GPI +) over time. This was assessed further in 
Section 6.62 where T-cells were added back into the T-cell depleted culture experiments. 
 
6.62 T-Cell Removal Immediately Prior to the CFAs 
 
Anti-CD3-mediated depletion of the cells produced in the LTBMC experiments was also 
evaluated to determine whether the effect of T-cell removal on colony formation occurs 
during the CFAs. 
 
 
Figure 6.26 T-cell removal in a normal bone marrow MNC sample prior to the 
CFA, showing the proportion of CD45+ and CD3+ input cells after 1 week (A and 
B) and 2 weeks (B and C) of culturing.  (E and F) shows the same populations in a 
sample that has undergone T-cell depletion prior to CFA at 1 week of culturing.  
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T-cells are present in the cells undergoing CFAs. However the process of T-cell 
depletion, using anti-CD3 microbeads just prior to CFA, although effective, reduces the 
number of cells for evaluation to such an extent that the T-cell depleted sample is 
incomparable with the unmanipulated sample (Figure 6.26).  
 
 
6.7 Add-Back Experiments 
 
Three PNH bone marrow samples were manipulated so that MNCs, T-cell depleted 
MNCs and T-cell depleted MNCs with the T-cells added back to the depleted sample at 
the time they were put into the culture system could be assessed. The T-cell depletion 
was performed by CD15 selection followed by T-cell depletion using anti-CD3 
MicroBeads as described in 2.4.4. As the T-cells removed by this method were positively 
selected it is possible that they may have been activated. An equal number of MNCs to 
those undergoing the T-cell depletion were used to extract T-cells, using the Pan T-cell 
Isolation Kit II (Miltenyi Biotech) described in 2.4.5. This method allows collection of 
the T-cells via negative selection and the T-cells from 1 of these samples is shown in 
Figure 6.27. 
 
 
Figure 6.27 An example of T-cells removed using the Pan T-cell Isolation Kit II 
(Miltenyi Biotech) (U.P.N. 19). 99.7% of the cells in this sample are CD3+. 
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The number of cells produced from T-cell depleted samples in LTBM cultures were 
similar to the normal control samples and is shown in Figure 6.22. The number of 
colonies produced in the experiments where the T-cells were added back into the culture 
system is reduced to a level similar to the cultures where unmanipulated PNH MNCs 
were used and is shown in Figure 6.23. This observation suggests an important role for T-
cells in inhibiting colony formation in this in vitro model. Flow cytometry analysis of the 
colonies formed from these 3 patient samples was performed and is shown below. 
 
The samples from U.P.N. 80 showed no colony formation from unmanipulated MNCs, 
colonies for 5 weeks MNCs where T-cells were removed and colonies for 3 weeks where 
the T-cells were removed and added back to the target cells. Although flow cytometry 
analysis was performed it was not possible to always discern distinct populations of 
FLAER+ and FLAER- populations of CD45+ cells. This is the case for the analysis of the 
colonies from the add-back samples and for some of the colonies in the T-cell depleted 
samples. The latter is shown in Figure 6.28. Overall there appears to be an increase in the 
proportion of FLAER+ cells produced the longer the cells are in the in vitro model. 
 
The samples from U.P.N. 19 showed colonies for 3 weeks from unmanipulated MNCs, 
colonies for 5 weeks for MNCs where T-cells were removed and colonies for 2 weeks 
where the T-cells were removed and added back to the target cells. As mentioned above, 
it was not possible to confidently identify distinct populations of FLAER+ and FLAER- 
populations of CD45+ cells for either the unmanipulated MNCs or the first week of the 
samples where T-cells were removed and then added back. The colonies from the second 
week in the add-back experiment showed 95.2% FLAER+ CD45+ cells.  Figure 6.29 
shows flow plots of the colonies from the T-cell depleted MNCs which initially were 
impossible to distinguish as discrete populations. 
 
No colonies were formed from either unmanipulated MNCs or MNCs where T-cells were 
added back from U.P.N. 79. Figure 6.30 shows flow plots of the colonies from the MNCs 
where T-cells were removed and colonies were observed for 3 weeks in this sample.  
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Figure 6.28 Flow cytometry of colonies formed from a PNH sample (U.P.N. 92). (A) 
Gating of CD34+ cells (red). (B, C, D, E and F) T-cell depleted PNH MNCs at weeks 
1-5, respectively. FLAER+ cells are depicted in green and negative cells are shown 
as blue. 
  
removeremoveremoveremoveremoveremoveremoveeeeeeeeeeeeeeeeeeeeeeeeeeeee 
cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc This needs to be included in the text please if at all possible 
today  
This needs to be included in the text please if at all possible 
today  
A B 
C D This needs to be included in the text please if at all possible 
today  
E This needs to be included in the text please if at all  
This needs to be included in the text please if at all possible 
today  
This needs to be included in the text if at all possible 
today  This needs to be included in the text if at all possible today  F 
1.1%$FLAER+ 
97.7%%FLAER+ 90.3%&FLAER+ 
H
i 
 191 
 
 
Figure 6.29 Flow cytometry of colonies formed from a PNH sample (U.P.N. 19). (A) 
Gating of CD34+ cells (red). (B, C, D, E and F) T-cell depleted PNH MNCs at weeks 
1-5, respectively. FLAER+ cells are depicted in green and negative cells are shown 
as blue. 
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Figure 6.30 Flow cytometry of colonies formed from a PNH sample (U.P.N. 79). (A) 
Gating of CD34+ cells (red). (B, C and D) T-cell depleted PNH MNCs at weeks 1-3, 
respectively. FLAER+ cells are depicted in green and negative cells are shown as 
blue. 
 
Unlike the other T-cell depleted samples evaluated the proportion of normal (FLAER+) 
cells did not increase with each successive week but in fact was dramatically reduced by 
the second week in culture. 
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6.8 Discussion 
 
This is the first time that a reproducible in vitro model using liquid media and bone 
marrow cells from patients with PNH, has been shown to consistently support the PNH 
cells for a similar duration of time to control bone marrow cells from unaffected 
individuals. Prior studies have produced progenitor cells at a significantly reduced rate 
when compared to normal ones (Maciejewski et al, 1997; Elebute et al, 2003). This 
model is likely to form a platform for further research into the pathogenesis of the disease 
as it raises a number of questions, whilst at the same time supporting an underlying 
immune mechanism as the cause for clonal expansion within the bone marrow. 
 
The technique to support the cultures relies on the use of an irradiated murine bone 
marrow fibroblast cell line, M210B4, which provides a constant microenvironment to 
support haematopoiesis in this in vitro model. The use of this cell line to support the 
culture experiments is the main technical difference employed when compared to 
previous attempts to grow PNH bone marrow cells in culture. The method used remains a 
difficult technique to maintain the experiments over a number of weeks as is shown in 
Section 6.4. The efficacy of this murine cell line in supporting the maintenance and 
differentiation of PNH bone marrow stem cells suggests that the endogenous stroma is 
not having a direct effect on haematopoiesis in PNH in vitro. This is consistent with the 
findings of Nishimura et al, (Nishimura et al, 2002) who reported no difference in long-
term culture experiments when comparing the use of stroma from both normal 
individuals and those with PNH in conjunction with normal bone marrow cells. 
 
The main limitation to these experiments was consistently the number of bone marrow 
MNCs obtained from patients with PNH for this research. In most cases the individuals 
that consented to samples being used were having a bone marrow sample taken, either on 
commencing anti-complement therapy or to assess their underlying condition. Adding to 
this, individuals with PNH often have a degree of aplasia, which causes a further 
reduction in the number of MNCs available for this research. Seven patient bone marrow 
samples were not able to be used as the number of MNCs collected was less 1 x 107 cells 
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per millilitre, which is the minimum amount of cells consistently required when 
manipulation of the sample was required. Unfortunately the experiments performed to 
minimise the LTBM cultures was unsuccessful with the number of progenitor cells 
produced declining rapidly over only 3-4 weeks (Section 6.5). 
 
The finding that removal of T-cells from PNH samples, using anti-CD3 MicroBeads, 
improves the ability of the MNCs to produce progenitor cells capable of forming colonies 
was shown consistently in all but 1 of the 18 PNH samples (U.P.N. 65) as shown in 
Figure 6.23. The case of U.P.N 65 is unusual in that he has had PNH for over 35 years 
and it may be that his MNCs act similarly to the control samples as the immune effect on 
the bone marrow has reduced over this long time period. During the course of these 
experiments, a number of samples contained an unusually high number of T-cells in the 
bone marrow. The use of CD15 selection of bone marrow MNCs prior to the removal of 
CD3+ cells is an efficient method to reduce the T-cell numbers present (Figures 6.20 and 
6.21). Although the addition of T-cells removed using the Pan T-cell Isolation Kit II 
(Miltenyi Biotech) to CD3 depleted MNCs was only performed in 3 samples, these 
preliminary results are encouraging in that they support the hypothesis that T-cells are 
exerting a cell extrinsic effect on the PNH cells within the bone marrow. 
 
Flow cytometry analysis of the colonies formed from progenitors of T-cell depleted 
MNCs showed an increase in the proportion of GPI+ cells over time in 4 of the 5 samples 
assessed (Figures 6.24, 6.25, 6.28, 6.29, 6.30). This further supports an immune 
mechanism for clonal expansion in PNH, but requires greater numbers of samples to be 
analysed to verify this finding. PNH stem cells have no intrinsic growth advantage in 
comparison with normal stem cells (Mukhina et al, 2001; Araten et al, 2002). In this 
model PNH stem cells may have a selective advantage over normal stem cells when T-
cells are present but in the absence of a T-cell mediated attack normal stem cells have a 
growth advantage over PNH stem cells. 
 
It is possible that some bias has been introduced in this work. The normal or control 
group was not composed of completely normal individuals, in that they were having bone 
marrow removed as part of their assessment/investigation for lymphoma. Whilst 
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individuals with either any abnormality of their blood count or formal bone marrow 
evaluation were excluded, this group may not be entirely comparable to the normal 
population. A further issue is that a number of samples from PNH patients were not used 
in the culture system as the number of bone marrow MNCs was too low for manipulation 
in the experiments. These individuals have been selected out and they are likely to have 
been more severely affected with aplasia. Samples from these patients may have behaved 
differently in the culture model. Lastly although attempts were made to try to ensure that 
the T-cells added back to the culture system were not activated, the process of extracting 
them still may have stimulated them, thereby creating an immune response in the add-
back experiments, although if this were the case a more pronounced reduction in colony 
formation might be expected. 
 
This initial work has led to the development of a model that can be used to further 
examine the expansion of the PNH clone. These experiments will require repeating in a 
larger series of cases to confirm the initial findings. Further work should also focus on a 
number of different approaches. This includes replication of this work, using smaller 
sized culture experiments, to allow the limited number of bone marrow MNCs from each 
PNH bone marrow sample available to be maximally manipulated. This model appears to 
show that in the presence of T-cells, PNH stem cells appear to have a growth advantage 
over normal stem cells, whereas in the absence of T-cells normal stem cells have a 
growth advantage over the PNH stem cells thereby confirming the role T-cells appear to 
play in the bone marrow in PNH. 
 
Further experiments should also look to determine the type of T-cells responsible for the 
relative selection of PNH cells and explore whether the T-cell effect is due to T-cell 
killing. It is likely that CD8+ T-cells are the subtype responsible (Poggi et al, 2005; van 
Bijnen et al, 2011), but depletion of different T-cell subsets as well as adding these T-cell 
subsets back to depleted samples using this in vitro model will need to be performed to 
determine this. A suppressive effect on the immune response directed towards GPI-
deficient cells by regulatory T-cells (Tregs) is also a possible explanation but NK cells do 
not appear to be implicated as the effect of CD3 depletion, improving colony formation, 
will not have had an effect on the number of NK cells in the culture system. 
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Although T-cell depletion of PNH MNCs allows the progenitor cells to produce colonies 
they do not make as many as the normal control samples evaluated (Figure 6.23). There 
may be other factors in addition to the direct effect of T-cells that are also responsible for 
the selective advantage of PNH cells. 
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7.1 Clinical Overview of PNH 
 
Paroxysmal Nocturnal Haemoglobinuria (PNH) is an acquired disorder of haemopoietic 
stem cells. The condition can occur at any age but is predominately one that affects 
young adults. It can remain either undiagnosed or misdiagnosed for many years, as the 
initial symptoms are often non-specific in nature. Patients commonly undergo 
investigations for anaemia, including bone marrow examinations, upper and lower 
gastrointestinal endoscopies and for “haematuria,” cystoscopies due to haemoglobinuria. 
It is often only when haemoglobinuria develops or thrombotic complications occur, that 
testing for PNH is undertaken. PNH is a chronic progressive condition, which untreated, 
can have a dramatic effect on the quality of life experienced due to the symptoms of the 
disease. Chronic intravascular haemolysis underlies the morbidity and mortality 
observed. Mortality rates in those treated with supportive therapies alone are high with 
the median survival from diagnosis being between 10 and 22 years (Hillmen et al, 1997; 
de Latour et al, 2008). The only curative treatment is that of allogeneic bone marrow 
transplantation.  Whilst it can cure an individual, it is usually not recommended as a 
therapy due to a high incidence of both acute and chronic graft versus host disease and 
high mortality (Saso et al, 1999; Hegenbart U et al, 2003; Takahashi Y et al, 2004; 
Peffault de Latour et al, 2012). In addition, the possibility that the disease can 
spontaneously remit and the experience of using anti-complement therapy in PNH, has 
made consideration of transplantation to only be considered when the predominant 
clinical issue is severe AA or in countries where anti-complement therapy is unavailable. 
 
Eculizumab is a humanised monoclonal antibody that binds to the complement protein 
C5, preventing its cleavage and thereby stopping terminal complement formation. It has 
revolutionised treatment in PNH and has become the standard of care for symptomatic 
patients. Clinical trials have shown it significantly reduces the symptoms experienced in 
PNH, stopping intravascular haemolysis and the subsequent need for transfusions, 
stopping haemoglobinuria, reducing the risk of thrombosis, stabilising or improving renal 
function, reducing pulmonary hypertension and significantly improving quality of life 
(Hillmen et al, 2004; Hillmen et al, 2006; Hillmen et al, 2007; Brodsky et al, 2008; 
Hillmen et al, 2010; Hill et al, 2010b). These studies have demonstrated that eculizumab 
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provides significant improvements in terms of reduced morbidity. The work in this thesis 
confirms both the reduction in morbidity previously described and the overall safety 
profile of eculizumab in PNH patients over a long duration of treatment. It is also the first 
time that eculizumab has been shown to alter the natural course of the disease, reducing 
the observed mortality to a level equivalent to normal over the initial 8 years of it being 
used in PNH. 
 
The overall improvement in symptoms observed since the introduction of eculizumab in a 
condition which mainly affects young adults, has led to an increased number of women 
with PNH deciding to become pregnant. Although eculizumab is not a licensed treatment 
in pregnancy, this work, using eculizumab for the first time in pregnancy, indicates that it 
appears safe to use and does not seem to either cross the placenta or be secreted in breast 
milk. The findings in this present study need to be confirmed in a greater number of 
pregnancies, but the results are encouraging when compared with the era before 
eculizumab was available – reported maternal and foetal mortality rates were 8-11.6% 
and 4-7.2%, respectively (Fieni et al, 2006; de Guibert et al, 2011), during pregnancy and 
the post-partum period. A further evaluation of the safety and effects of eculizumab in 
pregnancy is already being undertaken on behalf of the global PNH registry, which at the 
time of completing this work includes just over 50 completed pregnancies whilst on 
eculizumab therapy. 
 
 
7.2 Complement and Future Therapies  
 
The complement system is composed of over 30 different plasma proteins. It is an 
essential part of the innate immune system that helps or “complements” the role of 
antibodies and phagocytic cells in destroying pathogens, opsonising cells and inducing 
inflammation. Inactive complement proteins circulate in the bloodstream, and on 
activation via innate recognition proteins or secreted antibody, trigger sequential 
reactions resulting in the generation of effector molecules and a pro-inflammatory 
response. Complement is activated by 1 of 3 distinct pathways, and the effect of initiating 
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small numbers of proteins early in the cascade results in an exponential increase in 
effector molecules produced (Figure 1.5). 
 
Usually complement activation is closely regulated to ensure that the effects of this 
activation are confined to the surface of the offending pathogen. The absence of the 
complement regulatory proteins on PNH blood cells (CD55 and CD59) leads to 
generalised complement activation and subsequent intravascular haemolysis, which 
underlies the morbidity and mortality observed in patients with PNH. The complement 
protein C5 seems to be the ideal molecule to target in PNH, as all 3 activation pathways 
require cleavage of C5 for terminal complement activation. Eculizumab has had a 
remarkable effect in alleviating disease complications in PNH but there are some patients 
who have a sub-optimal response to therapy, continuing to require blood transfusions. 
The reasons for these continued transfusions include concurrent aplasia, complement 
breakthrough and in some cases, extravascular haemolysis (Risitano et al, 2009; Hill et 
al, 2010a; Kelly et al, 2011). As well as these sub-optimal responders, there are other 
factors such as the mode and frequency of administration, the increased risk of 
meningococcal infection and the cost of therapy that will drive research for treatments to 
improve on eculizumab.  
 
New agents that bind to C5 but at different sites and anti-C3 or anti-C9 molecules may 
provide alternative therapies to eculizumab. TT30, a fusion protein made from joining the 
iC3b/C3dg binding domain and the alternative pathway inhibitory domain of factor H, 
has been shown, in vitro, to prevent extravascular haemolysis of PNH erythrocytes from 
C3 opsonisation (Risitano et al, 2012). The concern with inhibiting C3 in vivo relates to 
the possibility of recurrent infections with polysaccharide-coated bacteria and an increase 
in mortality, as is seen in inherited C3 deficiency (Ross and Densen, 1984; Sjoholm, 
1990; Overturf, 2003; Daha, 2010). TT30 itself, although currently being evaluated in a 
phase 1 trial in PNH patients, is unlikely to be of clinical use in this illness due to its short 
half-life and requirement to be administered intravenously. Targeting C9 may provide a 
better option than C3 as suggested by a report by Yonemura et al, which described a 
patient with both PNH and a co-existing congenital deficiency of C9 (Yonemura et al, 
1990). They described a 47-year-old woman with both PNH and an inherited deficiency 
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of C9. She had a significant PNH clone with 95% of her erythrocytes being DAF-
negative but she only experienced mild haemolysis and did not suffer with episodes of 
massive spontaneous haemolysis. The deficiency of C9 in this individual prevented the 
formation of the MAC but still allowed immune reactions due to the production of C5a 
and C5b-C8. New therapies targeting C5 may also become the next generation therapies 
for treating PNH but they would need to demonstrate a non-inferior efficacy and a similar 
safety profile as well offer an improvement on eculizumab. This improved benefit could 
be in the mode of administration, such as a subcutaneous preparation, increasing the 
duration of action to reduce the frequency of administration or a reduction in the cost of 
therapy, which in a number of countries precludes eculizumab being available. 
 
 
7.3 Disease Pathogenesis – Secondary Genetic Events 
 
Since the identification that somatic mutations of the PIG-A gene are responsible for 
developing PNH cells (Takeda et al, 1993), there has been slow progress in determining 
why only some patients who have PNH cells identified in the blood go on to develop 
PNH. 
 
The possibility that a second separate genetic event occurs after the development of an 
initial PIG-A mutation, providing the impetus for clonal expansion, is an excellent 
concept and both V617F JAK2 mutations and aberrant production of HMGA2 could 
potentially provide the driving force for the expansion of the PNH clone. The JAK2 
protein makes up part of the JAK/STAT signaling pathway, which transmits chemical 
signals from outside the cell to the cell nucleus. JAK2 is involved in the control and 
production of erythrocytes, leucocytes and platelets from haemopoietic stem cells. The 
V617F mutation keeps the JAK2 protein in an activated state, which in turn 
phosphorylates STAT5, which is responsible for initiating the transcription of genes 
governing cell proliferation. These gain of function mutations of the JAK2 gene have 
been implicated in the development of myeloproliferative disorders, especially 
polycythaemia rubra vera (Baxter et al, 2005; James et al, 2005). Unfortunately only 1 
JAK2 mutation was found in this series and the mutation has only been reported in 3 out 
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of 29 other patients with PNH, indicating that it is unlikely to have an important role in 
clonal expansion. 
 
The initial report of 2 patients with chromosomal rearrangements affecting the 3’ 
untranslated region of the HMGA2 gene on chromosome 12 causing ectopic expression of 
HMGA2 in the bone marrow led to the investigation into HMGA2 in this study (Inoue et 
al, 2006). This initial report and the knowledge that over-expression of HMGA2 has been 
described in several cancers including a small number of cases of haematological 
malignancy (Berner et al, 1997; Rogalla et al, 1997; Santulli et al, 2000; Abe et al, 2003; 
Pierantoni et al, 2003; Andrieux et al, 2004; Miyazawa et al, 2004; Odero et al, 2005; 
Meyer et al, 2007a; Meyer et al, 2007b; Motoyama et al, 2008; Nyquist et al, 2012) made 
it an exciting target gene for clonal expansion in PNH. However, the effect of 
overexpression in some instances may require the presence of the full-length 3’UTR 
since this region contains microRNA binding sites, which were recently shown to 
function as a competing endogenous RNA in the development of lung cancer (Kumar et 
al, 2014). HMGA2 is reported as being present at very low levels in blood cells, as 
confirmed in this series (Rogalla et al, 1996). The difference between this study, where 
peripheral blood HMGA2 mRNA levels were persistently lower than the control group, 
and the report by Murakami et al, where peripheral blood HMGA2 mRNA levels were 
elevated compared to a control group in 18 out of 24 patient samples assessed, is difficult 
to explain (Murakami et al, 2012). In order to explore this difference further, the primers 
used by Murakami et al were used to see if their findings could be replicated. The results 
again showed a reduced level of HMGA2 mRNA in this series. The difference in findings 
might be explained by an alternative pathogenesis, as there are some reported differences 
in phenotype in Japanese patients (i.e. a reduced propensity to develop thrombosis). 
 
However a cell intrinsic effect is not in keeping with some features specific to PNH. The 
association with PNH and bone marrow failure, usually AA (Dameshek, 1967; Young, 
1992; Griscelli-Bennaceur et al, 1995; Schrezenmeier et al, 1995), the inability of clones 
to become dominant in normal individuals (Araten et al, 1999; Ware et al, 2001; Hu et al, 
2005), the lack of an in vitro or in vivo proliferative advantage (Kawagoe K et al, 1996; 
Rosti V et al, 1996; Tremml et al, 1999) and the spontaneous recovery in some cases 
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(Hillmen et al, 1995) cannot be explained by an intrinsic advantage. The possibility of 2 
separate independent genetic mutations, occurring as causative factors in PNH have also 
been described as unlikely, due to both the small size and the slow rate of replication of 
the active HSC pool available (Dingli and Pacheco, 2006; Traulsen et al, 2007). 
 
 
7.4 Disease Pathogenesis – Escape of the Immune Attack 
 
This work supports the likelihood that an extrinsic effect is likely to be responsible for the 
relative growth advantage in PNH, but it has also generated a number of questions that 
will need to be determined through further research into the disease. This is the first time 
that an in vitro model has been shown to be able to consistently support PNH bone 
marrow MNCs. In this model PNH stem cells have no intrinsic growth advantage over 
their normal counterparts. In the presence of T-cells PNH stem cells appear to have a 
growth advantage over normal stem cells whereas in the absence of T-cells normal stem 
cells have a growth advantage over the PNH stem cells. These results are compatible with 
the hypothesis that T-cells specifically target normal stem cells in the context of PNH, 
while GPI-deficient cells are spared. 
 
Further work needs be done to repeat these findings in a greater number of patient 
samples. Ideally, the model needs to be modified by a reduction in culture volume to 
allow each bone marrow sample to be maximally evaluated. As well as this, further work 
should look at determining whether the T-cell effect is contact mediated by 
isolating/separating the T-cells added back to the samples. Work should also look to see 
if the T-cell effect is inhibitory or that of T-cell killing. If direct killing is implicated, it 
may be possible to visualise GPI-anchored proteins at the immunological synapse as GPI-
linked proteins have previously been reported to have the potential to provide a TcR-like 
signal to activate or inhibit T-cells (Loertscher and Lavery, 2002). However it is more 
likely that the absence of a GPI-linked protein on the surface of the target cell rather than 
on T-cells provides the escape from T-cell killing (Karadimitris and Luzzatto, 2001; Hall 
et al, 2002).   
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The T-cells responsible for this effect will also need to be identified. There is evidence 
that this effect is due to autoreactive T-cells (Karadimitris and Luzzatto, 2001; Murakami 
et al, 2002; Poggi et al, 2005), with CD8 T-cells the most likely subtype responsible 
(Poggi et al, 2005; van Bijnen et al, 2011), but this needs confirmation. A role for 
regulatory T-cells (Tregs) is unlikely, as in the in vitro model, the removal of CD3+ T-
cells caused increased colony formation with GPI-positive cells appearing to have a 
relative growth advantage. If Tregs were responsible they would need to be exerting a 
suppressive effect on the immune response directed towards GPI-deficient cells. NK cells 
are unlikely to be responsible as CD3 depletion will not have removed them from the 
culture system, but NK T-cells may instead be implicated. Finally, both differences in T-
cell activation states should be determined in PNH and control bone marrow samples, as 
well as evaluating the T-cell activation used in add back experiments. Bone marrow T-
cells from U.P.N. 65 should also be examined to look for specific differences between 
this patient and the others affected by PNH. 
 
 
PNH is a fascinating disease that requires ongoing research to determine its underlying 
pathogenesis. This work, whilst providing evidence for an extrinsic effect causing clonal 
expansion, will provide a basis and a model to assess this further. New anti-complement 
therapies, targeting either C5 or C9, may provide the next generation of treatment in PNH 
but it may be difficult to demonstrate an improvement over eculizumab, which has 
revolutionised the management of patients with this rare condition. 
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